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ABSTRACT 
Decoding biological gene regulatory networks by quantitative modeling 
by 
Bin Huang 
Gene regulatory network is essential to regulate the biological functions of cells. 
With the rapid development of “omics” technologies, the network can be inferred for a 
certain biological function. However, it still remains a challenge to understand the 
complex network at a systematic level.  In this thesis, we utilized quantitative modeling 
approaches to study the nonlinear dynamics and the design principles of these biological 
gene regulatory networks.  We aim to explain the existing experimental observations with 
the model, and further propose reasonable hypothesis for future experimental designs. 
More importantly, the understanding of the circuit’s regulatory mechanism would benefit 
the design of a de novo gene circuit for a new biological function.  
We first studied the plasticity of cell migration phenotypes during cancer 
metastasis, which contains two key cellular plasticity mechanisms - epithelial-to-
mesenchymal transition (EMT) and mesenchymal-to-amoeboid transition (MAT). In this 
study, we quantitatively modeled the core Rac1/RhoA gene regulatory circuit for MAT 
and later connected it with the core regulatory circuit for EMT.  We found four different 
stable states, consistent with the amoeboid (A), mesenchymal (M), the hybrid 
amoeboid/mesenchymal (A/M), and the hybrid epithelial/mesenchymal (E/M) 
phenotypes that are observed in the experiment. We also explored the effects of 
 
 
microRNAs and EMT-inducing signals like Hepatocyte Growth Factor (HGF), and 
provided a new insight for the transitions among these phenotypes. 
To improve the traditional modeling approaches, we developed a new 
computational modeling method called Random Circuit Perturbation (RACIPE) to 
explore the dynamic behaviors of gene regulatory circuits without the requirement of 
detailed kinetic parameters. We applied RACIPE on several gene circuits, and found the 
existence of robust gene expression patterns even though the model parameters are wildly 
perturbed. We also showed the powerful aspect of RACIPE to decipher the operating 
principles of the circuits. 
This kind of quantitative models not only works for gene regulatory network, but 
also is capable to be extended to study the cell-cell interactions among cancer and 
immune cells.  The results shown the co-occurrence of three cancer states: low risk 
cancer with intermediate immunity (L), intermediate risk cancer with high immunity (I) 
and high risk cancer with low immunity state (H). We further used the model to assess 
the different combinations of cancer therapies. 
 
  
Acknowledgments 
I would like to express my deep appreciation to my advisors, Prof. Jose Onuchic 
and Prof. Eshel Ben-Jacob, for their patience, inspiration and immense knowledge to 
support my Ph.D. research. None of the work in the thesis would be possible without 
their guidance and help. It is my privilege to work with them. Eshel has passed away in 
2015, but the memory of him will always be my heart.  
In addition, I would like to thank Prof. Herbert Levine, Prof. Peter Wolynes, and 
Prof. Mingyang Lu, for their insightful comments and hard questions on my projects to 
incent me to explore my research from various perspectives. 
I’m also grateful to my committee member, Prof. Cecilia Clementi, for her help 
and advice on both my Ph.D. Qualifying Exam and the Thesis Defense. 
Many thanks to my group members, including but not limited to Dr. Mohit Jolly 
Kumar, Dongya Jia, and Dr. Jingcheng Feng, for the sharing of their knowledge and the 
fantastic collaborations on projects. Also, I thank all CTBP members and my friends at 
Rice University for the helpful discussions and all the fun we have in the last five years. 
Last but not the least, I would like to thank my parents and my girlfriend for their 
unconditional love and infinite support throughout my Ph.D. research and my entire life. 
 
 
 
  
Contents 
Acknowledgments ............................................................................................................ iv 
Contents ............................................................................................................................. v 
List of Figures .................................................................................................................. vii 
Introduction ....................................................................................................................... 9 
1.1. Biological gene regulatory networks ........................................................................ 9 
1.2. Quantitative modeling approaches ......................................................................... 11 
1.3. Scope of the thesis .................................................................................................. 18 
Towards elucidating the plasticity of cell migration phenotypes during cancer 
metastasis ......................................................................................................................... 20 
2.1. Introduction ............................................................................................................ 21 
2.2. Methods .................................................................................................................. 27 
2.3. The three-way switch operation of Rac1/RhoA GTPase-based circuit controlling 
amoeboid-hybrid-mesenchymal transition .................................................................... 41 
2.4. Modeling the Transitions between Collective and Solitary Migration Phenotypes in 
Cancer Metastasis .......................................................................................................... 52 
2.5. Discussion .............................................................................................................. 67 
Development of Random Circuit Perturbation (RACIPE) method to interrogate the 
topological robustness of gene regulatory circuits ....................................................... 71 
3.1. Introduction ............................................................................................................ 72 
3.2. Random Circuit Perturbation (RACIPE) Method .................................................. 75 
3.3. Applications ........................................................................................................... 83 
3.3.1. Simple toggle-switch like circuits ................................................................... 83 
3.3.1.1. Introduction ............................................................................................... 83 
3.3.1.2. Methods ..................................................................................................... 84 
3.3.1.3. Results ....................................................................................................... 86 
3.3.2. Epithelial-to-Mesenchymal circuit .................................................................. 96 
3.3.2.1. Introduction ............................................................................................... 96 
3.3.2.2. Methods ..................................................................................................... 96 
3.3.2.3. Results ..................................................................................................... 101 
3.4. Discussion ............................................................................................................ 103 
Decoding Stem Cell Regulatory Circuit by Random Circuit Perturbation Method
......................................................................................................................................... 106 
vi 
 
4.1. Introduction .......................................................................................................... 107 
4.2. Methods ................................................................................................................ 109 
4.3. Results .................................................................................................................. 119 
4.4. Discussion ............................................................................................................ 128 
Modeling putative therapeutic implications of exosome exchange between tumor 
and immune cells ........................................................................................................... 132 
5.1. Introduction .......................................................................................................... 133 
5.2. Methods ................................................................................................................ 136 
5.3. Results .................................................................................................................. 142 
5.4. Discussion ............................................................................................................ 165 
References ...................................................................................................................... 169 
Supplementary Information ........................................................................................ 193	
 
 
  
List of Figures 
Figure 1.1 Process of gene expression ........................................................................... 10	
Figure 1.2 Modeling and analysis of toggle switch circuit. ......................................... 16	
Figure 2.1 Plasticity of cell migration phenotypes in terms of the activities of 
Rac1/RhoA GTPases. ...................................................................................................... 23	
Figure 2.2 Core gene regulatory circuits for MAT and EMT. ................................... 26	
Figure 2.3 Schematic diagram of the regulation of a typical Rho family GTPase 
(denoted as Rho). ............................................................................................................. 28	
Figure 2.4 Rac1/RhoA circuit as a three-way switch. .................................................. 43	
Figure 2.5 The circuit response to input signals from Grb2 and Gab1. .................... 46	
Figure 2.6 Temporal dynamics of the cells to HGF/SF treatment. ............................ 49	
Figure 2.7 Phenotype distribution of a population of cells. ........................................ 51	
Figure 2.8 The association between the core regulatory circuits for EMT/MET and 
MAT/AMT. ...................................................................................................................... 54	
Figure 2.9 Bifurcation of Rac1-GTP protein levels in response to microRNAs (µ) 
signal regulating the translation of Rac1 and RhoA. .................................................. 55	
Figure 2.10 The circuit response to the input signals µ1 and µ2. ............................... 57	
Figure 2.11 Temporal dynamics of the circuit in response to different rates at which  
µ1 and µ2 decrease. ......................................................................................................... 59	
Figure 2.12 Effective landscapes of the circuit with Gaussian white noise. ............... 61	
Figure 2.13 The circuit response to Grb1 and Grb2 at different levels of the µ signal.
........................................................................................................................................... 64	
Figure 2.14 Phenotype distribution of a population of cells driven by the signal µ. . 66	
Figure 3.1 Schematics of the random circuit perturbation (RACIPE) method. ....... 77	
Figure 3.2 Randomization scheme to estimate the ranges of the threshold 
parameters. ...................................................................................................................... 82	
viii 
 
Figure 3.3 RACIPE identifies robust features of toggle-switch-like motifs. ............. 88	
Figure 3.4 The gene states of the toggle-switch motif are robust against different 
types of distributions used to sample the parameters. ................................................. 92	
Figure 3.5 Application of RACIPE to coupled toggle-switch circuits. ....................... 95	
Figure 3.6 RAICPE identifies multiple EMT cell states from gene network analysis.
........................................................................................................................................... 98	
Figure 4.1 The RACIPE method uncovers robust gene states for the stem cell 
circuit. ............................................................................................................................ 120	
Figure 4.2 Comparison between the stem cell circuit and a random circuit. .......... 124	
Figure 4.3 Hierarchical structure of the stem cell circuit inferred from the 
perturbation analysis. ................................................................................................... 126	
Figure 5.1 Illustration of the EM model for cancer-immune interplays. ................ 139	
Figure 5.2 Phase plane analysis for the EM model. ................................................... 144	
Figure 5.3 Bifurcation diagrams for the steady states as a function of the level of 
immune recognition ρ. .................................................................................................. 147	
Figure 5.4 Sensitivity of the occurrence of the intermediate state to the model 
parameters. .................................................................................................................... 149	
Figure 5.5  The effects of time delay in exosome-mediated communication on the 
cancer-immunity landscape. ........................................................................................ 154	
Figure 5.6 Assessment of hypothetical radiation therapy with the EM model. ...... 157	
Figure 5.7 Assessment of various therapeutic strategies with the EM model. ........ 161	
Figure 5.8 The effects of noise on the treatment by hypothetical immunotherapy. 164	
 
 9 
 
Chapter 1 
Introduction 
1.1. Biological gene regulatory networks 
Cell fates are regulated by a substantial number of genes. Instead of acting alone, 
genes interact with each other and form a very complex gene regulatory network to 
tightly control cell behaviors[1,2]. This type of collective regulation raises the new 
challenge to understand the functions of genes at a systematic level, which would be 
crucial to decipher the association between the genotype and phenotype of cells and 
further contribute to the synthesis of new circuits for de novo biological functions[3,4]. 
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Figure 1.1 Process of gene expression 
During transcription, a gene serves as a template to synthesize the precursor mature 
message RNA (Pre-mRNA) by RNA polymerase. Some regions (Introns) of Pre-mRNA 
are removed before it is exported out of the nucleus. In cytoplasm, mRNA can be used by 
the ribosomes to construct a protein dictating certain functions. Adopted from 
http://www.nature.com/scitable/topicpage/gene-expression-14121669.   
  
Genes are a part of DNA that encode the information of proteins (Figure 1.1). 
During transcription, a gene serves as a template to synthesize the precursor mature 
message RNA (Pre-mRNA) by RNA polymerase. Some regions (Introns) of Pre-mRNA 
are removed before it is exported out of the nucleus. In cytoplasm, mRNA can be used by 
the ribosomes to construct a protein dictating certain functions. Several steps in the gene 
expression process can be regulated.  For example, epigenetic regulations could 
chemically change DNA methylation and histone modifications to silent or activate the 
expression of genes[5]. Also, the protein expressed by one gene may be able to move 
 11 
 
back to the nucleus to bind to the promoter regions of the other genes to transcriptionally 
inhibit or activation the genes’ expressions. These multiple layers of regulations increase 
the difficulty in understanding the mechanism of gene regulatory network.  
As a possible solution to these challenges, system biology has been rapidly 
developed in the past few decades to provide a system-level understanding of the 
complex biological behaviors[6,7]. There are two general approaches for system biology: 
“top-down” approach to integrate the omics data to reconstruct the regulatory network to 
discover new insights of biological behaviors, and “Bottom-up” approach to model detail 
interactions among molecules to explain the operational mechanism behind certain 
biological behaviors. These two approaches have been successfully applied in several 
areas. For instance, “Top-down” approaches are used to reconstruct the metabolic 
networks[8,9], and drug discovery for diseases[10]. Also, “Bottom-up” approaches have 
been used for the modeling of biological process such as Epithelial-to-Mesenchymal 
transition (EMT) during cancer metastasis[11–13], cell cycles[14,15], and circuit design 
in synthetic biology, such as genetic toggle switch[3], and repressilator[4]. However, 
these two approaches have largely been developed separately until now. Recently, several 
works[16] including our work in Chapter 3 and 4 start to bridge these approaches as a 
more powerful method to understand complex biological problems. 
1.2. Quantitative modeling approaches 
This thesis mainly focuses on using “Bottom-up” approaches to study gene 
regulatory networks.  In “Bottom-up” approaches, we assumed that for a certain 
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biological function to study, there exists a core gene circuit containing the master 
regulatory genes for the function. The other genes outside the core circuit have little 
effects on this specific function.  The core gene circuit can be constructed according to 
either the literature, interaction databases (e.g. Ingenuity pathway analysis (IPA®, 
QIAGEN Redwood City, www.qiagen.com/ingenuity), KEGG[17], GO[18]), or 
computational methods[19]. 
There are typically two ways to study the core gene circuit in “Bottom-up” 
approaches, one is by the deterministic model, such as ordinary differential equations 
(ODEs), partial differential equations (PDEs), and the other is by stochastic model, such 
as master equations or Langevin equations. The work in this thesis mainly used the 
deterministic model to study the nonlinear dynamics and time dynamics of the core gene 
circuits. Here, I will take a simple gene circuit, toggle switch, to illustrate the modeling 
approach and the analysis tools. 
As shown in Figure 1.2a, the toggle switch circuit is two genes (A and B) 
mutually inhibiting the expression of each other. When gene A is expressed, protein A 
could move back into nucleus and bind the promoter region of gene B to inhibit its 
expression. Gene B could also inhibit the expression of gene A in a similar way. The 
chemical reactions of these processes are described as following: 
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where 	ga0  is the basal transcriptional rate for gene A, while 	ga  is the inhibited 
transcriptional rate when protein B binds to the promoter region of gene A. 	kaB  and 	kdB   
are the binding and unbinding rate for protein B to the promoter region of gene A. 	gam  is 
the translational rate for mRNA A, and 	Km  and 	K A  are the degradation of mRNA A and 
protein A. Similar meanings for the kinetic parameters for gene B. These 12 chemical 
reactions can be modeled by the set of six ordinary differential equations (ODEs) as 
following: 
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dGAB
dt
= kaB iGA iB −kdB iGAB
dmA
dt
= ga0 iGA+ ga iGAB −KmA imA
dA
dt
= gam imA−KA i A
dGBA
dt
= kaA iGB i A−kdA iGBA
dmB
dt
= gb0 iGB + gb iGBA−KmB imB
dB
dt
= gbm imB −KB iB
 , (1) 
where GAB, mA and A are the concentration of gene A-protein B complex, the mRNA A 
and the protein A respectively.  Usually, the binding/unbinding process of regulators 
(protein A and B) to the promoter regions are much faster than the transcription and 
translation processes, thus we can assume that these processes get to the equilibrium very 
fast, namely dGAB/dt = 0 and dGBA/dt = 0 in Equation (1), and after combining it with the 
principle of mass balance, we can get 
	 
GAB = B
B +kdB kaB
iGAtot =H
+(B)iGAtot
GA=
kdB kaB
B +kdB kaB
iGAtot =H
−(B)iGAtot
GBA= A
A+kdA kaA
iGBtot =H
+(A)iGBtot
GB =
kdA kaA
A+kdA kaA
iGBtot =H
−(A)iGBtot
 , (2) 
where GAtot  is the total concentration of gene A, while GBtot  is the total concentration of 
gene B. Also, the degradation of mRNA is typically four times faster than that of 
protein[20], so we can further assume that the mRNAs achieve the equilibrium fast, 
 15 
 
namely dmA/dt = 0 and dmB/dt = 0 in Equation (1). Therefore, we can further reduce the 
model to two ODEs to describe the behavior of toggle switch circuit: 
 
dA
dt = ga0
' iH − (B)+ ga' iH + (B)− KA i A
dB
dt = gb0
' iH − (A)+ gb' iH + (A)− KB i B
ga0' = ga0 i gam iGAtot KmA
ga' = ga i gam iGAtot /KmA
gb0' = gb0 i gbm iGBtot KmB
gb' = gb i gbm iGBtot /KmB
, (3) 
Typically, we can use numerical simulations to analyze the temporal or nonlinear 
dynamics of the model. By using the Euler method or Runge-Kutta methods (e.g. ODE 
solver in Matlab), we can solve the ODEs to obtain the temporal trajectories of genes in 
the circuit starting from a certain initial condition. Notably, for a multi-stable system such 
as toggle-switch circuit, different initial conditions will finally end up at different stable 
steady states after a long-time simulation (Figure 1.2b).  
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Figure 1.2 Modeling and analysis of toggle switch circuit. 
(a) Details about toggle switch circuit. Gene A and gene B mutually inhibit the 
expression of each other. The proteins expressed by one gene are able to get into the 
nucleus and transcriptionally inhibit the expression of the other gene by binding to the 
promoter region of that gene. (b) Temporal trajectories of toggle switch circuit starting 
from 100 different initial conditions. There are two different stable states of the system. 
(c) Nullclines for toggle switch circuit, where black nullcline is for dA dt = 0  and red 
nullcline is for dB dt = 0 . Green solid circles denote the stable fixed points, and green 
hollow circles denote the unstable fixed points. (d) One parameter bifurcation of toggle 
switch circuit when gene A is regulated by the external signal (I). In Equation (3), we 
multiply the ga0'  and ga'  by the level of signal (I). Red lines stand for stable states while 
the blue line stands for the unstable states. The orange dots represent the transition 
(bifurcation) points. (e) Two parameters bifurcation when gene A and gene B are both 
Gene	A
Gene	B
A
B
mRNA A
mRNA B
A B
a
b c
d e
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regulated by the external signals. In Equation (3), we multiply the ga0'  and ga'  by the 
level of signal IA, and multiply the gb0'  and gb'  by the level of signal IB. Blue area stands 
for the bi-stability while the white area stands for the mono-stability.  
To thoroughly explore all possible stable steady states of a model, there are 
usually two different methods. First method is an extension of above simulations. Instead 
of running the simulation from one initial condition, we can repeat the long-time 
simulation from thousands of different initial conditions and identify the distinct 
solutions from all the solutions.  As shown in Figure 1.2b, we used this method with 100 
different initial conditions to find the two stable steady states for the toggle switch circuit.  
This method can be applied to very large gene regulatory network, but may miss out 
some rare stable states. For second method, we can calculate the nullclines to find out the 
stable steady states. To use this method, the model should be able to be reduced to two 
ODEs with two variables (x and y) by setting all other ODEs to be zeros and representing 
the other variables as the function of x and/or y. 
	
dx
dt
= f (x , y)
dy
dt
= g(x , y) , (4) 
A x-nullcline is defined as a set of points on the x-y dimensions so that dx/dt = 0. 
Similarly, a y-nullcline is a set of points so that dy/dt = 0. The intersections of these two 
nullclines are the steady states for the whole system. The stability of the steady states can 
be further determined by the linear approximation method[21]. This method can explore 
all possible stable steady states, but the restriction of this method is obvious since it 
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required the possible reduction of the ODEs model. Therefore, this method only works 
well for a small gene circuit, such as toggle switch circuit (Figure 1.2c). This limit of the 
method could be released by using continuation method[22] to calculate the nullclines for 
a high-dimensional model, which are provided by MATCONT[23] package. 
Furthermore, we can apply bifurcation analysis to understand the response of 
circuit stability against the modification of model parameters, which may be caused by 
some external signals.  The bifurcation diagrams can be calculated either by the nullcline 
method at different level of signals or by the continuation method provided by 
MATCONT[23]. Taking toggle switch circuit as an example, if gene A receives a 
constant transcriptional activation by an activator, one-parameter bifurcation diagram 
could show the circuit stability at different level of the signal and indicate the transitions 
between different stable states (Figure 1.2d). We can also calculate two-parameter 
bifurcation phase diagram if both gene A and gene B receive external signals (Figure 
1.2e).   
1.3. Scope of the thesis 
This thesis aims to use quantitative modeling approaches to understand the 
important roles of gene regulatory circuits in controlling biological functions.  The 
remainder of the thesis is organized as follow: 
• Chapter 2 focuses on the understanding of the plastic cell migration phenotypes 
during cancer metastasis via quantitatively modeling the involved core gene 
circuit. 
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• Chapter 3 presents the development of a new computational method, Random 
Circuit Perturbation (RACIPE), unbiasedly model a gene circuit with the absent 
of accurate model parameters. We applied RACIPE on several simple circuits and 
a biological circuit controlling epithelial-to-mesenchymal transition of cancer 
cells. 
• Chapter 4 shows the application of RACIPE method on stem cell circuit, which 
controls the early development of mouse embryo. The predictions by RACIPE 
have good agreements with single cell genomic data.  
• Chapter 5 extended the traditional modeling approached for gene regulatory 
network towards the interaction network among cancer-immune cells.  We used 
the model for the assessment of different therapeutic treatments. 
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Chapter 2 
Towards elucidating the plasticity of cell 
migration phenotypes during cancer 
metastasis 
Cellular plasticity during cancer metastasis is a major clinical challenge. Two key 
cellular plasticity mechanisms - epithelial-to-mesenchymal transition (EMT) and 
mesenchymal-to-amoeboid transition (MAT) – have been widely investigated, yet a 
comprehensive understanding of their underlying mechanisms remain enigmatic. These 
transitions are mediated by two core gene regulatory circuits - miR-200/ZEB/miR-
34/SNAIL circuit for EMT and Rac1/RhoA circuit for MAT.  The regulatory mechanism 
of the EMT circuit is well studied in the previous work of our lab[24]. Here, we focused 
on the study of Rac1/RhoA circuit for MAT by using detailed modeling of GTPase-based 
regulations. We found that the circuit can operate as a three-way switch. We proposed to 
associate the circuit’s three possible states to the amoeboid (A), mesenchymal (M) and 
amoeboid/mesenchymal (A/M) hybrid phenotype. Furthermore, we studied the coupling 
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between these two core circuits by considering the two microRNAs (miR-200 and miR-
34) as external signals to the core MAT circuit. We showed that this coupled circuit 
enables an additional stable steady state that corresponds to the hybrid 
epithelial/mesenchymal (E/M) phenotype. Our model also recapitulated the metastasis-
suppressing role of the microRNAs even in the presence of EMT-inducing signals like 
Hepatocyte Growth Factor (HGF). It also enabled mapping the microRNA levels to the 
transitions among various cell migration phenotypes. These results offer a mechanistic 
understanding for the observed phenotypic transitions among different cell migration 
phenotypes during cancer metastasis. 
2.1. Introduction 
Plasticity of cell migration phenotypes during cancer metastasis 
Metastasis causes more than 90% of cancer-related deaths[25,26]. For 
carcinomas, the most common type of tumors, metastasis begins when some epithelial 
cells from the primary tumor lose their apico-basal polarity and cell-cell adhesion and 
acquire migratory and invasive characteristics, through a process known as Epithelial–to-
Mesenchymal Transition (EMT)[27]. Cells can undergo a partial or complete EMT and 
consequently move collectively or individually while treading through the extra-cellular 
matrix (ECM) and circulating in the bloodstream[28,29]. Upon reaching the secondary 
site, these circulating tumor cells (CTCs) exit the bloodstream and usually undergo a 
Mesenchymal-to-Epithelial Transition (MET) to seed metastases[27]. 
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The collectively migrating cells display both epithelial (E) (cell-cell adhesion) and 
mesenchymal (M) (migration) properties, thereby reflective of the hybrid 
epithelial/mesenchymal (E/M) or partial EMT phenotype; while the individually moving 
cells display at least two distinct phenotypes—mesenchymal (M) and amoeboid (A) (here 
we specifically refer to blebby amoeboid (BA) (Figure 2.1)). Cells of the M phenotype 
are elongated and spindle-shaped with their leading edge characterized by lamellopodia 
(LAM) and/or filopodia (FIL). These cells are able to remodel and even degrade the 
ECM by secreting Matrix Metalloproteinases (MMPs) and therefore act as ‘path 
generators’[29,30]. Conversely, rather than secreting MMPs to remodel the ECM, cells 
that exhibit the A phenotype have higher shape plasticity that enables them to squeeze 
into the gaps in the ECM, thus acting as ‘path finders’[29,30].  In 3D environment, many 
carcinoma cells exhibit Mesenchymal-to-Amoeboid Transition (MAT) and Amoeboid-to-
Mesenchymal Transition (AMT)[31] either spontaneously or in response to external 
signals from the microenvironment[32–34]. Recent studies also have identified several 
individually migratory phenotypes displaying mixed amoeboid and mesenchymal 
characteristics[31,35–37], indicative of a hybrid amoeboid/mesenchymal (A/M) 
phenotype[38]. Such rich plasticity allows cancer cells to adapt to the changing 
microenvironment quickly and facilitates tumor metastasis[27,29,39]. 
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Figure 2.1 Plasticity of cell migration phenotypes in terms of the activities of 
Rac1/RhoA GTPases.  
Background colors correspond to the different level of Rac1-GTP and RhoA-GTP - red 
for high level of Rac1-GTP, green for high level of RhoA-GTP, yellow for high levels of 
both of them, and blue for low levels of both of them.  The activity of the GTPases is 
hypothetically associated with the cell morphology and mobility. The phenotypes are 
depicted as cartoons displaying their corresponding morphological features - epithelial 
phenotype (E), hybrid epithelial-mesenchymal phenotype (E/M), mesenchymal 
phenotype (M), amoeboid phenotype (A), and hybrid amoeboid-mesenchymal phenotype 
(A/M).  M phenotype is characterized with lamellopodia (LAM) and/or filopodia (FIL), 
and A phenotype here is specifically referred to Blebby amoeboid (BA) phenotype, 
which is characterized by blebbing.  The A/M phenotype is considered as a set of 
different morphologies - Lamellipoida with blebs (LB), Lobopodia (LP) and Pseudopodal 
amoeboid (PA).  The blue color is also associated with strong cell-cell adhesion, as 
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observed in E or E/M phenotypes, while the rest colors are associated with single cell 
migration modes. 
 
Core gene regulatory circuits controlling the transition among different migration 
phenotypes 
The choice among the aforementioned phenotypes is operated by the regulations 
of key genes in the context of complex interactions among them.  Our previous 
theoretical work has explained how the core EMT/MET regulatory circuit allows 
transitions between E/M phenotype displaying collective cell migration and the 
mesenchymal (M) phenotype displaying individual migration[40].  The core regulatory 
circuit consists of two interconnected mutually inhibitory circuits between a microRNA 
and a transcription factor (TF) – miR-34/SNAIL and miR-200/ZEB4[28] (Figure 2.2b). 
miR-34/SNAIL acts as an integrator of various external signals for inducing or inhibiting 
EMT, and feeds to miR-200/ZEB that acts as the three-way decision making switch for 
EMT/MET, thereby allowing for three distinct phenotypes – E (high miR-200, low ZEB), 
M (low miR-200, high ZEB) and E/M (medium miR-200, medium ZEB)[40]. 
Amoeboid-to-Mesenchymal Transition (AMT) is operated by the Rac1/RhoA 
regulatory circuit. Rac1 and RhoA belong to the Rho family of small GTPases and act as 
molecular switches by changing between their active (the GTP-bound state) and inactive 
(the GDP-bound state and the GDI-bound state) forms[41]. This switching process is 
regulated by three sets of proteins: GEFs (Guanine Nucleotide Exchange Factors) that 
catalyze the exchange of bound GDP for GTP, thus elevating the levels of the active 
GTPases; GAPs (GTPase-activating proteins) that promote the intrinsic GTP hydrolysis 
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rates, thus reducing the concentration of the active GTPases; and GDIs (Guanine 
nucleotide dissociation inhibitors) that sequester GTPases from the membrane to the 
cytosol and stabilize the proteins by preventing degradation[42]. 
Rac1 and RhoA regulate the phenotypic transitions by controlling the actin 
polymerization and actomyosin contraction[43]. Therefore, the activities of these two 
GTPases have been observed to correlate with cell morphology and motility. For 
example, actomyosin contractility increases in response to the RhoA activation, thus 
resulting in membrane blebbing and facilitating the amoeboid phenotype (A)[35,44,45]. 
On the other hand, the activation of Rac1 results in the formation of focal adhesions and 
actin polymerization, which leads to the formation of lamellopodia and enables a 
mesenchymal phenotype (M)[36,44,46]. Appropriate changes in the relative strengths of 
these two driving forces (actomyosin contraction vs. actin polymerization) allow for not 
only the transitions between the A and M phenotypes, but also might enable the transition 
into/from the hybrid A/M phenotype[31]. These transitions can be triggered by 
extracellular signals such as Hepatocyte Growth Factor/Scatter Factor (HGF/SF) (Figure 
2.2a) through the c-MET pathway[47]. c-MET, the specific tyrosine kinase receptor for 
HGF/SF, is often overexpressed in many carcinomas and correlates with poor patient 
survival[48,49]. The activated c-MET recruits Grb2 (Growth-factor receptor bound 
protein 2) and Gab1 (Grb2 associated binding protein 1) to regulate the activity of both 
RhoA and Rac1 (Table S1.1 and Figure S1.1). It is contradictory that the HGF/SF/c-MET 
pathway has been reported to be able to induce either mesenchymal[50,51] or 
amoeboid[52] phenotype, therefore the underlying mechanisms of the HGF/SF/c-MET 
pathway remain elusive.  
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More importantly, these two regulatory circuits are coupled through the 
microRNAs, miR-200 and miR-34, that inhibit both RhoA as well as Rac1[53–58] 
(Figure 2.2b). Therefore, the analysis of the coupled circuit between them may help us 
understand the operating principles of inter-conversion between collective (E/M) and 
these different individual modes of migration (A, A/M, M). 
 
Figure 2.2 Core gene regulatory circuits for MAT and EMT. 
(a) Rac1/RhoA gene regulatory circuit connected with the c-MET pathway. The 
AMT/MAT is mainly regulated by the Rac1/RhoA regulatory circuit, while RhoA and 
Rac1 are regulated via Grb2 and Gab1 by the c-MET pathway, which receives the 
external signal from HGF/SF. (b) Coupling between EMT and AMT circuit. The core 
EMT/MET regulatory circuit consists of two coupled mutually inhibitory circuits 
(SNAIL/miR-34 and ZEB/miR-200). It can receive external EMT-inducing signals such 
as HGF, and regulate the Rac1/RhoA circuit by inhibiting the translation of RhoA and 
Rac1 via miR-34 and miR-200. A solid arrow denotes activation, and a solid bar denotes 
repression. A solid line represents transcriptional regulation, a dotted line represents 
indirect regulations such as protein-protein interactions, and a dashed line represents 
translational inhibitions by microRNAs. 
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The aim of this study was: 1) to elucidate how Rac1/RhoA circuit regulates the 
AMT/MAT transitions by developing a new framework to model the small GTPase-
based regulation in the context of the Rac1/RhoA circuit. 2) to understand the coupling 
between EMT/MET and AMT/MAT transitions by analyzing the coupling of their core 
regulatory circuits. 
2.2. Methods 
Theoretical framework to model the Small GTPase-based Regulatory Circuit. 
The challenge posed in modeling the small GTPase-based regulatory circuit is to 
incorporate the elaborate transitions between different forms of the GTPases. Typically, a 
GTPase protein can switch among its active (GTP-bound state) and inactive (GDP-bound 
state and GDI-bound state) forms under the regulation of three sets of proteins (GEFs, 
GAPs and GDIs)[41]. To understand these features of the GTPases, we developed the 
theoretical framework for GTPase-based circuit by specifically modeling the detailed 
molecular interactions as illustrated in Figure 2.3.  
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Figure 2.3 Schematic diagram of the regulation of a typical Rho family GTPase 
(denoted as Rho).  
(a) Schematic diagram of the regulation of a typical Rho family GTPase (denoted as 
Rho).  The inactive GDP-bound state of Rho (Rho-GDP) and the active GTP-bound state 
of Rho (Rho-GTP) both bind to the membrane. They can interconvert through the 
regulations of GAPs (at rate J([I1]) ) or GEFs (at rate B([I2 ]) ), which may be activated 
by some external input signals (I1 and I2).  Rho-GDP can be released from the membrane 
by binding to a GDI molecule (at rate gdi _R ) and revert to its membrane-bound state by 
releasing GDI (at rate dgdi _R ).  Rho-GDP and Rho-GTP degrade at rate KR  and KR*  
respectively, while the degradation of Rho-GDI was not considered, because GDI 
binding can stabilize the Rho protein[42]. (b) The RhoA-Rac1 regulatory circuit.  The 
GTP-bound states of RhoA or Rac1 can promote GTP loading of its own, and meanwhile 
activate the GTP hydrolysis of the other. RhoA-GTP is also transcriptionally self-
activated. Grb2 inducees the GTP loading of Rac1, while Gab1 induces that of both Rac1 
and RhoA.  (c) The effective (reduced Rac1/RhoA) circuit.  In terms of Rac1-GTP and 
Rho-GTP, their mutual inhibitions form a non-canonical toggle switch with positive auto-
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regulations. A solid arrow denotes activation, a solid bar indicates repression, and the 
wavy line represents regulation by external signals.  The solid double line represents the 
GTP loading or hydrolysis process while the dashed double one represents the binding or 
unbinding process of GDI molecules. The dotted lines indicate the indirect regulations on 
GTP loading or hydrolysis process via GEFs or GAPs.  (d) Typical values of the B and 
the J functions with respect to the concentrations of the GTPases.  The B and J functions 
represent the GTP loading and hydrolysis rates of both Rac1 and RhoA respectively. 
Both functions increase with the level of GTP-bound Rac1 and RhoA. 
 
Here, we show in detail how we derived the model from binding and unbinding 
reactions at molecular level.  We first focused on the process of cycling for a typical Rho 
GTPase (denoted as Rho) (Figure 2.3).  The reactions for this process are 
 
where Rho-DNA represents the gene encoding this Rho GTPase, and Rho-GTP, Rho-
GDP and Rho-GDI stand for Rho GTPase bound to GTP, GDP and GDI respectively.  
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
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Reaction (1) is for the production of Rho GTPase. Reaction (2) represents our assumption 
that Rho protein first binds to GDP instead of GTP when it is translated.  Reaction (3) is 
the reversible binding and releasing of GDI to Rho protein.  Reaction (4) is the intrinsic 
GTP loading process and Reaction (5) is the activated GTP loading by GEFs.  Reaction 
(6) is the intrinsic GTP hydrolysis process and Reaction (7) is the activated GTP 
hydrolysis by GAPs.  At first, we did not consider the signals (I1, I2) that can regulate 
some GEFs or GAPs, thus [GEF] and [GAP] involved in the regulations of the GTP 
loading and hydrolysis are constant.  Reaction (8) and (9) stand for the degradations of 
Rho-GDP and Rho-GTP, respectively.  Since GDI is reported to stabilize Rho GTPases, 
we do not consider the degradation of Rho-GDI [42].  	kn  (n = 1,2 …) is the reaction rate 
constant for each reaction.  The model for these reactions can be given as: 
, (5) 
where 	R f  and 	Rg  represent the Rho GTPase without binding to any molecules and the 
gene encoding Rho GTPase respectively.  In order to simplify the equations, we proposed 
three assumptions here: 
d[R f ]
dt = k1 •[R
g ]− k2 •[GDP]•[R f ]
d[RI ]
dt = k3 •[GDI ]•[R]− k4 •[R
I ]
d[R]
dt = k2 •[GDP]•[R
f ]+ k4 •[RI ]+ k7 •[R*]+ k8 •[GAP]•[R*]
− k3 •[GDI ]•[R]− k5 •[GTP]•[R]− k6 •[GTP]•[GEF]•[R]− k9 •[R]
d[R*]
dt = k5 •[GTP]•[R]+ k6 •[GTP]•[GEF]•[R]− k7 •[R
*]− k8 •[GAP]•[R*]− k10 •[R*]
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1) The levels of GDI, GTP and GDP are assumed to be constant, thus we can reduce 
some parameters by integrating the number of [GDI], [GTP] and [GDP] into the 
reaction rate constants (such as k '3 = k3 •[GDI ] ). 
2) The levels of each GEF and GAP are constant except the ones activated by the 
signals (I1, I2) we discussed later.  Therefore, we can also integrate them into the 
reaction rate constants (such as  k8
' = k8 i [GAP] ). 
3) We assume that GDP is present in abundant amount. Rho can bind to GDP to 
produce inactive GDP-bound form (Rho-GDP) as soon as Rho protein is produced.  
Thus the  equals to 0.  
With these assumptions, the model can be converted to: 
, (6)
 
where . k '3  and k4  are binding and releasing rate constant for GDI 
respectively. k7  and k5'  are intrinsic GTP hydrolysis and loading rate constants 
respectively, while k '8  and k '6  are activated GTP hydrolysis and loading rate constants 
due to GAPs and GEFs respectively.  
Now we consider signals (I1, I2) in the GBC model, as shown in Figure 2.3.  
These signals can regulate the activity level of Rho GTPase through GEFs or GAPs. 
d[R f ]
dt
d[RI ]
dt = k3
' •[R]− k4 •[RI ]
d[R]
dt =G + k4 •[R
I ]+ (k7 + k8' )•[R*]
− k3' •[R]− (k5' + k6' )•[R]− k9 •[R]
d[R*]
dt = (k5
' + k6' )•[R]− (k7 + k8' )•[R*]− k10 •[R*]
G = k1 •[Rg ]
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These signals can be external, such as Grb2 and Gab1 from c-Met pathway or other Rho 
GTPases like RhoA that can promotes the GTP hydrolysis of Rac1-GTP by activating its 
relevant GAPs; or internal such as the auto-regulations for Rac1 and RhoA.  Therefore, 
the total GTP hydrolysis and loading rate constants (described by B and J functions 
respectively as given below) can be divided into three parts: the intrinsic ones, the 
activated ones by the GAPs and GEFs that are independent of the regulations of signals, 
and the activated ones by the GAPs and GEFs that depend on the signals.  The first two 
parts, which can be grouped as basal GTP hydrolysis and loading rate constants, are both 
constant.  Yet, the latter activated rate constants ( kA ) are related with the level of signals 
(I) and can be described by Hill function as:  
H + ([I ]) = [I ]
n
Kdn + [I ]n
= kAkAmax
, (7) 
where kAmax  is the maximum activated rate constant.  Kd  is the dissociation constant 
which represents the threshold at which the activated rate ( kA ) is at half maximum value.  
n is the Hill coefficient determining the steepness of the function. Thus, the activated 
GTP hydrolysis and loading rate constants by signal I1 and I2 can be expressed as 
 kA
GAPmax iH + ([I1])  and  kA
GEFmax iH + ([I2 ]) , respectively. Considering these signals into the 
model above (Equation (6)), the signals-driven model can be given as: 
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d[RI ]
dt = k3
' •[R]− k4 •[RI ]
d[R]
dt = G + k4 •[R
I ]+ (k7 + k8'' + kAGAPmax iH + ([I1]))•[R*]
− k3' •[R]− (k5' + k6'' + kAGEFmax iH + ([I2 ]))•[R]− k9 •[R]
d[R*]
dt = (k5
' + k6'' + kAGEFmax iH + ([I2 ]))•[R]− (k7 + k8'' + kAGAPmax iH + ([I1]))•[R*]− k10 •[R*]
, (8) 
where we use k8''  and k6''  to represent the signal-independent activated rate constants for 
GTP hydrolysis and loading, respectively. To simplify Equation (8), we defined two 
functions: one is B function standing for total GTP loading rate constant and the other is J 
function standing for total GTP hydrolysis rate constant. Both of them depend on the 
signals.  
 
B([I2 ]) = k5' + k6'' + kAGEFmax iH + ([I2 ])
J([I1]) = k7 + k8'' + kAGAPmax iH + ([I1])
, (9) 
Integrating Equation (8) and (9), we can get a generic deterministic model 
(Equation (10)) to describe the transition among GDI state, GDP state and GTP state of a 
typical Rho GTPase (Figure 2.3).   
d[RI ]
dt = k3
' •[R]− k4 •[RI ]
d[R]
dt = G + k4 •[R
I ]+ J([I1])•[R*]− k3' •[R]− B([I2 ])•[R]− k9 •[R]
d[R*]
dt = B([I2 ])•[R]− J([I1])•[R
*]− k10 •[R*]
, (10) 
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Mathematical Model of Rac1/RhoA regulatory circuit 
We utilized the approach to investigate the dynamics of the core Rac1/RhoA 
regulatory circuit, as shown in Figure 2.3.  The deterministic dynamics of the circuit 
could be modeled by a set of six chemical rate equations presented as below: 
d[RcI ]
dt = gdi _Rc •[Rc ]− dgdi _Rc •[Rc
I ]
d[Rc ]
dt = gRc + JRc ([Rh
*])•[Rc*]+ dgdi _Rc •[RcI ]
− gdi _Rc •[Rc ]− BRc ([Rc*])•[Rc ]− IRc •[Rc ]− KRc •[Rc ]
d[Rc*]
dt = BRc ([Rc
*])•[Rc ]+ IRc •[Rc ]− JRc ([Rh*])•[Rc*]− KRc* •[Rc
*]
d[RhI ]
dt = gdi _Rh •[Rh ]− dgdi _Rh •[Rh
I ]
d[Rh ]
dt = (gRh + gRhA •H
+ ([Rh*]))+ JRh ([Rc*])•[Rh*]+ dgdi _Rh •[RhI ]
− gdi _Rh •[Rh ]− BRh ([Rh*])•[Rh ]− IRh •[Rh ]− KRh •[Rh ]
d[Rh*]
dt = BRh ([Rh
*])•[Rh ]+ IRh •[Rh ]− JRh ([Rc*])•[Rh*]− KRh* •[Rh
*]
, (11) 
where 
 
BRc ([Rc*]) = gtp_Rci + gtp_RcB + gtp_RcA iH + ([Rc*])
JRc ([Rh*]) = dgtp_Rci + dgtp_RcB + dgtp_RcA iH + ([Rh*])
IRc = (gtp_RcI1 iH + ([I1])+ gtp_RcI2 iH + ([I2 ]))
BRh ([Rh*]) = gtp_Rhi + gtp_RhB + gtp_RhA iH + ([Rh*])
JRh ([Rc*]) = dgtp_Rhi + dgtp_RhB + dgtp_RhA iH + ([Rc*])
IRh = gtp_RhI2 iH + ([I2 ]) , (12) 
Here, RcI , Rc , Rc*  stand for Rac1 in GDI-bound state, GDP-bound state, and 
GTP-bound state, respectively, RhI , Rh , Rh* stand for the different states for RhoA.  B 
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function is the total GTP loading rate constant, which contains the intrinsic GTP loading 
rate constant ( gtp_Rci  and gtp_Rhi ), the activated GTP loading rate constant (
gtp_RcB  and gtp_RhB ) by GEFs not involved in the auto-regulations and the activated 
GTP loading rate constant ( gtp_RcA  and gtp_RhA ) resulting from auto-regulations. J 
function is the total GTP hydrolysis rate constant, which also contains the intrinsic GTP 
hydrolysis rate constant (dgtp_Rci  and dgtp_Rhi ), the activated GTP hydrolysis rate 
constant ( dgtp_RcB  and dgtp_RhB ) by GAPs not involved in the mutually regulations 
and the activated GTP hydrolysis rate constant (dgtp_RcA  and dgtp_RhA ) resulting 
from the mutual regulations.  gdi _Rc , dgdi _Rc , gdi _Rh , and dgdi _Rh  are the binding 
and unbinding rate constants for GDI.  There are two external signals here: Grb2 (I1) and 
Gab1 (I2). IRc  is the activated GTP loading rate constant for Rac1 by both Grb2 (
gtp_RcI1 ) and Gab1 ( gtp_RcI2 ) signals, and IRh  is the activated GTP loading rate 
constant for RhoA by Gab1 ( gtp_RhI2 ) signal. 
As the GTP-bound states of RhoA and Rac1 are the only active regulators of cell 
migration, we focus on the concentration of Rac1-GTP and RhoA-GTP and reduce the 
equations to two coupled equations for  and .  Assuming the total expression of 
Rac1 and RhoA reach equilibrium with their degradation, therefore 
d[Rctot ]
dt =
d[RcI ]
dt +
d[Rc ]
dt +
d[Rc*]
dt = 0
d[Rhtot ]
dt =
d[RhI ]
dt +
d[Rh ]
dt +
d[Rh*]
dt = 0 , (13) 
Rc* Rh*
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Then we can get   
 
gRc − KRc i [Rc ]− KRc* i [Rc
*]= 0
(gRh + gRhA iH + ([Rh*]))− KRh i [Rh ]− KRh* i [Rh
*]= 0
, (14)
 
If  ( ) is same as  ( ), and  can be expressed as a function of  
and : 
 
[Rc ]=
gRc
KRc*
− [Rc*]
[Rh ]=
(gRh + gRhA iH + ([Rh*]))
KRh*
− [Rh*]
, (15)
 
By substituting these expressions back into Equation (11), we simplified the original 
model to four equations as below: 
d[RcI ]
dt = gdi_Rc •[Rc ]− dgdi_Rc •[Rc
I ]
d[Rc*]
dt =
gRc
KRc*
• (B([Rc*])+ IRc )− (B([Rc*])+ J([Rh*])+ IRc + KRc* )•[Rc
*]
d[RhI ]
dt = gdi_Rh •[Rh ]− dgdi_Rh •[Rh
I ]
d[Rh*]
dt =
(gRh + gRhA •H + ([Rh*]))
KRh*
• (B([Rh*])+ IRh )− (B([Rh*])+ J([Rc*])+ IRh + KRh* )•[Rh
*]
, (16)
 
 
Since only active Rac1 and RhoA cause downstream reactions, we can focus on the two-
coupled equations with variable  and  as an effective model to approximate the 
detail model.  
KRc KRh KRc* KRh* [Rc ] [Rh ] [Rc
*]
[Rh*]
[Rc*] [Rh*]
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d[Rc*]
dt =
gRc
KRc*
• (B([Rc*])+ IRc )− (B([Rc*])+ J([Rh*])+ IRc + KRc* )•[Rc
*]
d[Rh*]
dt =
(gRh + gRhA •H + ([Rh*]))
KRh*
• (B([Rh*])+ IRh )− (B([Rh*])+ J([Rc*])+ IRh + KRh* )•[Rh
*]
, (17) 
 where the first part such as 
gRc
KRc*
• (B([Rc*])+ IRc )  is the effective production rate, while 
the second part such as (B([Rc*])+ J([Rh*])+ IRc + KRc* )•[Rc
*]  is the effective degradation 
part.  Notice that the self-activation on GTP loading process can activate both the 
effective production rate and the effective degradation rate. These simplified equations 
describe the interaction between active Rac1 and RhoA more clearly, and can be used to 
determine the stability of Rac1/RhoA regulatory circuit. The effective model was used 
for stability and bifurcation analysis while the detailed model was used for the 
dynamic simulations.  
Mathematical Model of the Coupled Circuit 
The EMT regulatory circuit regulates the Rac1/RhoA circuit via miR-34 and miR-
200 (Figure 2.2b). Here, we use an effective (reduced) model (Figure 2.8a) to represent 
the association between these two circuits – miR-34/SNAIL/miR-200/ZEB (the core 
circuit for EMT/MET) and RhoA/Rac1 (the core circuit for AMT/MAT) (Figure 2.2b). 
As shown in Figure 2.8a, the effect of EMT regulatory circuit is treated as two external 
signals to the Rac1/RhoA circuit, where (µ1) represents the inhibition on RhoA by either 
of the two microRNAs (miR-34 or miR-200) while (µ2) represents a similar inhibition on 
Rac1. 
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We have previously developed the theoretical framework for microRNA-based 
regulatory circuit like miR-34/SNAIL and miR-200/ZEB. Here, we use both these 
frameworks to study the dynamics of the coupled effective circuit. The deterministic 
dynamics of the circuit can be modeled by two rate equations as below:
  
d[Rc*]
dt =
gRc
KRc*
PRc ([µ2 ])(BRc ([Rc*])+ IRc )− (BRc ([Rc*])+ JRc* ([Rh
*])+ IRc + KRc* )[Rc
*]
d[Rh*]
dt =
(gRh + gRhAHRh*
+ ([Rh*]))
KRh*
PRh ([µ1])(BRh ([Rh*])+ IRh )− (BRh ([Rh*])+ JRh* ([Rc
*])+ IRh + KRh* )[Rh
*]
,   (18) 
where 	RC* represents the active Rac1 (Rac1-GTP), and 	Rh*  represents the active RhoA 
(RhoA-GTP). is the production rate for Rac1, and  are basal and excitatory 
production rates for RhoA respectively.  and  are the corresponding degradation 
rates for Rac1 and RhoA.  and  represent two external signals that drive the GTP 
hydrolysis/loading process of the Rac1/RhoA circuit, such as Grb2 and Gab1 in c-MET 
signaling, whose effects have been analyzed in our previous work[38]. The Hill function 
HRh
+ ([Rh*])  represents the transcriptional self-activation of RhoA. B and J functions are 
defined to represent the total GTP loading and hydrolysis rates including the intrinsic 
ones for RhoA and Rac1 and also the activated ones by GEFs or GAPs (See above)[38].  
The inhibition effect of microRNAs is described by the function  whose value 
ranges from 0 to 1 – 0 denotes a strong silencing effect, and 1 denotes no effect[11]. 
 
 
gRc gRh gRhA
KRc* KRh*
IRc IRh
P([µ])
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Parameters estimation 
The values of most of the parameters considered in our model are not known 
exactly, but we hereby explain how we estimated the parameter values. The detail 
parameters are summarized in Table S1.2. 
The degradation rates are selected due to the half-lives of each molecule from 
experiments.  The half-life for Rac1 is about 2 hours[59], while the half-life of RhoA is 
about 5 hours[60].  Thus, we set their degradation rate to be 0.1 h-1.  
The total amount of Rac1 and RhoA protein are respectively 82-123 ng/106 cells 
and 38-75 ng/106 cells. These values are averaged from two epithelial cell lines, MDCK 
and ECV[61]. MDCK and ECV have similar amount of Rac1 and RhoA, where MDCK 
cells have about 56±14 ng/106 cells RhoA and 124±27 ng/106 cells Rac1 while ECV304 
cells have about 50±15 ng/106 cells RhoA and 82±14 ng/106 cells Rac1. We used the 
average values of them here to ensure validity of our parameters.  Since the molecular 
weight of these small G-proteins is about 22 kDa (3.65×10-11ng), the molecular numbers 
of Rac1 and RhoA per cell are 2.25×106 -3.37×106 molecules and 1.04×106-2.05×106 
molecules, respectively [61]. Thus, we set the basal transcriptional rates for Rac1 ( ) 
and RhoA ( ) to 3.40×105 molecules/hour and 1.60×105 molecules/hour. Also, due to 
the transcriptional self-activation by RhoA, we assume that for the cells in amoeboid 
state, they can have high expression of RhoA similar to that of Rac1 in cells with 
mesenchymal morphology.  Thus, the activated transcriptional rate ( ) for RhoA is 
also set to 3.40×105 molecules/hour.  
gRc
gRh
gRhA
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GTPases have a slow intrinsic GTP hydrolysis and loading ability.  Experiments 
show that the intrinsic GTP hydrolysis rates for Rac1 and RhoA are about 6.6 h-1 and 
1.32 h-1, respectively[62,63].  GAPs can accelerate the hydrolysis rates by 5 to 4000 
folds[63,64].  Thus we set dgtp_RcB  to 110 h-1 and dgtp_RcA  to 200 h
-1 for Rac1, and 
set dgtp_RhB  to 311 h-1 and dgtp_RhA  to 88 h-1 for RhoA. For GTP loading process, 
the intrinsic rates are both about 0.54 h-1 for active Rac1 and RhoA[65]. Experiments 
show that GEFs can accelerate the rates by 3.5 to 1000 folds[65–67].  Similarly, we set 
gtp_RcB  to 20 h-1 and gtp_RcA  to 530 h-1 for Rac1, and set gtp_RhB  to 110 h-1 and 
gtp_RhA  to 196 h-1 for RhoA.  Also, we take 2000 h-1 for both GDI binding ( gdi_Rc  
and gdi_Rh ) and releasing ( dgdi_Rc  and dgdi_Rh ) rate constants because Rac1 was 
observed to stay on the membrane for 2s[68].   
In addition, since regulations such as the auto-regulations and the mutual 
inhibitions between Rac1-GTP and RhoA-GTP are indirect, we considered Hill function 
coefficients to be 4.  Also, for Grb2 and Gab1 signals, we integrated them in the model 
using hill functions. Since their concentration is suggested to be about 1µM[69], namely 
about 1×106 molecules by considering the typical diameter of a eukaryotic cell to be 
10µm, we set their corresponding hill function thresholds (Tsd _ gtp_RcI1 , 
Tsd _ gtp_RhI2  and Tsd _ gtp_RcI2 ) to 5×10
5 molecules. Since we integrated these 
signals into our model by hill functions, it is worthy to note that it is the ratio between the 
concentration of Gab1 and Grb2 to their thresholds instead of their absolute concentration 
values that actually affects the effects of these signals. Thus, the absolute values we used 
for Gab1 and Grb2 signals can always be adopted by modifying the threshold values.  
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miR-34a could either suppress the transcription of RhoA by targeting its 
transcriptional complexes or directly Rac1[53,57]. Also, the bioinformatics tool, 
TargetScan[70–73], indicates the possible inhibition of miR-200 on Rac1 and RhoA, 
which is consistent with several experimental results[54–56]. To simplify these 
connections between miR-34/miR-200 and Rac1/RhoA, we here consider both of them 
directly inhibit the expression of Rac1 and RhoA, and group their inhibitions on RhoA to 
be ‘µ1 ’ while the ones on Rac1 to be ‘µ2 ’. The effective binding sites for µ1  and µ2  on 
both RhoA and Rac1 is set to 2, and we use the same parameters for the P functions as we 
used before[40]. Therefore, the protein expressions of target proteins of these 
microRNAs come down to 30% of the control case (no inhibition by microRNAs).  The 
thresholds for P function is set to be 10, 000 molecules, but it should be noted that it is 
the ratio between the concentration of microRNAs to their threshold levels instead of 
their absolute concentration values that actually governs the effects of these signals. 
2.3. The three-way switch operation of Rac1/RhoA GTPase-based 
circuit controlling amoeboid-hybrid-mesenchymal transition 
The Rac1/RhoA Circuit as a Three-way Switch 
We started by analyzing the circuit dynamics in the absence of external signals 
(Grb2 = 0 and Gab1 = 0). As illustrated by a typical phase-plane diagram in Figure 2.4a, 
Rac1/RhoA regulatory circuit can act as a three-way switch among the following three 
states: (high active RhoA/low active Rac1), (low active RhoA/high active Rac1), and 
(both high active RhoA and Rac1), which we denote as (1, 0), (0+, 1) and (1, 1) 
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respectively. According to the experimental observations[35,44–46,74], we associate the 
states (1, 0) and (0+, 1) with the amoeboid (A) and mesenchymal (M) phenotypes. Again, 
we used “0+” to denote some minimal level of active RhoA present in the rear end of 
mesenchymal cells and required for their individual migration[75]. Furthermore, we 
proposed to associate the (1, 1) state with the amoeboid-mesenchymal (A/M) hybrid 
phenotype that has been suggested in some recent experiments both for cancer cells and 
normal cells during early embryonic development[31,35,37,76–80]. Although these 
experiments lack quantitative measurement of the activity of Rac1 and RhoA, the mixed 
morphologies of these cells share the traits of both amoeboid and mesenchymal 
phenotypes. These properties may be indicative of relative high levels of both active 
RhoA and Rac1. Yet, it is clear that a direct measurement of these proteins is necessary to 
establish a direct association between these phenotypes and the model predicted hybrid 
phenotype. 
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Figure 2.4 Rac1/RhoA circuit as a three-way switch. 
(a) Dynamical system characteristics of the Rac1/RhoA regulatory circuit. The plot 
shows the nullclines and possible steady states corresponding to Equation (17). Without 
any external signal (Grb2 = 0, Gab1 = 0), the circuit can be tristable. Red nullcline is for 
d[Rc*] / dt = 0  and black nullcline is for d[Rh*] / dt = 0 . Green solid circles denote the 
stable fixed points, and green hollow circles denote the unstable fixed points. Each stable 
point can be associated with a cell phenotype, depicted as a cartoon beside them. (b) 
Bifurcation of RhoA-GTP protein levels in response to an external signal regulating the 
GTP loading rates of RhoA.  The signal can either increase (activation) or decrease 
(inhibition) the GTP loading rate. The response to activation/inhibition is shown on the 
right/left side of the bifurcation respectively. The red solid lines indicate stable states and 
the blue dashed lines indicate unstable states.  The bifurcation illustrates the possible 
coexistence (for some range of the signal) of four states: (i) the (1, 0) state with high 
RhoA-GTP and low Rac1-GTP, which corresponds to A phenotype; (ii) the (0+, 1), 
which corresponds to M phenotype; (iii) the (1, 1), which correspond to A/M phenotype; 
(iv) the (0, 0) state, which corresponds to E/M phenotype. The corresponding bifurcation 
of Rac1-GTP protein levels is showed in Figure S1.2. Co-existence of different 
phenotypes is associated with a multistable phase, highlighted by different background 
colors (see legend at the bottom). Starting from the (0+, 1) state (M phenotype, at bottom 
left part of the red curve), the system stays in the M phenotype when the inhibition signal 
is reduced; further switching the inhibition signal to an increasing activation signal leads 
the system to undergo a transition to the (1, 0) state (A phenotype, at top right part of the 
red curve). The transition is indicated by the dashed upward arrow at the boundary of the 
phase {A, M} and {A}.  Similarly, increasing the inhibition signal can induce the 
transition from the (1, 0) state (A phenotype) back to the (0+, 1) state (M phenotype), as 
indicated by the downward arrow at the boundary of the phase {M} and {A, M}.  Besides, 
cells may switch to the A/M or E/M phenotype due to noises in gene expression. 
 
The Switch Response to External Activation and Inhibition Signals 
Next, we analyzed the response of the Rac1/RhoA circuit to an external input 
signal that drives the circuit through either Rac1 or RhoA. We modeled that the signal 
directly increases or decreases the basal GTP loading rates. In Figure 2.4a, we show the 
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response to the external signal that affects the RhoA loading rate by the effective model. 
When the signal activates the basal GTP loading rate for RhoA, it gives rise to the 
coexistence of the diverse phenotypes A, M, A/M, all of which correspond to solitary 
movement. However, when the signal inhibits the loading rate, it also gives rise to 
collective cell migration of the E/M hybrid phenotype. As is also evident from Figure 
2.4b, a high activation of the GTP loading rate leads the cell to a monostable phase {A} 
in which only amoeboid phenotype (A) exists, whereas low levels of GTP loading rate 
correspond to the monostable phase {M} in which only the mesenchymal phenotype (M) 
exists. Our model is consistent with the experiments showing that cells with 
constitutively active RhoA are associated with amoeboid (A) or blebby amoeboid (BA) 
phenotype[81]; while cells with dominant negative RhoA usually exhibit a mesenchymal 
(M) phenotype[32]. It also predicted that, when the external signal acts only on RhoA, 
the induced transitions between A and M phenotypes are much easier than the transitions 
from A or M phenotype to A/M or E/M phenotype. This may explain why these hybrid 
phenotypes, A/M and E/M, were rarely observed during AMT in most of the 
experiments[36]. 
The Switch Response to Input Signals from Grb2 and Gab1 
As was mentioned earlier, Grb2 activates only Rac1, and Gab1 activates both 
Rac1 and RhoA. To understand the circuit response to these regulations, we first 
investigated the response of the circuit dynamics to either Grb2 or Gab1 (in terms of the 
corresponding bifurcation diagram) when they act individually. We found that when 
Grb2 level is increased, the cells adopt a mesenchymal (M) phenotype; whereas Gab1 
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induces the cell to adopt an amoeboid (A) phenotype (Figure S1.3). However, further 
high Gab1 signal can induce the cell to adopt the amoeboid/mesenchymal (A/M) 
phenotype since Gab1 can activate both Rac1 and RhoA (Figure S1.3). 
Next, to understand the combined effect of Grb2 and Gab1, we constructed the 
two-parameter bifurcation diagram, as shown in (Figure 2.5). Each phase corresponds to 
a particular situation in which one or several different phenotypes can coexist. More 
specifically, the possible phases are: 1. Phases with only one phenotype – {A}, {M} and 
{A/M}. 2. Phases in which two phenotypes can coexist – {A, A/M}, {M, A/M} and {A, 
M}. 3. A phase in which all three phenotypes coexistence – {A, M, A/M}. The detailed 
information of the various phases indicates the plasticity of cell migration as driven by 
different combinations of Grb2 and Gab1 signals. Depending on how Grb2 and Gab1 
increase temporally, the cells follow different trajectories in this phase diagram and thus 
go through different phenotypic transitions as is illustrated in Figure 2.5. Understanding 
the circuit response to input signal from Grb2 and Gab1 provides crucial clues regarding 
the pleiotropic effects of the c-MET pathway in promoting either the amoeboid or 
mesenchymal mode of migration and also transitions between them (AMT and MAT). 
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Figure 2.5 The circuit response to input signals from Grb2 and Gab1.  
(a) Two-parameter bifurcation phase diagram. Two input signals Grb2 (x-axis) and Gab1 
(y-axis) are selected as the two bifurcation parameters. As explained in the text, each 
phase corresponds to a different combination of coexisting phenotypes (Phase plane 
diagrams for each phase are showed in Figure S1.4).  For example, the orange area is the 
phase {M, A/M}, which means that cells in this phase can belong to either the M or the 
A/M phenotype.  The colors used for different phases are explained by the legend in 
Figure 2.4.  (b) One-parameter bifurcation diagram for the circuit driven by Gab1 when 
the Grb2 level is fixed to be 8×105 molecules. The corresponding trajectory in the two-
parameter bifurcation phase diagram (Panel a) is shown by a purple line. The transitions 
between the M and A/M phenotypes are illustrated by the dashed upward and downward 
arrows.  (c) One-parameter bifurcation diagram for the circuit driven by Grb2 when the 
Gab1 level is fixed to be 2.5×105 molecules. The corresponding trajectory in the two-
parameter bifurcation phase diagram (Panel a) is shown as a brown line. The transitions 
between the A and A/M phenotypes are illustrated by the upward and downward arrows. 
 
 
a b
c
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Phenotypic Transitions Driven by the c-MET pathway 
To better understand the phenotypic transitions, we investigated the response 
dynamics of the Rac1/RhoA circuit when the input signals, Gab1 and Grb2, change in 
time. To recapitulate the possible response of the circuit to HGF/SF treatment, we chose 
time dependent functions for the levels of the Gab1 and Grb2 to mimic the cells’ 
response to HGF/SF treatment (Figure 2.6). The HGF/SF signal leads to increase c-MET 
phosphorylation, which in turn regulates Gab1 and Grb2 together with Met-Induced 
Mitochondrial Protein (Mimp) in a form of two coupled feed-forward loops (FFLs) as is 
shown in Figure 2.2[82,83]. Hence, the levels of Gab1 and Grb2 were modeled as two 
pulse signals with a time delay as shown in Figure 2.6[84]. 
The form of the pulses is similar to that of a typical response of a FFL. Time 
delay is incorporated to reflect the effect of the feed-forward like coupling of Grb2 and 
Gab1 to c-MET (Gab1 responses ahead of Grb2). The simulated treatment starts with cell 
in the amoeboid (A) phenotype at the left bottom corner (shown as blue star) in the phase 
diagram shown in Figure 2.6. The cell stays in this phenotype when Gab1 is increased 
(Figure 2.6) but makes a transition into the hybrid (A/M) phenotype after Gab1 decreases 
and Grb2 increases, thus the activity of Rac1 increases while that of RhoA remains 
almost unchanged. Finally, after Grb2 also decreases, the cell goes through another 
transition from the hybrid (A/M) phenotype into the mesenchymal (M) one. The results 
illustrate how c-MET pathway can regulate the cells to switch between different 
migrating phenotypes. In Figure 2.6, we demonstrated the result for the same simulation 
but for a cell with different circuit parameters (a cell in which Gab1 activation of Rac1 
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GTP loading is stronger than its activation of the RhoA loading). In this case, the increase 
of Gab1 signal induces the cell to transit into the hybrid A/M phenotype instead of 
maintaining it in A phenotype. The different signal-response behaviors of these two 
simulations support that different cell lines (cells with different parameters) may respond 
differently to the regulatory signals Gab1 and Grb2. 
The aforementioned results are consistent with experimental results and help to 
explain several experimental observations. In particular, c-MET pathway is reported to 
induce both the mesenchymal phenotype for several non-cancer and cancer 
cells[50,51,85] and the amoeboid phenotype for some breast cancer cells[52]. Other 
experiments show that Grb2 is essential for TGF-beta to induce a mesenchymal 
phenotype for some cancer cells[86] and Gab1 can stimulate AMT by forming dorsal 
ruffles through its adaptor Nck[87]. These observations have been well captured by our 
simulations showing that mesenchymal phenotype can be induced either by Grb2 in one 
cell line or by Gab1 in another cell line with different parameters (Figure 2.6). 
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Figure 2.6 Temporal dynamics of the cells to HGF/SF treatment.  
(a) The time dependent Gab1 and the Grb2 signals that imitate the effect of HGF/SF 
treatment, as explained in the text.  (b) Trajectory of the cell response projected on the 
phase diagram. The results are for a cell in which Gab1 activation of RhoA GTP loading 
is stronger than its activation of the Rac1 GTP loading (The parameters are
gtp_RhI2 = 240h−1  and gtp_RcI2 = 90h−1  respectively).  The solid line is the trajectory, 
and both the arrows on the line and the color gradient of the line (from black to white) 
indicate the time evolution. The blue star marks the initial condition, the green star marks 
the peak of Gab1 expression and the pink star marks the peak of Grb2 expression.  (c) 
a
b
d
c
e
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Time dynamics of the expression levels of Rac1-GTP (Red) and RhoA-GTP (Black) in 
response to the signals, Gab1 and Grb2. The different phenotypes during the transition 
are highlighted by different background colors, where green, yellow and red areas stand 
for A, A/M and M phenotype respectively.  (d) Similar to (b) but for a cell in which Gab1 
activation of Rac1 loading is stronger than its activation of the RhoA loading (The 
parameters are gtp_RcI2 = 1000h−1  and gtp_RhI2 = 240h−1  respectively).  (e) Similar to 
(c) but for the case shown in (d). 
 
Phenotype Distribution 
Cells belonging to the same cell line often display non-heritable phenotypic 
variability[88,89]. Such variability can originate, for example, from local differences in 
the microenvironment (such as ECM rigidity) leading to differences in the circuit 
parameters of the individual cells. We have shown earlier that cells with different circuit 
parameters can respond in a different way to the input signals. Hence, we expect to see a 
distribution of phenotype for given input signals. As a first step to assess the expected 
nature of the population level distribution, we extended our simulations to a population of 
5,000 cells, each with different circuit parameters. More specifically, the cells that 
compose the populations have ±5% variations from the original parameters. 
In Figure 2.7, we showed the percentages of cells that can be in one of the three 
different possible phenotypes, (A, A/M and M), for different levels of the input signals. 
We found that for high Grb2 or high Gab1 signal, a significant percentage of cells adopt 
the A/M phenotype (Figure 2.7). This result, which is obtained due to a weak robustness 
(high sensitivity to the circuit parameters), indicates that cells under high Grb2 or Gab1 
signal are still sensitive to the conditions of their microenvironment. However, both high 
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Grb2 and Gab1 signals can result in more cells being in the hybrid A/M phenotype 
(Figure 2.7).  
 
Figure 2.7 Phenotype distribution of a population of cells.  
(a) Phenotype distribution of a population of cells driven by Grb2 signal (Gab1 = 0). The 
cell parameters are randomly distributed over ±5% relative to the original parameters. 
a
b
c
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The y-axis denotes the percentage of cells corresponding to a specific phenotype. The 
color of each line represents a phenotype. Under the stimulation of different level of 
Grb2, a population of cells has different phenotype distribution (percentage of cells 
showed in y-axis). For each point, the original phase of the cells depends on the level of 
Grb2 signal. Note that due to the co-existence of different phenotypes in one phase (e.g. 
in both the phases {A, M, A/M} and {A, M}; A and M phenotypes are present), the sum 
of the total percentages for one particular signal level can be more than 100%.  For 
example, the initial phase with neither Gab1 nor Grb2 signals is {A, A/M, M}. About 
100% cells can be A or M phenotype, and about 36% cells can be A/M. Some of these 
cells were in some multistable regime comprised of one or more of the phenotypes of A, 
M and A/M. (b) Phenotype distribution driven by Gab1 signal (Grb2 = 0). (c) Phenotype 
distribution under Grb2 and Gab1 regulations. The color of each bar, corresponding to 
the color definition above represents the initial cell phase. When both Grb2 and Gab1 
signals are high, the cells are highly likely to be maintained in hybrid A/M phenotype. 
 
2.4. Modeling the Transitions between Collective and Solitary 
Migration Phenotypes in Cancer Metastasis 
The additional stable steady state corresponding to collective migration phenotype 
In the first study, we found that the standalone Rac1/RhoA circuit (i.e. without 
any input from miR-34 and miR-200) can act as a three-way switch enabling these three 
states: (a) (high active RhoA/low active Rac1), denoted by (1, 0), (b) (low active 
RhoA/high active Rac1) denoted by (0+, 1) and (c) (both high active RhoA and Rac1) 
denoted by (1, 1). Based on experimental observations[31,35–37], these states can be 
associated with the amoeboid (A), mesenchymal (M) and hybrid amoeboid/mesenchymal 
(A/M) phenotypes respectively. 
Now, considering the connections between Rac1/RhoA circuit and EMT 
regulatory circuit, i.e. in presence of low levels of microRNAs (miR-34 and miR-200), 
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the system can display another stable state that has relatively low levels of both active 
RhoA and Rac1, as denoted by (0, 0) (Figure 2.8b). At certain levels of microRNAs, the 
system can also behave as a four-way switch such that all these steady states—(0, 0), (1, 
0), (1, 1), and (0+, 1)– co-exist (Figure 2.8c). We hereby propose to associate this new (0, 
0) state with the hybrid epithelial/mesenchymal (E/M) phenotype. This association is 
corroborated by experimental observations of the presence of balanced, moderate levels 
of active Rac1 and RhoA in cells of the hybrid E/M phenotype not only during cancer 
metastasis (type III EMT), but also during wound healing (type II EMT), and embryonic 
development (type I EMT)[90–92]. 
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Figure 2.8 The association between the core regulatory circuits for EMT/MET and 
MAT/AMT.  
(a) The effective (reduced) circuit, where µ1 represents the inhibition on RhoA by either 
miR-34 or miR-200, and µ2  represents similar inhibition on Rac1. A solid arrow denotes 
activation, and a solid bar denotes repression. A solid line represents transcriptional 
regulation, a dotted line represents indirect regulations on GTP loading or hydrolysis 
process via GEFs or GAPs, and a dashed line represents translational inhibition by 
microRNAs (b, c) Dynamical system characteristics of the effective circuit. The plot 
shows the nullclines and possible steady states corresponding to equation (18). When  
µ1= µ2 = 100 molecules, the circuit can be tri-stable (M, E/M, A). Red nullcline is for 
d[Rc*] / dt = 0  and black nullcline is for d[Rh*] / dt = 0 . Green solid circles denote the 
stable steady states, and green hollow circles denote the unstable steady states. Each 
stable state can be associated with a cell phenotype, as depicted by a cartoon beside them. 
 
The RhoA/Rac1 Circuit Response to microRNA Signals 
Next, as the first step towards analyzing the response of the Rac1/RhoA circuit to 
different levels of the external microRNA signals (µ1 and µ2), we consider µ1 and µ2 to 
be equal at all times; and that allows us to consider them together as a single external 
signal denoted by µ (Figure 2.9). Different levels of the signal µ enable different sets of 
co-existing phenotypes and hence different multi-stable phases, each marked by a distinct 
color in the figure. At a high level of µ, cells have relatively lower activities of both 
RhoA and Rac1, and can thereby adopt only the E/M state, i.e. a hybrid E/M phenotype 
(marked by the pink region). As the level of microRNAs decreases, cells may undergo 
the transition to adopt a M state or a A state either deterministically or stochastically. 
With further decrease in the levels of µ, cells can attain relatively high levels of both 
active RhoA and active Rac1, thereby adopting the A/M state. Our results are consistent 
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with experiments showing that miR-34 and miR-200 can act as gatekeepers of metastasis 
and that their decrease leads to collective as well as individual migration[93,94]. 
 
Figure 2.9 Bifurcation of Rac1-GTP protein levels in response to microRNAs (µ) 
signal regulating the translation of Rac1 and RhoA.  
Red solid lines mark the stable states, and blue dashed lines represent unstable states. The 
bifurcation illustrates the possible co-existence (for some range of the signal) of four 
states (E/M, M, A/M, and A). The corresponding bifurcation of RhoA-GTP protein levels 
is shown in Figure S1.5. The co-existence of different phenotypes is associated with a 
multi-stable phase, highlighted by different background colors ( legends given at the 
bottom). This bifurcation also indicates the possible state transitions when signal µ 
changes. Starting from the A state (the red line at bottom left part of the diagram), the 
system could undergo a transition to the A/M state (the red line at top left part of the 
diagram) when µ signal decreases. The transition is indicated by the dashed upward 
arrow at the boundary of the phase {A, A/M} (cyan region) and {A/M} (yellow region).  
Similarly, starting from M state, the increasing µ signal can induce the transition from the 
M 
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M state to the E/M state, as indicated by the downward arrow at the boundary of the 
phase {E/M} (pink area) and {E/M, M} (light blue region). 
 
Two-parameter Bifurcation Diagram 
Next, we analyze the response of the circuit when the two microRNA signals (µ1 
and µ2) can change independently (Figure 2.10). We considered the initial condition such 
that the cells can adopt any of the three individually migrating phenotypes – A, M, and 
A/M (marked by black dashed line in Figure 2.9 where µ = 25,000 molecules). At 
different levels of these two signals (µ1 and µ2), one or several different states or 
phenotypes can co-exist to form different phases. More specifically, the possible phases 
are: 1. Phases with only one state – {A}, {M} and {E/M}. 2. Phases in which two states 
can coexist – {A, E/M }, {M, E/M} and {A, M}. 3. A phase in which three states can 
coexist – {A, M, E/M} and {A, M, A/M}. 4. A phase in which all four states can coexist 
– {A, M, E/M, A/M}. These various phases indicate the plasticity of cell migration 
phenotypes as driven by different combinations of microRNAs (µ1 and µ2 signals). 
Depending on how µ1 and µ2 change temporally, the cells follow different 
trajectories in this phase diagram and thus go through different phenotypic transitions as 
is illustrated in Figure 2.10b–d. When both the microRNAs – one inhibiting RhoA and 
the one inhibiting Rac1 – are decreased at the same rate, we see the co-existence of all 
three solitary migration phenotypes—M, A/M and A phenotypes, i.e. plasticity of cell 
migration phenotypes is quite rich (Figure 2.10). However, if only one of the microRNAs 
decreases, cells finally adopt either A or M phenotype (Figure 2.10). 
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Figure 2.10 The circuit response to the input signals µ1 and µ2.  
(a) Two-parameter bifurcation phase diagram, where the two bifurcation parameters are 
the two input signals µ1 (y-axis) and µ2 (x-axis). Each phase, marked by a distinct color 
(shown in bottom), corresponds to a different combination of coexisting phenotypes 
(Phase plane diagrams for each phase are showed in Figure S1.6). (b) One-parameter 
bifurcation diagram when both µ1 and µ2 change simultaneously at the same rate, 
allowing them to merge into one parameter (here it is referred to as µ), as shown by the 
trajectory I in the two-parameter bifurcation phase diagram. (c) One-parameter 
bifurcation diagram for the circuit driven by varying levels of µ1 for a fixed µ2 = 4,000 
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molecules, corresponding to the trajectory II in the two-parameter bifurcation phase 
diagram. (d) One-parameter bifurcation diagram for the circuit driven by varying levels 
of µ2 at a fixed µ1 = 4,000 molecules, corresponding to the trajectory III in the two-
parameter bifurcation phase diagram.  
 
Temporal Dynamics 
We demonstrate the temporal dynamics of a phenotypic transition of a cell from 
collective migration (E/M phenotype) to individual migration (A, M and A/M 
phenotypes). In the E/M phenotype, cells have high levels of microRNAs (µ1 and µ2). 
When these signals decrease, cells gradually gain the ability to migrate and can 
eventually start moving individually in one of the solitary migration phenotypes—A, M 
and A/M. Notably, in different biological contexts, the two microRNAs (the one 
inhibiting RhoA (µ1) and the other inhibiting Rac1 (µ2)) may decrease at different rates, 
thus leading to a difference in the dynamics of phenotypic transition. If the microRNA 
inhibiting RhoA (µ1) decreases faster than the microRNA inhibiting Rac1 (µ2) (Figure 
2.11), the cells transit from the E/M phenotype to A phenotype, i.e. they undergo direct 
collective to amoeboid transition (CAT) as observed in fibrosarcoma cells[95]. Similar 
behavior is observed when both microRNAs decrease at same rate (Figure 2.11). In 
contrast, when (µ2) decreases faster (Figure 2.11), E/M to M phenotype transition may 
occur (Figure 2.11), i.e. the cells undergo a complete EMT. 
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Figure 2.11 Temporal dynamics of the circuit in response to different rates at which  
µ1 and µ2 decrease.  
When µ1 decreases faster than µ2 (a), the cell undergoes a transition from the E/M to the 
A state (b). When µ1 and µ2 decrease at the same rate (c), cell still switches from the 
E/M to the M state (d). When µ1 decreases slower than µ2 (e), the cell switches to the 
E/M state from the M state (f). 
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Effective Landscape 
To understand the relative stability of the co-existing stable states (phenotypes), 
we construct the effective landscape by considering the biological noise that can be 
present due to fluctuations in gene expression. Noise can originate from many sources 
such as birth/death of species and binding/unbinding of proteins, and can induce switches 
among its stable steady states spontaneously without the action of any external signal. 
The effective potentials of the landscape are defined as the negative logarithm of the 
probability (P) of each state (−ln(P))[96,97]. Therefore, the more common (or frequently 
adopted) steady state (or phenotype) would have a lower effective potential as shown by 
blue color. The larger the blue area surrounds a steady state, the more frequently the state 
or the phenotype is observed. 
Here, we have simulated Langevin dynamics of our model by adding Gaussian 
white noise (see the method section for details) for three cases (Figure 2.12), each of 
which corresponds to a different level of µ. Without this inhibition signal (µ), four steady 
states (A, M, A/M, E/M) can be detected. Notably, without the effect of noise, i.e. in the 
deterministic analysis, the system had three stable states (A, M, A/M) (Figure 2.8), but 
noise can induce transitions to another steady stable state (E/M). The states representing 
the A, E/M and M phenotypes are relatively more frequently observed than the state 
representing the state of the A/M phenotype, as indicated by the higher effective 
potentials for the A/M basin (Figure 2.12). Also, we observed more transitions between 
the A and E/M or M and E/M, rather than the other possible transitions (Figure S1.8a). 
However, with increasing levels of µ, the A/M state disappears and the system could still 
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stay in the A, M or E/M states, but the probability of staying in the E/M state increases 
while that for the A and the M states decreases (Figure S1.8b). For even higher levels of 
µ, the transitions from the collective to the solitary migration is largely inhibited (Figure 
S1.8) therefore indicating that microRNAs can potentially stabilize the E/M phenotype 
against the biological noise. 
 
Figure 2.12 Effective landscapes of the circuit with Gaussian white noise.  
(a) Bifurcation diagram of the stable Rac1-GTP levels in response to different level of µ. 
Three different levels of µ are highlighted, as they are the conditions to calculate the 
effective landscape values (-ln(P)) by Langevin simulation. (b-d) show effective 
3 2 
1 
3 
2 
1 
RhoA-GTP (×106 molecues) 
RhoA-GTP (×106 molecues) RhoA-GTP (×106 molecues) 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ue
s)
 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ue
s)
 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ue
s)
 
M 
A/M 
A E/M 
-ln(P) 
a b 
c d 
M 
A E/M 
M 
E/M 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ue
s)
 
µ (molecues) 
 62 
 
landscapes for (b): µ = 0, (c): µ = 1000, and (d) µ = 3000 (all units in molecules).  The 
basins associated with each state is labeled for each case. The larger the blue region 
surrounding a particular steady state, the more frequent the state is.  
 
The switch responds to the input signals from c-Met pathway at different 
microRNA levels 
Until now, we have considered the effect of microRNAs on the AMT/MAT 
circuit in the absence of any EMT-inducing signal. Here, we analyze the response of the 
AMT/MAT switch or circuit in the presence of an EMT-inducing signal – the HGF/c-Met 
pathway. c-MET is a tyrosine kinase receptor that is encoded by an oncogene, and is 
activated when the signaling molecule HGF binds to it[47]. The downstream effectors of 
the c-MET/HGF pathway include Grb2 and Gab1 that can regulate cell migration 
phenotypes by activating RhoA or Rac1[98–102] respectively. 
To consider the regulatory functions of all these signals combined together, we 
first calculated the two-parameter bifurcation diagrams (Figure 2.13) when the 
Rac1/RhoA regulatory circuit is driven by two of these signals – (a) µ and Grb2, and (b) 
µ and Gab1 (Figure S1.9). As expected, high levels of microRNAs suppress the 
stimulation of solitary migration by Grb2 and Gab1 signals and therefore retain the cells 
in the hybrid E/M phenotype. When the level of µ or microRNAs is further decreased, 
high Grb2 signal can induce the cell to undergo complete EMT to attain the M 
phenotype, while the regulatory function of Gab1 signal depends on the level of signal µ. 
Gab1 induces the cells to the M phenotype at the intermediate level of µ, but to A 
phenotype at the low level of µ. Therefore, the regulatory functions of Grb2 and Gab1 in 
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inducing cell migration depend on the amount of microRNAs (miR-34 and miR-200), 
and their functions are more distinguished when the microRNAs are at lower levels, such 
that Grb2 leads to an M phenotype while Gab1 leads to an A phenotype. 
Next, we have calculated the two-parameter bifurcation diagrams of Rac1/RhoA 
circuit driven by Grb2 and Gab1 signals for various values of µ (Figure 2.13). For the 
high level of µ, the expression of Rac1 and RhoA is strongly inhibited, thus the plasticity 
of cell migration driven by Grb2 and Gab1 is limited only to {E/M} and {M} phases, 
indicating that only EMT/MET could occur (the 1st-2nd panels to the left, Figure 2.13a). 
However, with a decrease in the levels of µ, cells can also adopt the A state (the 3rd panel 
to the left, Figure 2.13a); and this phenotypic plasticity for cells only increases with the 
decrease in the signal µ. At extremely low levels of µ, the cells can adopt any of the three 
solitary migration phenotypes – A, M, or A/M – depending on the Gab1 and Grb2 levels 
(the 4th-5th panels to the left Figure 2.13a). Again, these results are consistent with the 
experiments suggesting that the miR-200 and miR-34 inhibit cell migration and 
consequently metastasis, and their loss can lead the cells to display a spectrum of solitary 
migration phenotypes[93,94]. Also, we notice that this series of phase diagrams shows an 
asymmetry for the induction of different solitary migration phenotypes by Gab1 and Grb2 
signals at different microRNA levels. Cells in the E/M phenotype may undergo a 
transition to the M phenotype (i.e. complete EMT) even at high levels of µ, but they can 
transit to the A or the A/M phenotypes only at low levels of µ. This asymmetry might 
underlie why different cell lines might prefer different migration phenotypes (or different 
distributions of migration phenotypes) during metastasis[37]. 
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Also, for a different parameter set where the Rac1/RhoA circuit is more 
responsive to Grb2 and Gab1 (the threshold for Grb2 and Gab1 signals was reduced (see 
supplementary information section 2)). Cells can attain the {A} phase for a larger range 
of parameters even in the presence of high level of µ, indicating a more metastatic 
behavior (the 1st-2nd panels to the left, Figure 2.13b). When µ is reduced, the plasticity 
in cell migration is enhanced significantly (the 3rd-5th panels to the left, Figure 2.13b). 
This difference in the response to the c-MET pathway can be attributed to different cell 
lines with distinct metastatic potential. 
 
Figure 2.13 The circuit response to Grb1 and Grb2 at different levels of the µ signal.  
For both panels a and b, the µ level for each phase diagram decreases from left to right. 
(a) The thresholds of both the Gab1 and Grb2 signals to activate RhoA and Rac1 were set 
to be 500,000 molecules. At high levels of the microRNAs (first figure of panel a), only 
two phases are observed – {E/M} and {M}. As the level of µ decreases, the phases with 
solitary cell migration phenotypes become more common, and many multistable phases 
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appear. (b) The thresholds of both Gab1 and Grb2 to activate RhoA and Rac1 were set to 
be 250,000 molecules. All other parameters and the µ levels for each case are same as 
that in panel a. The color scheme for different phases is shown at the bottom. 
 
Phenotype Distribution 
Even in the same cell line, cells often have non-heritable phenotypic variability or 
heterogeneity[88,89]. Such variability can often account for different model parameters 
for each cell. To capture this heterogeneity, we calculated the population distribution of 
the phenotypes for the cells with the same levels of microRNAs, but some variability in 
other model parameters. More specifically, we extended our simulations to a population 
of 5,000 cells. Each cell has different circuit parameters, which can be ±5% different 
from the original parameters (details in Method section). In Figure 2.14, we show the 
percentages of cells in one of the four different possible phenotypes — (A, E/M, M, and 
A/M) — for different levels of the signal µ. We found that for a high level of signal µ, a 
significant percentage of cells adopt the E/M phenotype, thereby indicating that the cells 
with high levels of microRNA are more robust to the parameter variability against 
maintaining the E/M phenotype. 
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Figure 2.14 Phenotype distribution of a population of cells driven by the signal µ.  
(a) The cell parameters are randomly distributed over ±5% relative to the original 
parameters. The y-axis denotes the percentage of cells corresponding to a specific 
phenotype. The color of each line represents a phenotype. Under the different levels of µ, 
a population of cells has different distributions for cell phenotypes (percentage of cells 
shown in y-axis). (b) At different level of signal µ, the original phase of the cells are 
colored according to the color definition in Figure 2.9. At high levels of the signal µ, the 
cells are highly likely to stay in the E/M phenotype. 
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2.5. Discussion 
In this study, we first showed that the RhoA/Rac1 circuit could perform as a 
three-way switch allowing three stable steady states – (high RhoA-GTP, low Rac1-GTP), 
(low RhoA-GTP, high Rac1-GTP), and (high RhoA-GTP, high Rac1-GTP). These three 
states can be associated with the A, the M and the hybrid A/M phenotypes respectively, 
as supported by several experimental evidences. For example, amoeboid cells have been 
shown to have high actomyosin contractility due to high levels of RhoA-GTP[43]; 
mesenchymal cells have high actin polymerization due to high levels of Rac1-GTP[43]; 
the hybrid A/M phenotype displays mixed amoeboid and mesenchymal characteristics, 
suggesting a comparable level of both actin polymerization and actomyosin contractility 
due to high levels of both Rac1-GTP and RhoA-GTP[31,35,36]. Notably, similar ‘hybrid’ 
manifestations of mixed amoeboid and mesenchymal traits may not be unique to cancer, 
but can also be observed in other instances, such as neutrophils and leukocytes[76–78]. 
When incorporating the microRNA signaling on the RhoA/Rac1 circuit, we 
observed an additional stable state (0, 0), when cells of which have relatively low levels 
of both RhoA-GTP and Rac1-GTP as compared to the other states (M, A/M, and A). We 
propose to associate this new state with the hybrid E/M phenotype. Although there is no 
direct quantitative measurement yet of the active levels of RhoA-GTP and Rac1-GTP in 
the hybrid E/M cells, our association of the (0, 0) state with hybrid E/M phenotype is 
consistent with the following experiments. First, moderate levels of both active Rac1 and 
RhoA have been reported to promote wound healing[91], a typical case of the collective 
migration of the hybrid E/M cells[27]. Second, a moderate level of active RhoA has been 
 68 
 
shown to induce the hybrid E/M phenotype for the human colon adenocarcinoma 
cell[90], while both dominant-negative and constitutively active Rac1 has been reported 
to damage the collective migration of boarder cells during Drosophila early 
development[92]. Both evidences support the relatively low activity of Rac1 and RhoA in 
collectively migrating hybrid E/M cells as compared with the solitarily migrating cells in 
A, M and A/M phenotypes. 
One limitation of our current model is the exclusion of the epithelial (E) 
phenotype from our analysis because this model is too simple to explain the elusive 
dynamics of active RhoA and Rac1 in epithelial tissue establishment and maintenance. 
Epithelial cells are reported to have higher levels of microRNAs (miR-200 and miR-34) 
than in the hybrid E/M cells[40,103]. Therefore, according to our model, these cells are 
likely to have even lower levels of active RhoA and Rac1 than those in hybrid E/M cells. 
On the other hand, experiments suggest that the active levels of RhoA and Rac1 vary 
significantly in different stages of epithelial establishment[104]. For instance, at the 
initial stage of epithelialization, de novo cell-cell adhesion and adherent junctions 
expansion require the activity of Rac1 and RhoA respectively. But when EMT is induced, 
levels of active Rac1 decrease at first and then increase again[105]. Therefore, the 
dynamics of Rac1/RhoA activity need to be fine-tuned either spatially and/or temporally 
in order to maintain the E-cadherin-mediated cell-cell adhesion. But we currently have 
not yet modeled the spatial heterogeneity of the two GTPases, RhoA and Rac1, as needed 
to allow investigation of the role of spatiotemporal dynamics of these proteins in 
determining the changes in cell shape during epithelialization and transitions between 
different phenotypes. Besides, to understand the complex temporal dynamics of the 
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activity of Rac1 and RhoA, additional models should incorporate the interplay among the 
key proteins in the regulatory circuit such as E-cadherin, N-cadherin, and the Rho 
GTPases. 
From the perspective of dynamical systems, we found that the Rac1/RhoA 
regulatory circuit can behave as a multi-stable switch in the regulation of different 
phenotypes. Such multi-stability is a hallmark of self-activating toggle switches (SATS), 
i.e. mutually inhibitory feedback loop with self-activations on both elements of the 
loop[106] as seen in RhoA/Rac1 circuit (Figure 2.2). Similar multi-stability is also seen 
in circuits governing Cancer Stem Cells (CSCs)[107,108] and in circuits governing cell-
cell communication[109,110], and can often be used by the cancer cells to adapt to their 
rapidly changing microenvironments during metastasis[28]. Restricting such cellular 
plasticity as enabled by these multistable systems can inhibit possible co-operation 
between different subpopulations and hence hamper tumor metastasis[111–114]. 
To conclude, our model provides a better understanding of the plasticity of cell 
migration and its regulation by external signals. Furthermore, it paves a promising way to 
understand how c-MET pathway is involved in carcinoma metastasis. Given the large 
number of current attempts to therapeutically target the c-MET pathway, understanding 
this relationship can provide some useful non-intuitive insights for therapeutic 
interventions to prevent metastasis. 
We also present the first tractable framework towards understanding the 
transitions among the collective migration phenotype and the solitary migration 
phenotypes. We found that the microRNAs, miR-34 and miR-200, govern various 
 70 
 
phenotypic transitions and can also mediate the effect of other signaling pathways such as 
Grb2/Gab1 signals on such transitions. Our framework can be further extended by 
incorporating many other extracellular signals to explore their impact on cellular 
plasticity and migration, and can possibly provide important insights into cancer therapies 
that target cell migration during metastasis. 
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Chapter 3 
Development of Random Circuit 
Perturbation (RACIPE) method to 
interrogate the topological robustness of gene 
regulatory circuits 
Cells are able to robustly carry out their essential biological functions, possibly 
because of multiple layers of tight regulation via complex, yet well-designed, gene 
regulatory networks involving a substantial number of genes.  State-of-the-art genomics 
technology has enabled the mapping of these large gene networks, yet it remains a 
tremendous challenge to elucidate their design principles and the regulatory mechanisms 
underlying their biological functions such as signal processing and decision making.  One 
of the key barriers is the absence of accurate kinetics for the regulatory interactions, 
especially from in vivo experiments. To this end, we have developed a new 
computational modeling method, Random Circuit Perturbation (RACIPE), to explore the 
dynamic behavior of gene regulatory circuits without the requirement of detailed kinetic 
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parameters. RACIPE takes a network topology as the input, and generates an unbiased 
ensemble of models with varying kinetic parameters. Each model is subjected to 
simulation, followed by statistical analysis for the ensemble.  We tested RACIPE on 
several gene circuits, and found that the predicted gene expression patterns from the 
models converge to experimentally observed gene state clusters. We expect RACIPE to 
be a powerful method to identify the role of network topology in determining network 
operating principles. 
3.1. Introduction 
State-of-the-art molecular profiling techniques[115–118] have enabled the 
construction or inference of large gene regulatory networks underlying certain cellular 
functions, such as cell differentiation[119,120] and circadian rhythm[121,122].  
However, it remains a challenge to understand the operating principles of these 
regulatory networks and how they can robustly perform their tasks, a prerequisite for cell 
survival. Mathematical and computational systems biology approaches are often applied 
to quantitatively model the dynamic behaviors of a network[123–134]. Yet, quantitative 
simulations of network dynamics are usually limited due to several reasons. First, a 
proposed network might contain inaccurate or missing regulatory genes or links, and 
modeling an incomplete network might produce inaccurate predictions. Second, kinetic 
parameters for each gene and regulatory interaction, which are usually required for 
quantitative analyses, are difficult to be obtained directly for all of them from in vivo 
experiments[135]. To deal with this problem, network parameters are either inferred from 
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existing data [136,137] or educated guesses, an approach which could be time-consuming 
and error-prone.  This approach is hard to extend to very large gene networks due to their 
complexity.  
Alternatively, a bottom-up strategy has been widely used to study the regulatory 
mechanisms of cellular functions. First, one performs a comprehensive analysis and 
integration of experimental evidence for the essential regulatory interactions in order to 
construct a core regulatory circuit, typically composed of only a small set of essential 
genes.  The core gene circuit is then modeled either by deterministic or stochastic 
approaches with a particular set of parameters inferred from the literature.  Due to the 
reduced size of the systems and the inclusion of data derived directly from the literature, 
the bottom-up approach suffers less from the above-mentioned issues. Examples of the 
bottom-up approach include the modeling of biological process such as Epithelial-to-
Mesenchymal transition (EMT)[12,13,40], cell cycles[14,15], and circuit design in 
synthetic biology, such as genetic toggle switch[3], and repressilator[4]. 
Due to the success of these and other circuit-based modeling studies, we 
hypothesize that a core circuit module should emerge from a complex network and 
dictate the decision-making process. It is reasonable to assume that a large gene network 
could be decomposed into a core gene circuit and a peripheral part with the residual 
genes.  The core would then be the driving force for the network dynamics and should be 
robust against cell-to-cell variability and extrinsic fluctuations in stimuli arising from cell 
signaling, while the peripheral genes would act to regulate the signaling status for the 
core circuit and probably also enhance the robustness of the core dynamics by 
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introducing redundancy.  This scale-separation picture is consistent with ideas such as the 
existence of master regulators and network modularity[138,139]. 
On the basis of this conceptual framework, we developed a new computational 
method, named random circuit perturbation (RACIPE), for modeling possible dynamic 
behaviors that are defined by the topology of a core gene regulatory circuit.  In RACIPE, 
we focus the modeling analysis on the core circuit and regard the effects of the peripheral 
genes and external signaling as random perturbations to the kinetic parameters. In 
contrast to traditional modeling methods[140], RACIPE generates an ensemble of 
mathematical models, each of which has a different set of kinetic parameters representing 
variations of signaling states, epigenetic states, and genetic backgrounds (including cells 
with genetic mutations leading to disease). Here we randomize the model parameters by 
one or two orders of magnitude and utilize a specially designed parameter sampling 
scheme (details in Methods) to capture the key role of circuit topology. This random field 
approach allows the inclusion of the contributions from the peripheral genes to the 
network dynamics and the evaluation of their roles in modulating the functions of the 
core circuit. From the in silico generated data, we apply statistical analysis to identify the 
most probable features within all of the models, a process which can uncover the most 
robust functions of the core circuit.  It is worth-noting that RACIPE is unique in the way 
it utilizes perturbation and the integration of statistical tools, compared to the traditional 
parameter sensitivity analysis[141–145]  and the previous studies on random circuit 
topology[146,147]. 
 75 
 
In the following, we will first describe in detail the RACIPE method, and then 
present the results of applying RACIPE to several simple standalone circuit motifs and 
also coupled toggle switch motifs.  In addition, we will show the application of RACIPE 
to a 22-component network for the decision-making core of the Epithelial-to-
Mesenchymal Transition (EMT). We will see that RACIPE is capable of identifying 
accessible gene states via statistical analysis of the in silico generated data, from which 
we can further decode the design principles and evaluate the robustness of the core gene 
circuit.  We therefore expect RACIPE to be a powerful tool to analyze the dynamic 
behavior of a gene network and to evaluate the robustness and accuracy of proposed 
network models. 
3.2. Random Circuit Perturbation (RACIPE) Method 
We developed a new computational method, namely random circuit perturbation 
(RACIPE), for modeling a gene network. The procedure of RACIPE is illustrated in 
Figure 3.1. The input of RACIPE is the topology of the core circuit under study, which 
can be constructed according to either the literature, interaction databases (e.g. Ingenuity 
pathway analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity), 
KEGG[17], GO[18]), or computational methods[19]. From the circuit topology, we 
establish a set of mathematical equations for the time evolution of the levels of all the 
genes. We then generate an ensemble of models where the parameters from the rate 
equations are sampled by a carefully designed randomization procedure (see below for 
details) so that these kinetic models can capture the behavior of the circuits under 
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different conditions. Each model is subject to standard analysis to discover possible 
dynamics of the circuit (Figure 3.1b).  The dynamics could converge to a stable steady 
state, a stable oscillation, or chaotic behavior.  To find all possible behaviors for a gene 
network, we typically choose many different sets of initial conditions (randomly sampled 
on a logarithmic scale) and numerically solve the rate equations for each case. The 
procedure is repeated for many times to collect sufficient data for statistical analysis.  In 
particular, for a multi-stable system, this ODE-based method is useful for identifying all 
the distinct stable states for a multi-stable system. Thus, the RACIPE method can 
generate a large amount of simulated gene expression data, which can be further analyzed 
by biostatistics tools (Figure 3.1c). Potentially, RACIPE can also be extended to study 
oscillatory or adaptive dynamics (Figure S2.1), and is also compatible with other types of 
modeling methods such as stochastic analysis, but these are out of scope this study.  In 
the following, we will illustrate RACIPE in the context of a multi-stable gene circuit by 
deterministic analysis. In the following, we will illustrate RACIPE in the context of a 
multi-stable gene circuit by deterministic analysis.   
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Figure 3.1 Schematics of the random circuit perturbation (RACIPE) method.  
(a) The gene regulatory network for a specific cellular function is decomposed into two 
parts – a core gene circuit modeled by chemical rate equations and the other peripheral 
genes whose contribution to the network is regarded as random perturbations to the 
kinetic parameters of the core circuit. (b) RACIPE generates an ensemble of models, 
each of which is simulated by the same rate equations but with randomly sampled kinetic 
parameters. For each model, multiple runs of simulations are performed, starting from 
 78 
 
different initial conditions, to identify all possible stable steady states. (c) The in silico 
gene expression data derived from all of the models are subject to statistical analysis 
As an example, we start with the deterministic rate equations for a toggle switch 
circuit (Figure 3.2) with mutually inhibitory genes A and B. The kinetic model takes the 
form: 
 
!A = gAH
S (B, BA0 ,nBA,λBA
− )− kA A
!B = gB H
S ( A, AB0 ,nAB ,λAB
− )− kB B
,  (19) 
where A and B represent the expression levels of gene A and B respectively. gA  and gB  
are the basal production rates (the production rate for the gene without any regulator 
bound to the promoter). Ak  and Bk  are the innate degradation rates. Regulation of gene B 
expression by A is formulated as a non-linear shifted Hill function ( 0( , , , )
S
AB ABH A AB n l
-
), defined as 0(1 ) ( , , )AB AB ABH A AB nl l
- - -+ - , where  H
− = 1/ (1+ ( A / AB0 )
nAB )  is the 
inhibitory Hill function,  AB0  is the threshold level for A,  nAB  is the Hill coefficient of 
the regulation, ABl
-
 is the maximum fold change of the B level caused by the inhibitor A (
1ABl
- < ).  In the case of an activator, the fold change is represented by ABl
+  ( λAB
+ >1 ).  
The inhibitory regulation of gene A by gene B can be modeled in an analogous way. 
In RACIPE, randomization is performed on all five types of circuit parameters: 
two of them are associated with each gene, including the basal production rate ( g ) and 
the degradation rate ( k ); and three of them are associated with each regulatory link, 
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including the maximum fold change of the gene expression level ( ), the threshold level 
of the regulation ( X0 ) and the Hill coefficient  (n).  
Our parametric randomization procedure is designed to ensure that the models can 
represent all biologically relevant possibilities.  In detail, the Hill coefficient  is an 
integer selected from 1 to 6, and the degradation rate  k  ranges from 0.1 to 1 (See Table 
S2.1 for the explanation of the units).  Here each parameter is assigned by randomly 
picking values from either a uniform distribution or some other distributions, for example 
the Gaussian distribution.  The fold change l +  ranges from 1 to 100 if the regulatory link 
is excitatory, while l-  was varied from 0.01 to 1 if the regulatory link is inhibitory.  Note 
that for the latter case, a probability distribution (e.g. a uniform distribution) is sampled 
for the inverse of l- , i.e. 1/ l- , instead of l-  itself.  By doing so, we make sure that the 
mean fold change is about 0.02, instead of ~ 0.5.  The choice of such a wide range of  
values ensures the consideration of both strong and weak interactions. 
In addition, two assumptions are made in RACIPE to ensure that it generates a 
representative ensemble of models for a specific circuit topology.  First, the maximum 
production rate of each gene should lie roughly within the same range (from 1 to 100 in 
this study, see Table S2.1), as the maximum rate is determined by how fastest the 
transcriptional machinery can work.  For a gene regulated by only one activator, the 
maximum production rate is achieved when the activator is abundant, and thus the basal 
production rate of the gene g =G / λ+ .  For a gene regulated by only one inhibitor, the 
maximum rate is achieved in the absence of the inhibitor, i.e. g G= .  This criterion can 
λ
n
λ
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be generalized to genes regulated by multiple regulators.  Therefore, in practice, we 
directly randomize the maximum production rate (G) instead of the basal production rate 
(g), and then calculate the value of g according to the above criterion.  The ranges of 
these parameters are summarized in details in Table S2.1.  The RACIPE randomization 
procedure allows a gene to have a relative expression ratio of up to 1,000 for two sets of 
parameters, even when it is not regulated by other genes. 
Second, we also assume that, for all the members of the RACIPE model 
ensemble, each regulatory link in the circuit should have roughly equal chance of being 
functional or not functional, referred to as the half-functional rule.  For example, in the 
case that gene A regulates gene B, all the parameters are selected in such a way that for 
the RACIPE ensemble, the level of A at the steady states has roughly 50% chance to be 
above and 50% chance to be below its threshold level.  Otherwise, if the threshold level is 
too large or too small, the regulatory link is either not functional most time or 
constitutively active, thereby changing the effective circuit topology, and limiting a 
comprehensive understanding of circuit function (Figure S2.2). 
To achieve this, we estimate the range of the threshold levels by a mean-field 
approximation, and use this range for randomly sample of the threshold parameters. For a 
regulatory link from gene A (regulator) to gene B (target), the threshold level AB0  can be 
estimated as follows.  We first estimate the range of expression of gene A without 
considering any of its regulators.  The A level without regulation satisfies 
 !A = G − kA ,  (20) 
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By randomizing both  G  and  by the aforementioned protocol (Table S2.1), we 
generate an ensemble of random models, from which we obtain the distribution of the 
steady state levels of gene  (Figure 3.2a).  To meet the half-functional rule, the median 
of the threshold level should be chosen to be the median of this distribution.  When gene 
A is regulated by some other genes (i.e. its upstream regulators), we estimate the median 
threshold level by considering the inward regulators of A, and assume that the levels of 
all these regulators (e.g. gene B, C etc.) follow the same distribution as an isolated gene 
(top right panels in Figure 3.2a section 2).  We set the threshold of every inward 
regulation to be 0.02M to 1.98M, where M is the median of the distribution of an isolated 
gene.  With all of the information, we can again generate a new ensemble of models, 
from which we calculate the distribution of gene A (bottom panel in Figure 3.2a section 
2) and its median. For every target gene regulated by the gene A, we select the threshold 
levels of the regulations in the range from 0.02M to 1.98M, where M is the above 
obtained median level of gene A.  The same approach is used to estimate the threshold 
levels of the other genes.  It is worth-noting that this self-consistent strategy works quite 
well for the cases we have tested (Figure 3.2b) according to the half-functional rule. 
k
A
 82 
 
 
Figure 3.2 Randomization scheme to estimate the ranges of the threshold 
parameters. 
(a) Schematics of the procedure to estimate the ranges of the threshold parameters, so 
that the level of a regulator has 50% chance to be above or below the threshold level of 
each regulatory link (“half-functional rule”).  First, for a gene A without any regulator, 
the RACIPE models are generated by randomizing the maximum production rate and the 
degradation rate according to Table S2.1.  The distribution of A level is obtained from the 
stable steady state solutions of all the RACIPE models (top left panel, yellow histogram).  
Second, for a gene A in a gene circuit, the distribution of A level is estimated only on the 
basis of the inward regulatory links (i.e. the B to A activation and the C to A inhibition in 
the bottom left panel).  The distributions of the levels of the inward regulators B and C 
are assumed to follow the same distributions as a gene without any regulator (bottom left 
panel, blue and red distribution); the threshold levels for these inward links are chosen 
randomly from (0.02M to 1.98M), where M is the median of their gene expression 
distributions. Finally, the distribution of A level is obtained by randomizing all the 
relevant parameters.  That includes the levels of B and C, the strength of the inward 
regulatory links, the maximum production rate and the degradation rate of the A, and the 
threshold for any regulatory link starting from A is chosen randomly from (0.02M to 
1.98M), where M is the median level of the new distribution of A level (orange in the 
bottom panel). The same procedure is followed for all other genes. (b) Tests on several 
a b
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simple toggle-switch-like circuit motifs and the Epithelial-to-Mesenchymal Transition 
(EMT) (Figure 3.6a) circuit show that the “half-functional rule” is approximately 
satisfied with this randomization scheme.  For each RACIPE model, we computed the 
ratio (x/x0) of the level of each gene X at each stable steady state (x) and the threshold 
(x0) for the outward regulations from gene X.  The yellow region shows the probability of 
x/x0 > 1 for all the RACIPE models, and the green region shows the probability of x/x0 < 
1. 
 
 
3.3. Applications 
3.3.1. Simple toggle-switch like circuits 
3.3.1.1. Introduction 
We first tested RACIPE on several basic toggle-switch-like circuit motifs (Figure 
3.3a).  These circuit motifs are considered to be some of the main building blocks of gene 
regulatory networks[148].  A genetic toggle switch (TS), composed of two mutually 
inhibitory genes, is commonly considered to function as a bi-stable switch - it allows two 
stable gene states, each of which is characterized by dominant expression of one gene.  
The TS has been shown to be a central piece of decision-making modules for cell 
differentiation in several incidences[149–151]. 
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3.3.1.2. Methods 
Mathematical models of toggle-switch like circuit motifs 
The circuits, including simple toggle-switch-like circuit motifs, coupled toggle-
switch (CTS) motifs, and the EMT circuit, were modeled by the deterministic rate 
equations as follows: 
Toggle-switch circuit (TS): 
,  (21)
 
Toggle-switch circuit with one-sided self-activation (TS1SA): 
,  (22)
 
Toggle-switch circuit with two-sided self-activation (TS2SA): 
,  (23) 
Coupled toggle-switch (CTS) motif with n toggle switches: 
 
!A1 = GA1 H
S (B1, B1A10 ,nB1A1 ,λB1A1
− )− kA1 A1
!Ai = GAi H
S (Bi , Bi Ai0 ,nBi Ai ,λBi Ai
− )H S ( Ai−1, Ai−1Ai0 ,nAi−1Ai ,λAi−1Ai
+ ) / λAi−1Ai
+ − kAi Ai (i >1)
!Bj = GBj H
S ( Aj , Aj Bj0 ,nAj Bj ,λAj Bj
− )H S (Bj+1, Bj+1Bj0 ,nBj+1Bj ,λBj+1Bj
+ ) / λBj+1Bj
+ − kBj Bj ( j < n)
!Bn = GBn H
S ( An , AnBn0 ,nAnBn ,λAnBn
− )− kBn Bn , (24)
 
 
!A = GAH
S (B, BA0 ,nBA,λBA
− )− kA A
!B = GB H
S ( A, AB0 ,nAB ,λAB
− )− kB B
 
!A = GAH
S (B, BA0 ,nBA,λBA
− )− kA A
!B = GB H
S ( A, AB0 ,nAB ,λAB
− )H S (B, BB0 ,nBB ,λBB
+ ) / λBB
+ − kB B
 
!A = GAH
S (B, BA0 ,nBA,λBA
− )H S ( A, AA0 ,nAA,λAA
+ ) / λAA
+ − kA A
!B = GB H
S ( A, AB0 ,nAB ,λAB
− )H S (B, BB0 ,nBB ,λBB
+ ) / λBB
+ − kB B
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where  Gi  represents the maximum production rate of gene i, and  ki  represents the 
degradation rate of gene i.  For the regulatory link (either activation or inhibition) from 
gene i to gene j,  ij0  represents the threshold level of gene i,  nij  is the Hill coefficient, and 
 
λij  is the maximum fold change of the gene j level caused by gene i.   λij
 < 1 for an 
inhibitory regulation, referred to as  
λij
− , while 
 
λij  > 1 for an excitatory regulation, 
referred to as  
λij
+ .  For the simple gene circuits (TS, TS1SA, TS2SA), A and B stand for 
the expression levels of the two transcription factors.  The notation for each gene in the 
CTS motifs is shown in Figure 3.5.  Through RACIPE method, we generated 10,000 sets 
of parameters (10,000 RACIPE models) for each circuit.  Each model is solved by the 
Euler method starting from 1,000 different initial conditions to find out all the distinct 
stable steady solutions. 
Normalization of gene expression data  
From an ensemble of the RACIPE models, we collected a large set of gene 
expression data, very similar to those obtained in experiment.  Therefore, we can apply 
tools for data analysis to these computationally generated data.  Here, we processed the 
computational expression data by a standard normalization method before we performed 
clustering analysis.  The gene expression levels from the models are normalized by first 
log transformation and standardization, i.e. 
, (25) 
 
xi →
log2(xi )− log2(xi )
σ (log2(xi ))
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Clustering analysis  
We performed cluster analysis on the normalized gene expression data from the 
RACIPE models.  Each column represents a gene, and each row represents a stable 
steady state of the circuit for a particular RACIPE model. For RACIPE models with more 
than one stable state, the gene expression profiles for all of the stable states were listed in 
multiple rows.  We applied average linkage hierarchical clustering analysis using 
Euclidean distance by Cluster 3.0[152] and the results were visualized by 
JavaTreeview[153].  The cutoff distance was chosen interactively so that major clusters 
can be identified and each cluster has a distinct gene expression pattern.  These clusters 
correspond to different gene states for the circuit.  Principal component analysis was 
performed on the same data by using “pca” function in Matlab/2014b.  The major gene 
clusters can be readily recognizable from the probability density map projected onto the 
first two principal component axes. 
3.3.1.3. Results 
For TS motif, we observed that about 20% of models allow two coexisting stable 
steady states (bi-stability), while the remainder allow only one steady state (mono-
stability).  The observation that only a small fraction of TS models work as a bi-stable 
system is consistent with a previous study[146].  Next, we tested RACIPE on a toggle 
switch with an extra excitatory auto-regulatory link acting on only one of the genes (a 
toggle switch with one-sided self-activation, or TS1SA).  The circuit motif now has ~ 
50% chances of being bi-stable, much larger than the original TS motif.  Interestingly, 
TS1SA also has ~1% chance of having three co-existing stable steady states (tri-
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stability), so it can potentially act as a three-way switch[148].  Hence, the RACIPE 
analysis suggests that TS1SA is more robust than TS for functioning as a switch.  
Moreover, adding excitatory auto-regulatory links on both sides of the TS motif (TS2SA) 
further increases the likelihood of bi-stability to ~60%, and meanwhile dramatically 
increases the likelihood of tri-stability to ~13%.  This suggests that TS2SA has more of 
an ability than these other motifs to function as a three-way switch.  Indeed, TS2SA has 
been proposed to be the core decision-making motif for several cell differentiation 
processes, and many of these processes exhibit multi-stability[149,150].  Thus, statistical 
analysis of the ensemble of random models generated by RACIPE can identify the most 
robust features of a circuit motif. 
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Figure 3.3 RACIPE identifies robust features of toggle-switch-like motifs. 
RACIPE was tested on three circuits – a simple toggle-switch (TS, top left) which 
consists of genes A and B that mutually inhibit each other (solid lines and bars), a toggle-
a
b
c
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switch with one-sided self-activation (TS1SA) which has an additional self-activation 
link on gene B, and a toggle-switch with two-sided self-activation (TS2SA) which has 
additional self-activation links on both genes. (a) Probability distributions of the number 
of stable steady states for each circuit. (b) Probability density maps of the gene 
expression data from all the RACIPE models. Each point represents a stable steady state 
from a model. For any RACIPE model with multiple stable steady states, all of them are 
shown in the plot. (c) Average linkage hierarchical clustering analysis of the gene 
expression data from all the RACIPE models using the Euclidean distance. Each column 
corresponds to a gene, while each row corresponds to a stable steady state from a model. 
The analysis shows that the gene expression data could be clustered into distinct groups, 
each of which is associated with a gene state, as highlighted by different colors on the 
right of the heatmaps. 
Another way to utilize RACIPE is to evaluate the possible gene expression 
patterns of a circuit motif.  We can construct a large set of in silico gene expression data, 
consisting of the gene expression levels of the circuit at every stable steady state for each 
RACIPE model.  In the dataset, the column corresponds to the genes and the rows 
corresponds to stable steady states.  For a RACIPE model with multiple stable steady 
states, we enter the data in multiple rows.  The expression dataset takes a form similar to 
typical experimental microarray data, and so it can be analyzed using common 
bioinformatics tools.  For each of the above two-gene cases, we visualized the expression 
data by a scatter plot of the levels of the two genes (Figure 3.3b).  Surprisingly, despite 
large variations in the circuit parameters across the RAICPE model ensemble, the 
expression data points converge quite well into several robust clusters.  For example, the 
TS circuit data has two distinct clusters, where one has a high expression of gene A but a 
low expression of gene B and the other vice versa. The TS2SA circuit has not only the 
above two clusters but also an additional cluster with intermediate expression of both 
genes.  These patterns have also been observed in previous experimental[3] and 
theoretical[148,149,154] studies of the same circuits.  Interestingly, if we only include 
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models with a fixed number of stable states (e.g. restrict the ensemble to mono-stable 
models, or bi-stable models), a similar pattern of clusters can still be observed (Figure 
S2.3).  These clusters represent distinct patterns of gene expression that the circuit can 
support, so we will refer to these clusters as “gene states”.  These gene states are robust 
against large perturbations of circuit parameters because the circuit topology restricts 
possible gene expression patterns.  RACIPE in a sense takes advantage of this feature to 
interrogate the circuit so that we can unbiasedly identify the robust gene states.  Since 
these states may be associated with different cell phenotypes during cell differentiation or 
cellular decision-making processes, RACIPE can be especially helpful in understanding 
the regulatory roles of the circuit during transitions among different states.  
These simple cases demonstrate the effectiveness of RACIPE in revealing generic 
properties of circuit motifs.  Recall that our basic hypothesis is that the dynamic 
behaviors of a circuit should be mainly determined by circuit topology, rather than a 
specific set of parameters. The rich amount of gene expression data generated by 
RACIPE allows the application of statistical learning methods for the discovery of these 
robust features.  For example, as shown in Figure 3.3c, we applied unsupervised 
hierarchical clustering analysis (HCA) to the RACIPE gene expression data, and again 
we identified similar gene state clusters for each circuit.  
Notably, the predictions of these gene states by RACIPE should be robust against 
different sampling distributions and different ranges of kinetic parameters. To verify this, 
we tested on the TS circuit versions of RACIPE created with three different distributions 
(uniform, Gaussian and exponential distribution) and three different ranges of parameters 
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(Figure 3.4).  Even though the precise shape of gene states appears to be slightly different 
for the different cases, the number and the locations of these gene states are consistent 
(Figure 3.4).  For the cases with exponential distribution, when the range of the 
parameters is reduced, the mean decreases as well; therefore, the two gene states become 
closer (Figure 3.4). We also found that the changes of the parameter range still result in 
similar gene states (Figure S2.4 and S2.5). 
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Figure 3.4 The gene states of the toggle-switch motif are robust against different 
types of distributions used to sample the parameters. 
(a) Uniform distributions in three different ranges were used to sample the kinetic 
parameters of the RACIPE models.  The top panels show the range of the distribution 
a
b
c
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(left panel: the full range; middle panel: half; right panel: 1/4).   The bottom panels show 
the probability density maps of the gene expression data from all the RACIPE models. 
Similarly, panels (b) and (c) show the use of a Gaussian distribution and an exponential 
distribution, respectively.  For the Gaussian distribution (b), its standard deviation was 
shrunk by a factor of two from left to right. For the Exponential distribution (c), its mean 
was reduced by a factor of two from left to right. 
 
To evaluate the effectiveness of RACIPE on larger circuits, we further applied the 
method to circuits with two to five coupled toggle-switch (CTS) motifs (Figure 3.5).  
Different from the above simple circuit motifs, the gene expression data obtained by 
RACIPE for these CTS motifs are now high-dimensional; thus in the scatter plot analysis 
we projected these data onto the first two principal components by principal component 
analysis (PCA).  For each circuit, we observed distinct gene states from PCA for the 
RACIPE models (Figure 3.5a).  More interestingly, the number of gene states found via 
PCA increases by one each time one more toggle switch is added to the circuit.  
Moreover, we applied HCA to the gene expression data, from which we identified the 
same gene states as from PCA (Figure 3.5b). At this stage, we can also assign high (red 
circles), intermediate (blue circles) or low expression (black circles) to each gene for 
every gene state.  Unlike in Boolean network models, the assignment in RACIPE is based 
on the distribution of expression pattern from all the models in the ensemble (Figure S2.6 
and S2.7).   
We can easily understand the meaning of each gene state.  In each case, the 
rightmost cluster in the scatter plot (Figure 3.5a) corresponds to the topmost cluster in the 
heatmap (Figure 3.5b), a state where all the A genes have high expression and all the B 
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genes have low expression.  Similarly, the leftmost cluster in the scatter plot corresponds 
to the bottommost cluster in the heatmap.  These two clusters are the most probable ones, 
and represent the two extreme states of the coupled toggle switch network.  As also 
illustrated in the scatter plots, for circuits with additional toggle switches, these two states 
separate from each other and the circuit now allows intermediate states.  By closely 
examining these intermediate states, we found that they (from top to bottom) correspond 
to a cascade of flips of the state of each consecutive toggle switch.  This explains why we 
observe one additional gene state every time we include an additional toggle-switch 
motif.  In addition, intermediate expression levels were frequently observed for genes 
lying in the middle toggle-switch motifs, instead of those at the edge.  The tests on CTS 
circuits demonstrate again the power of RACIPE in identifying robust features of a 
complex circuit. 
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Figure 3.5 Application of RACIPE to coupled toggle-switch circuits. 
RACIPE was tested on coupled toggle-switch circuits, as illustrated at the top of the 
figure. (a) 2D probability density map of the RACIPE-predicted gene expression data 
projected to the 1st and 2nd principal component axes. (b) Average linkage hierarchical 
clustering analysis of the gene expression data from all the RACIPE models using the 
Euclidean distance. Each column corresponds to a gene, while each row corresponds to a 
stable steady state. The clustering analysis allows the identification of several robust gene 
states, whose characteristics were illustrated as circuit cartoons to the right of the 
heatmap. The expression levels of each gene in these gene states are illustrated as low 
(grey), intermediate (blue), or high (red, see Figure S2.6 and S2.7 for the details). 
 
a
b
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3.3.2. Epithelial-to-Mesenchymal circuit 
3.3.2.1. Introduction 
EMT, as mentioned above, is crucial for embryonic development, wound healing 
and metastasis[155], a major cause for 90% cancer-related deaths[26]. Cells can undergo 
either a complete EMT to acquire mesenchymal phenotype or partial EMT to attain 
hybrid E/M phenotype[28,156], which maintains both E and M traits. Transitions among 
the Epithelial (E), Mesenchymal (M) and hybrid epithelial/mesenchymal (E/M) 
phenotypes have been widely studied either experimentally or theoretically[28].  Here, 
we utilized data from the literature and Ingenuity Pathway Analysis to construct a larger 
core gene regulatory circuit model of EMT (Figure 3.6a), which contains 13 
transcriptional factors (TFs), 9 microRNAs (miRs) and 82 regulatory links among them.  
Among the gene components, we have two biomarkers – CDH1 and VIM – that are 
commonly used to distinguish different phenotypes during EMT, and one signaling gene 
TGF-β.  The circuit is a much-extended version of several previous EMT models[12,40], 
which consist of only four gene families and one input signal.  It is similar in terms of 
scale to a recently proposed Boolean model of EMT[157], but as stressed here our 
models allow for continuous expression levels. 
3.3.2.2. Methods 
Construction of EMT circuit 
In our previous studies[28,40], we constructed a coarse-grained core gene 
regulatory circuit of EMT, consisting of two transcription factor (TF) families (SNAIL 
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and ZEB) and two microRNA (miR) families (miR-34 and miR-200) (Figure 2.2).  In 
addition, we also included an input node, representing the integration of multiple cell 
signaling pathways, such as HGF, NF-κB, WNT, TGF-β and HIF1-α, into SNAIL.  The 
outputs of the circuit are two commonly used biomarkers of EMT – CDH1 and VIM. 
Here, we expanded the size of the EMT circuit on the basis of the core EMT 
module as follows.  For each gene family, we considered individual members as separate 
nodes: SNAI1, SNAI2, TWIST1, TWIST2 for the SNAIL family, ZEB1 and ZEB2 for 
the ZEB family, miR-200a, miR-200b, miR-200c, miR-141 and miR-205 for the miR-
200 family, and miR-34a for the miR-34 family.  The input and output nodes, TGF-beta, 
CDH1 and VIM, were explicitly included in the new circuit model. We also included 
additional genes (FOXC2, KLF8, miR-101, miR-30c, miR-9, TCF3 and GSC) and the 
directed interactions among all the gene components according to recent experimental 
evidences[158,159], theoretical studies[13,160,161] and IPA(IPA®, QIAGEN Redwood 
City, www.qiagen.com/ingenuity). 
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Figure 3.6 RAICPE identifies multiple EMT cell states from gene network analysis.  
a b
c
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(a) A proposed Epithelial-to-Mesenchymal Transition (EMT) circuit is constructed 
according to the literature; the circuit consists of 13 transcriptional factors (circles), 9 
microRNAs (red hexagons) and 82 regulatory links. The blue solid lines and arrows 
represent transcriptional activations the red solid lines and bars represent transcriptional 
inhibition, and the green dashed lines and bars stand for translational inhibition. Two 
readout genes CDH1 and VIM are shown as green circles while the other transcriptional 
factors are shown in blue. (b) Average linkage hierarchical clustering analysis of the gene 
expression data from all the RACIPE models using the Euclidean distance. Each column 
corresponds to a gene, and each row corresponds to a stable steady state. Four major gene 
states were identified and highlighted by different colors. According to the expression 
levels of CDH1 and VIM, the four gene states were associated with epithelial (E in red), 
mesenchymal (M in grey) and two hybrid epithelial/mesenchymal (E/M I in purple and 
E/M II in brown) phenotypes. (c) The gene expression distribution of each gene state. 
The gene expression distribution of each gene for all of the RACIPE models is shown in 
blue, while that for each gene state is shown in red (50 bins are used to calculate the 
histogram of each distribution).  For clarity, each distribution is normalized by its 
maximum probability. Each row represents a gene and each column represents a gene 
state. (d-f) Gene expression data were projected to either CDH1/VIM, miR-200b/ZEB1, 
or miR-34a/SNAI1 axes.  Different gene states are highlighted by the corresponding 
colors and enclosed by the ellipses.  (g-i) Transcriptomics data from the NCI-60 cell lines 
were projected to either CDH1/VIM, miR-200b/ZEB1, or miR-34a/SNAI1 axes. The 
NCI-60 cell lines have been grouped into E, E/M and M phenotypes according to the 
ratio of the protein levels of CDH1 and VIM. Different gene states are highlighted by the 
corresponding colors and enclosed by the ellipses.   
 
Mathematical Model of EMT circuit 
For simplicity, we modeled the EMT circuit with the same approach as above, i.e. 
all the genetic components were coupled with Hill functions, typical of transcriptional 
control. This may not be completely accurate for translational regulation by microRNA 
(miR), but we leave this complication for future study. 
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, (26) 
where  Gi  represents the maximum production rate of gene i, and  ki  represents the 
degradation rate of gene i.  For the regulatory link (either activation or inhibition) from 
gene i to gene j,  ij0  represents the threshold level of gene i,  nij  is the Hill coefficient, and 
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+
X22X20 )/ 
+
X22X20 )
  kX20X20
X˙21 = GX21 (H
S (X20, X20X210, nX20X21 ,  
+
X20X21 )/ 
+
X20X21 )   kX21X21
X˙22 = GX22 (H
S (X9, X9X220, nX9X22 ,  
+
X9X22 )/ 
+
X9X22 )   kX22X22
1
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λij  is the maximum fold change of the gene j level caused by gene i.   
λij  < 1 for an 
inhibitory regulation, referred to as  
λij
− , while  
λij  > 1 for an excitatory regulation, 
referred to as  
λij
+ . For the model of the EMT circuit, Xi (i = 1, 2 … 22) stand for the 
expression levels of FOXC2, ZEB1, KLF8, CDH1, miR-101, ZEB2, SNAI1, miR-141, 
TGF-beta, miR-200a, miR-200b, miR-200c, miR-205, miR-30c, SNAI2, miR-34a, 
TWIST2, miR-9, VIM, TWIST1, TCF3, GSC, respectively. 
Analysis of EMT gene expression data from NCI-60 cell lines  
The gene transcript z scores of CDH1, VIM, ZEB1, miR-200b, SNAIL, miR-34a 
were downloaded from Cellminer[162]  and categorized into epithelial, hybrid E/M and 
mesenchymal sets based on the ratio of the E-cadherin and Vimentin levels[93]. 
3.3.2.3. Results 
Even with this simplification, RACIPE can already provide insightful information 
of the EMT regulation.  Consistent with what we learned from the test cases, 
unsupervised HCA of the RACIPE gene expression data can reveals distinct gene states 
(Figure 3.6b). Here there are four such states. We can map these gene states to different 
cell phenotypes possible during EMT – an E phenotype with high expression of the miRs, 
low expression of TFs, and CDH1HIVIMLO; a M phenotype with low expression of the 
miRs, high expressions of TFs, and CDH1LOVIMHI; and two hybrid E/M phenotypes with 
intermediate expression of both miRs, TFs and CDH1/VIM.  The E/M I state lies closer 
to the E state, and the E/M II state lies closer to the M state.  More intriguingly, we found 
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SNAI1 and SNAI2 become highly expressed in the E/M I phenotype while ZEB1 and 
ZEB2 are not fully expressed until the E/M II or the M phenotype (Figure 3.6c), which is 
a possibility supported by recent experimental results[12]. 
Moreover, RACIPE can help to find genes of similar function and filter out less 
important genes in the core circuit. As shown in Figure 3.6b, genes are grouped into two 
major clusters according to their expression levels throughout all the RACIPE models – 
miRs/CDH1 and TFs/VIM.  The former genes are highly expressed mainly in E 
phenotypes while the latter are highly expressed in M phenotypes.  We also found three 
microRNAs (miR-30c, miR-205 and miR-9) to be randomly expressed in the RACIPE 
models, indicating these three microRNAs are less important to these EMT phenotypes.  
From the topology of the circuit, we see that these three microRNAs lack feedback 
regulation and act solely as inputs.   
A typical approach taken in cell biology is to use two biomarkers to identify cells 
of different states in a mixed population by fluorescence-activated cell sorting (FACS).  
To mimic the analysis, we projected the gene expression data of the RACIPE models 
onto the two axes of important genes, as shown in the scatter plots in Figure 3.6d-f.  In all 
of the three cases, the E and the M phenotypes can be distinguished.  However, for the 
hybrid phenotypes, the E/M I and the E/M II states overlap in the CDH1-VIM plot 
(Figure 3.6d).  These two hybrid phenotypes can be separated more easily in the ZEB1-
miR200b plot (Figure 3.6e).  In the SNAIL1-miR34a plot (Figure 3.6f), however, the two 
E/M states overlap with the M state.  The theoretical prediction that the SNAIl1-miR34a 
axis is less efficient at distinguishing the states is supported by transcriptomics data from 
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the NCI-60 cell lines[162] (Figure 3.6g-i). We see here that either VIM-CDH1 or the 
ZEB1-miR200b axes are indeed better than the SNAIL1-miR34a axes in separating 
different EMT phenotypes. Our results are also consistent with our previous theoretical 
finding that ZEB1 is more crucial than SNAIL1 in the decision-making of EMT[12]. 
3.4. Discussion 
Recently, the rapid development of genomic profiling tools has allowed the 
mapping of gene regulatory networks.  Yet, it remains a challenge to understand the 
operating mechanisms and the design principles of these networks.  Conventional 
computational modeling methods provide insightful information; however, their 
prediction power is usually limited by the incompleteness of the network structure and 
the absence of reliable kinetics.  To deal with these issues, we have developed a new 
computational modeling method, called RACIPE, which allows unbiased predictions of 
the dynamic behaviors of a complex gene regulatory circuit.  Compared to traditional 
methods, RACIPE uniquely generates an ensemble of models with distinct kinetic 
parameters.  These models can faithfully represent the circuit topology and meanwhile 
capture the heterogeneity in the kinetics of the genetic regulation.  By modeling the 
dynamics of every RACIPE model, we can utilize statistical analysis tools to identify the 
robust features of network dynamics.  We have successfully tested RACIPE on several 
theoretical circuit motifs and a proposed core Epithelial-to-Mesenchymal Transition 
(EMT) gene regulatory circuit.  In each circuit, RACIPE is capable of predicting the 
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relevant gene states and providing insights into the regulatory mechanism of the decision-
making among gene states.  
Unlike other methods that utilize randomization strategies to explore the 
parameter sensitivity for gene circuit[141–144], RACIPE adopts a more carefully 
designed sampling strategy to randomize circuit parameters over a wide range, but 
meanwhile to satisfy the half-functional rule to gain a comprehensive understanding of 
circuit dynamics. Instead of looking for the sensitivity of the circuit function to parameter 
variations [141,144] and the parameters best fitting the experimental data[142,143], we 
focused on uncovering conserved features from the ensemble of RACIPE models. This 
was carried out by standard statistical learning methods such as hierarchical clustering 
analysis.  We showed the power of RACIPE to predict the robust gene states for a circuit 
with a given topology. Also, conceptually similar to the mixed-effects models used to 
describe a cell population for a very simple system [143], i.e. a one-gene transcription 
without a regulator, RACIPE could be potentially applied to a very large gene circuit to 
describe the gene expression dynamics of a cell population with an ensemble of models - 
an aspect we will work on in our future study.  Moreover, it is easy to implement gene 
modifications such as knockdown or overexpression treatments with the RACIPE method 
to learn the significance of each gene or link in the circuit.  Therefore, RACIPE provides 
a new way to model a gene circuit without knowing the detailed circuit parameters.  
Another parameter-independent approach people often use for gene circuit 
modeling is Boolean network model[163], which digitalizes the gene expression into on 
and off states and uses logic functions to describe the combinatorial effects of regulators 
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to their targets.  Compared with the Boolean network model, RACIPE is a continuous 
method, so it is not restricted to the on and off values.  Instead, RACIPE enables us to 
find the intermediate levels of gene expressions beyond the on and off states, as we 
showed in Figure 3.5 and Figure 3.6.  From the ensemble of RACIPE models, we can 
predict the expression distribution of each gene, which can be directly compared with 
experimental expression data.  The comparison will allow us to further refine the core 
circuit.  In addition, in RACIPE, we not only obtain in silico gene expression data, but we 
also know the kinetic parameters for each model.  From these parameter data, we can 
directly compare the parameter distributions for different gene states, from which we can 
learn the driving parameters that are responsible for the transitions among the states. 
To conclude, here we have introduced a new theoretical modeling method, 
RACIPE, to unbiasedly study the behavior of a core gene regulatory circuit under the 
presence of intrinsic or extrinsic fluctuations.  These fluctuations could represent 
different signaling environments, epigenetic states, and/or genetic backgrounds of the 
core circuit and can cause cell-cell heterogeneity in a population. By approximating these 
fluctuations as variations of the model parameters, RACIPE provides a straightforward 
way to understand the heterogeneity and to explain further how gene circuits can perform 
robust functions under such conditions.  Moreover, RACIPE uniquely generates a large 
set in silico expression data, which can be directly compared with experimental data 
using common bioinformatics tools.  RACIPE enables the connection of traditional 
circuit-based bottom-up approach with profiling-based top-down approach.  We expect 
RACIPE to be a powerful method to identify the role of network topology in determining 
network operating principles.   
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Chapter 4 
Decoding Stem Cell Regulatory Circuit by 
Random Circuit Perturbation Method 
Stem cells are capable to perform precise and robust fate decisions during 
development; however, how the underlying gene regulatory network reliably specify the 
fates under the influence of intrinsic and extrinsic noises is not well understood. Here, we 
applied Random Circuit Perturbation (RACIPE) method on a proposed stem cell gene 
regulatory circuit, and found that the stable states of all models converge to 
experimentally observed gene state clusters even when the parameters are strongly 
perturbed.  Compared to circuits with random topology, the stem cell circuit allows for 
more robust gene states and is less likely to have oscillatory/chaotic dynamics. From 
parametric perturbations for all the RACIPE models, we identified key genes and the 
concomitant hierarchical structure of stem cell differentiation.  Our results suggest that 
dynamics of the stem cell circuit is mainly maintained by its well-evolved topology, 
instead by detailed circuit parameters. 
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4.1. Introduction 
The differentiation of stem cells is an intense research area in developmental 
biology[164] and regenerative medicine[165].  Stem cells are unique in that they are 
capable of generating all types of cells in a precise and organized manner[166], and the 
dysregulation of the differentiation results in early fetal deaths or severe diseases.  Thus, 
the understanding of the mechanism of stem cell differentiation is crucial to the 
reprogramming of differentiated cells[167] and the stem cell-based therapies[168]. Due 
to their essential role in survival for all multicellular organisms, the mechanism of the 
differentiation is presumably highly conserved and able to precisely make decisions for 
each step lineage specification.  However, recent evidences suggest that some 
development-related regulators, such as Nanog, are expressed in large variation[169–
173].  Moreover, stem cells have been shown to have heterogeneous gene expression in 
culture[170–172], and cells with different expressions can sometimes convert into each 
other[171,172].  The observed heterogeneity seems to put precise fate decision at risk.  
This paradox may be reconciled by two possible explanations - either the regulatory 
mechanism of stem cell differentiation is robust in performing its functions against gene 
noises[174], or it takes advantage of the noises for its own functions[175].  A better 
understanding to this question, and thereafter to the role of gene noise in decision-
making, will be especially helpful for decoding the design principle of the underlying 
gene regulatory network for stem cell differentiation. 
Computational methods are well utilized in this field to study the regulatory 
mechanism of stem cell differentiation on the level of gene regulatory network, which 
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now is able to be constructed or inferred by current molecular profiling 
techniques[176,177]. Considering the complexity of these network, the bottom-up 
modeling approaches of the core gene regulatory circuit with master regulators such as 
Oct4, Cdx2 etc. are wildly studied by either deterministic models[178,179] or stochastic 
models[180–182].  Also, the dynamic Bayesian network (DBN) method[183] and the 
landscape and kinetic path approach[184] have been used to explore larger gene networks 
of the stem cell.  However, it still remains a challenge to fully understand the regulatory 
mechanisms by current quantitative methods, due to the lack of the experimental kinetic 
data for most of the regulatory processes, and also the potential over-simplified 
standalone circuits without considering the effects of many other genes and the complex, 
variable cellular microenvironment.  
In our previous work[185], we developed a new computational method, named 
random circuit perturbation (RACIPE), for modeling the possible dynamic behavior 
defined by the topology of a gene regulatory circuit without the prior knowledge of the 
accurate parameters of the circuit.  RACIPE generates an ensemble of mathematical 
models (Figure 3.1), each of which has a different set of kinetic parameters representing 
intrinsic and extrinsic noises caused by variations of signaling states, epigenetic states, 
and genetic backgrounds (including cells with genetic mutations leading to disease).  The 
parameters of each model differ by one or two orders of magnitude and are generated 
under a specially designed parameter sampling scheme to capture the key role of circuit 
topology. The computationally generated ensemble predicts the expressions of the genes 
in the circuit under variable environments, which is subject to statistical methods to 
identify the most probable and conservative features.  More importantly, RACIPE 
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provides a physical model underlying the gene expression data, enable us to decode the 
design principle and to evaluate the robustness of a core gene circuit. 
Here, we applied RACIPE on the core regulatory circuit of stem cell 
differentiation, and identified robust gene expression patterns in consistent with single 
cell gene expression data. We also demonstrated that the topology of stem cell circuit is 
well evolved to perform its functions. Furthermore, in silico perturbation treatments of 
the ensemble of RACIPE models reveal the hidden hierarchical structure in the circuit, 
allowing a two-step differentiation process. 
4.2. Methods 
Application of RACIPE on stem cell circuit 
Based on previous studies[183,184,186,187], we constructed a core gene 
regulatory circuit for mouse stem cell differentiation, composed of eight transcription 
factors (Oct4, Cdx2, etc.), a protein complex (OCT4-SOX2) and 25 regulations among 
them (Figure 4.1a). Due to the complexity of the regulatory links among genes, the 
operative functions of this circuit have to date remained elusive.  The dynamic behavior 
of stem cell circuit can be described by the deterministic rate equations as follows: 
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!X1 = GX1 H
S ( X1, X1X10 ,nX1X1 ,λX1X1
+ )H S ( X5, X5 X10 ,nX5X1 ,λX5X1
− )H S ( X7 , X7 X10 ,nX7 X1 ,λX7 X1
+ )H S ( X8, X8 X10 ,nX8 X1 ,λX8 X1
− )
/ (λX7 X1
+ λX7 X1
+ )− kX1 X1
!X2 = GX2 H
S ( X1, X1X20 ,nX1X2 ,λX1X2
+ )H S ( X3, X3 X20 ,nX3X2 ,λX3X2
+ ) / (λX1X2
+ λX3X2
+ )− kX2 X2
!X3 = GX3 H
S ( X3, X3 X3,nX3X3 ,λX3X3
+ )H S ( X5, X5 X30 ,nX5X3 ,λX5X3
− )H S ( X7 , X7 X30 ,nX7 X3 ,λX7 X3
− ) / λX3X3
+ − kX3 X3
!X4 = GX4 H
S ( X5, X5 X40 ,nX5X4 ,λX5X4
+ )H S ( X7 , X7 X40 ,nX7 X4 ,λX7 X4
+ )H S ( X9 , X9 X40 ,nX9 X4 ,λX9 X4
+ ) / (λX5X4
+ λX7 X4
+ λX9 X4
+ )− kX4 X4
!X5 = GX5 H
S ( X1, X1X50 ,nX1X5 ,λX1X5
− )H S ( X4 , X4 X50 ,nX4 X5 ,λX4 X5
+ )H S ( X5, X5 X50 ,nX5X5 ,λX5X5
− )H S ( X6 , X6 X50 ,nX6 X5 ,λX6 X5
+ )
H S ( X8, X8 X50 ,nX8 X5 ,λX8 X5
+ )H S ( X3, X3 X50 ,nX3X5 ,λX3X5
− ) / (λX4 X5
+ λX6 X5
+ λX8 X5
+ )− kX5 X5
!X6 = GX6 H
S ( X5, X5 X60 ,nX5X6 ,λX5X6
+ ) / λX5X6
+ − kX6 X6
!X7 = GX7 H
S ( X2 , X2 X70 ,nX2 X7 ,λX2 X7
− )H S ( X3, X3 X70 ,nX3X7 ,λX3X7
− )H S ( X8, X8 X70 ,nX8 X7 ,λX8 X7
+ ) / λX8 X7
+ − kX7 X7
!X8 = GX8 H
S ( X7 , X7 X80 ,nX7 X8 ,λX7 X8
+ )H S ( X9 , X9 X80 ,nX9 X8 ,λX9 X8
+ ) / (λX7 X8
+ λX9 X8
+ )− kX8 X8
!X9 = GX9 H
S ( X8, X8 X90 ,nX8 X9 ,λX8 X9
+ ) / λX8 X9
+ − kX9 X9
, (27)
 
where  Gi  represents the maximum production rate of gene i, and  ki  represents the 
degradation rate of gene i.  For the regulatory link (either activation or inhibition) from 
gene i to gene j,  ij0  represents the threshold level of gene i,  nij  is the Hill coefficient, and 
 
λij  is the maximum fold change of the gene j level caused by gene i.   λij
 < 1 for an 
inhibitory regulation, referred to as 
 
λij
− , while 
 
λij  > 1 for an excitatory regulation, 
referred to as 
 
λij
+ . Xn (n = 1, 2 … 9) stand for the expression levels of Gata6, Gcnf, Cdx2, 
Klf4, Nanog, Pbx1, Oct4, OCT4-SOX2 complex and Sox2, respectively. In this model, 
the OCT4-SOX2 complex is modeled as a transcription factor. 
Through RACIPE method, we generated 10,000 sets of parameters (10,000 
RACIPE models) for this circuit.  To find the stable steady states for each RACIPE 
model, we simulated the above ordinary differential equations (ODEs) using the Euler 
method until the system reaches to a steady state.  To explore the solution space 
thoroughly, we repeated the above calculations 1,000 times with different initial 
conditions. From the 1,000 steady state solutions, we identified the number of distinct 
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stable states and the expression of genes for each stable state.  The protocol was tested on 
the stem cell circuit with 10 independent runs, and we identified the converged 
probability distribution of the number of stable steady states for each model and the 
probability distribution of the identified gene states (Figure S3.1).  We found some rare 
occasions (<1%) to have a RACIPE model with more than six coexisting stable steady 
states.  Since they are not statistically significant, we excluded these data from further 
analysis.  The circuit also has ~ 2% chance to have oscillatory or chaotic dynamics, and 
we also excluded them from the analysis. 
Normalization of gene expression data  
From an ensemble of the RACIPE models, we collected a large set of gene 
expression data, very similar to those obtained in experiment.  Therefore, we can apply 
tools for data analysis to these computationally generated data.  Here, we processed the 
computational expression data by a standard normalization method before we performed 
clustering analysis.  The gene expression levels from the WT models are normalized by 
first log transformation and standardization, i.e. 
2 2
2
log ( ) log ( )
(log ( ))
WT WT
WT i i
i WT
i
x xx
xs
-
® , (28) 
The gene expression levels from the treatment models is normalized by first log 
transformation and standardization by the mean ( 2log ( )
WT
ix ) and the standard deviation (
2(log ( ))
WT
ixs ) of the WT models 
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i
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-
® , (29) 
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For the single cell gene expression data of mouse embryo cells[117], we followed the 
procedures in the original paper for data normalization. 
Clustering analysis  
We performed clustering analysis on the normalized gene expression data from 
the RACIPE models as shown in Figure 4.1b (left).  Each column represents a gene, and 
each row represents a stable steady state of the circuit for a particular RACIPE model. 
For RACIPE models with more than one stable state, the gene expression profiles for all 
of the stable states were shown in multiple rows.  We applied the average linkage 
hierarchical clustering analysis using Euclidean distance by Cluster 3.0[152] and the 
results were visualized by JavaTreeview[153].  The cutoff distance was chosen to be 0.8 
so that major clusters have probability more than 0.5% and each cluster has a distinct 
gene expression pattern.  These clusters correspond to different gene states for the circuit.  
Principal component analysis was performed on the same data by using “pca” function in 
Matlab/2014b (Figure 4.1d).  The major gene clusters can be readily recognizable from 
the probability density map projected onto the first two principal component axes. 
The single cell gene expression data of mouse embryo cells[117] were analyzed 
by the same average linkage hierarchical clustering analysis with Euclidean distance, 
from which we identified the same nine clusters (Figure S3.5) as those found in the 
original paper.  To compare the experimental data with the predicted data from the 
RACIPE, we extracted the data of the 6 common genes (Gata6, Cdx2, Klf4, Nanog, Oct4, 
and Sox2), as shown in the second heat map (Figure 4.1b, right). 
Random gene expression data  
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Throughout the study, we utilized randomly generated gene expression data for 
statistical significant test.  We first computed the histogram of gene expression for each 
gene from all the RACIPE models.  A random gene expression vector was constructed so 
that each element has value randomly sampled from the histogram of the corresponding 
gene. 
Comparison between the gene expression data from the RACIPE models and the 
experiments. The similarity between two gene expression vectors can be quantified by 
the mean square error ( XYMSE ) 
2
2
1XYMSE X Y
n
= - , (30) 
where X and Y are the gene expression vectors with the same number of genes n.  The 
choice of X and Y will be explained in the next two paragraphs.  X and Y were regarded 
to be significantly similar if XYMSE  is better than 99% XZMSE , where  
2
2
1XZ
i iMSE X Zn
= - , (31) 
Z consists of 10,000 random gene expression vectors (each vector is labeled by i, see the 
above section). 
Cluster-based analysis: An experimental gene state cluster was matched to a gene 
state cluster from RACIPE as follows.  We calculated the XYMSE  between the average 
gene expression vector of the experimental cluster (X) and the average gene expression 
vector for every RACIPE cluster (Y) (Figure S3.6).  Then, we calculated the XZMSE  
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between the average gene expression vector of the experimental cluster (X) and each of 
the 10,000 random gene expression vectors (Z).  The experimental cluster was considered 
to be significantly similar to a RACIPE cluster when the XYMSE  value is smaller than 
99% of the XZMSE  values.   
Individual-based analysis: Alternatively, we calculated the fraction of the 
RACIPE models whose gene expression vector matches any one of the experimental 
clusters by a one-on-one comparison.  For each experimental gene state cluster, we 
calculated the XYMSE  between the average gene expression vector of the experimental 
cluster (X) and the gene expression vector of each stable state for every RACIPE model 
(Y).  The RACIPE model was considered to be significantly similar to one of the 
experimental clusters according to the above criterion. 
Null model for hypothesis test: p values were computed for the comparison 
between the experimental data and the RACIPE data.  For the cluster-based analysis, we 
generated 15 random gene expression vectors to represent the average gene expression 
vectors of 15 gene states, and randomly assigned the probability of a different RACIPE 
cluster to each vector.  This data serves as a null model, and they were compared with the 
experimental data.  This procedure is repeated for 10,000 times for statistical analysis 
((Figure 4.1e and Figure S3.7a).  For the individual-based analysis, we performed two 
random tests.  First, we generated the same number of random gene expression vectors as 
the RACIPE models (Figure S3.7b), and used them as the null model. Second, the null 
model is the same RACIPE models, but for each cluster the gene identities were shuffled 
(Figure S3.7c). 
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Comparison of the parameters between two gene states.  
Each parameter from all of the RACIPE models was first standardized by 
subtracting its mean and dividing the difference by its standard deviation. Then, we found 
the RACIPE models (group I) that have stable states from the gene state cluster i but no 
states from the cluster j.  Similarly, we searched for the RACIPE models (group J) that 
have stable states from the gene state cluster j but no states from the cluster i.  The mean 
of each parameter in both groups was plotted in a 2D diagram (Figure 4.1d and Figure 
S3.8).  Note that the fold changes of the inhibitory regulations were inversed before the 
normalization. 
Comparison with random circuits 
We applied the RACIPE to each random circuit. Using the same cutoff distance as 
the stem cell circuit, we identified major clusters (gene states) by using hierarchical 
clustering analysis (Figure S3.11).  The clusters from the random circuits were compared 
with experimental data by both the cluster-based and the individual-based methods 
(Figure 4.2b and Figure S3.13).  
We used k nearest neighbors approach[188] to estimate the local density around 
each data point in the high dimensional gene expression space.  The local density of a 
point x is 
( )
( )DD k
k kP x
NV N c R x
@ =
× ×
, (32) 
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where k is number of nearest neighbors for the density estimation (set to be 100 here), N 
is the total number of data points and V is the volume that encloses the k neighbors 
surrounding the point x.  Dc  is the volume of the unit sphere in D dimensions, which is 
equal to /2 ( / 2 1)DDc Dp= G + . ( )
D
kR x  is the distance between the point x and its k-th 
nearest neighbor. 
Classification of the gene expression data  
By the hierarchical clustering analysis of the RACIPE models, we identified 15 
major gene state clusters (Figure 4.1d, left).  The gene expression data of these gene 
states serve as the references for later classification of an unclassified gene expression 
data.  To do this, we assigned the unclassified gene expression profile (i) to the gene state 
cluster with the smallest “minimum Euclidean distance” ( inD ) between the i and the 
reference gene state n. inD  is defined as 
 
Din =
1≤ j≤Nn
min( ( Xig − Rnjg )2
g=1
9
∑ ) , (33) 
where Nn  is the number of gene expression data in the gene state cluster n (n = 1, 2 … 
15). Xig  is the expression level of gene g in the steady state i, and  Rnjg
 is the expression 
level of gene g for every steady state j in the reference gene state n.  
To calculate the probability of observing each gene state cluster from all the 
RACIPE models (Figure 4.1c and Figure S3.1a), we computed the weighted count of all 
the gene expression data that belong to the cluster.  We weighted each gene expression 
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data by the number of stable steady states for the corresponding RACIPE model.  For 
example, if the RACIPE model is bi-stable, the contributions of both of the stable steady 
state data are ½ instead of 1.  
Perturbation treatment  
For the perturbation treatment, we generated a new ensemble of models by 
specifying certain parameters and randomizing the rest parameters in the same ranges as 
before.  We simulated the knockout (KO) of a gene by setting the maximum production 
rate ( Gi ) of the gene to be zero.  For the linkage removal, we set the fold change of the 
regulation to be 1 (no fold change).  For the activation (inhibition) of a gene, we scaled 
the maximum production rates ( Gi ) by a certain level.  We referred to the RACIPE 
models for the original circuit as WT models, and those for the circuit under certain 
treatment as treatment (T) models.   
Hybrid RACIPE data 
We randomly picked 1,000 steady states from the original RACIPE models (WT), 
and the ones with the treatment on each gene (except for the OCT4-SOX2 complex).  The 
treatment includes inhibition of a gene by 50 folds and activation of a gene by 50 folds.  
Together, we compiled a hybrid gene expression data set with 1,000 original data and 16 
times 1,000 new treatment data.  By using the same hierarchical clustering analysis on 
this hybrid data set, we again identified very similar gene state clusters as the original 
RACIPE models.  The comparison between the gene state clusters of the hybrid data and 
those of the original data was performed by the cluster-based analysis (Figure S3.9).   
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Analysis of knockout  
To measure the effects of the gene knockout, we calculated Kullback–Leibler 
(KL) divergence (Dkl) for the knockout of each gene, defined as 
DKLi (PWT || PiKO ) = PWT (n)ln
PWT (n)
PiKO (n)n
∑ , (34) 
where  PWT  is the probability distribution of the number of stable steady states for each 
RACIPE model for the circuit without treatment (WT), and  PiKD is that for the circuit with 
the knockout (KO) of gene i.  n stands for the RACIPE models with n stable states.  The 
KL divergence was also applied to evaluate the effects of the removal of each regulatory 
link (Figure 4.3b). 
Population heterogeneity  
We quantified the population heterogeneity by calculating the weighted 
information entropy (phylogenetic)[189] 
 
H = − l(b)P(b) log2 P(b)
branches b of T
∑ , (35) 
where T is a tree derived from the hierarchical clustering analysis on the RACIPE models 
(Figure 4.1b, left),  l(b)  is the length of a branch b of the T, and ( )P b  represents the 
probability of all the gene states that are represented by the leaves descending from b. 
More heterogeneous population tends to have higher entropy. 
 119 
 
4.3. Results 
Stem cell circuit performs robust functions against environmental variability 
For majority of the models (~98%), the circuit allows one or multiple stable 
steady states (Figure 4.2a and Figure S3.3a).  We collected into one dataset the gene 
expression profiles for the stable states of all the models (Figure 4.1b).  This dataset 
resembles experimental gene expression data, thus inspiring us to apply similar 
biostatistics tools to analyze the data. Using hierarchical clustering analysis (HCA, 
Methods), we found that these gene expression profiles form fifteen gene state clusters 
(Figure 4.1b, c).  The clustering results were confirmed by principal component analysis 
(PCA) (Figure 4.1d).  It is worth noting that these gene state clusters were observed even 
though there are large variations in the circuit kinetic parameters.  Similarly, robust 
clusters were also observed for several simple toggle-switch-like circuit motifs and a 
biological gene circuit for cancer metastasis in our previous study (Figure 3.3 and Figure 
3.6).  These observations suggest that the topology of gene circuits define all possible 
gene expression patterns, and the RACIPE method is ideal to identify these gene 
expression patterns in an unbiased manner. 
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Figure 4.1 The RACIPE method uncovers robust gene states for the stem cell 
circuit.  
(a) Diagram of the core gene regulatory circuit for stem cell differentiation.  Red lines 
and arrows represent activations; blue lines and bars represent inhibitions. (b) 
Comparison of the gene expression of the circuit between the RACIPE prediction (left) 
and mouse embryo single cell data (right).  In both heat maps, each column represents a 
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gene; each row represents the gene expressions for a stable steady state of a RACIPE 
model (left) or that for a single cell (right).  Robust clusters (gene states, colored 
hierarchical trees) were identified for both data sets by unsupervised hierarchical 
clustering analysis.  Four computationally predicted gene states match those from the late 
stage single cell data.  The histogram of the predicted expression levels for each gene is 
shown at the bottom (blue, 50 bins in each histogram). (c) Characteristic gene 
expressions for each gene state, ranked by the likelihood in the RACIPE models.  The 
four gene states that match the experimental data are highlighted by blue asterisks and are 
shown with their likelihoods. (d) 2D probability density map of the RACIPE predicted 
gene expression data projected to the 1st and 2nd principal component axes.  The most 
probable gene states (top 6) are labeled. (e) Histogram of the number of experimental 
gene states identified by a random dataset (see Methods). The RACIPE (red dotted line) 
outperforms more than 99% of random models. (f) Key parameters that are involved in 
the transitions among certain gene states. 
 
RACIPE predications are experimentally consistent 
Next, we evaluated the power of RACIPE in predicting experimentally observed 
gene expression profiles.  We found that the gene expression patterns for the most 
probable predicted RACIPE clusters have been observed experimentally in the literature 
(Figure 4.1c and Figure S3.1b).  During embryonic development, the first cell fate 
determination happens at the stage of blastocyst where the inner cell mass (ICM) and 
trophectoderm (TE) are formed[190]. Oct4 and Sox2 were reported to express throughout 
ICM[191].  At the early differentiation of inner cell mass (ICM), Gata6 and Nanog may 
co-express (State 6)[192,193], but Nanog is required together with Oct4 and Sox2 for 
cells to commit to epiblast and reach ground sate pluripotency (State 1 and 12)[191,194]. 
Further differentiation of mouse embryonic stem (mES) cells into mesendoderm requires 
Nanog and Oct4 instead of Sox2 (State 8)[195]. During the Gata6 induction of mES cells 
into extraembryonic endoderm (ExE), a step-wise pluripotency factor disengagement was 
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reported, with initial repression of Nanog and Esrrb, then Sox2, and finally Oct4, where 
the co-expression of Gata6 and Oct4 (State 5) was observed[194].  On the other hand, 
down regulation of Oct4 induces the differentiation of mES cells into trophoblast with the 
increase expression of Cdx2 and Gata6 (State 2)[196,197]. Overexpression Cdx2 is 
sufficient to generate proper trophoblast stem (TS) cells (State 3)[117,198].  TE could 
further differentiate into ExE, where Cdx2, Gata6 and Sox2 may be all expressed (State 
7,9, 11 and 15)[198–200].  
In addition, we compared the RACIPE results with single cell gene expression 
data for mouse embryo cells at different development stages[173] (Figure 4.1b).  
Interestingly, the RACIPE gene states only match those from the late stage of embryo 
development (≥32 cells), where totipotent cells start to differentiate into trophectoderm 
(TE) and inner cell mass (ICM), but not from the early stage (≤16 cells) (Figure 4.1b), 
suggesting that this specific core circuit may be only operative at the late stage.  These 
matched gene states - the Cdx2Hi state, the Gata6Hi/NanogHi/Oct4Hi/Sox2Hi state, the 
NanogHi/Oct4Hi/Sox2Hi state and the Gata6Hi/Oct4Hi/Sox2Hi state – are among the most 
probable gene states from the RACIPE models (Figure 4.1b, c).  Notably, the good 
matching to the experimental data is statistically significant (Figure 4.1e and Figure 
S3.7).   
Therefore, similar as single cell gene expression data measured by qPCR or RNA-
seq, RACIPE could predict the expression of genes in the circuit based on its topology 
information, subject to the same analysis for the experimental data to infer the 
information of subpopulations and characteristic expressed genes in each subpopulation.  
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However, more than statistical inference from the data, RACIPE meanwhile established 
the physical model of the circuit underlying the data, thus enable us to uncover the 
fundamental design principles of the circuit functions. For example, from the RACIPE 
models, we can identify the parameters that are significantly changed between two gene 
states (Figure 4.1f and Figure S3.8).  These parameters could be the best candidates to 
target to change during cell phenotypic transitions.   
Stem cell circuit is well evolved circuit to perform robust functions 
To further investigate the role of the circuit topology to its functions, we 
constructed two types of random circuits (Figure S3.10 and Methods) with similar 
structures as the stem cell circuit. Both types of circuits (Figure S3.10) preserve the total 
number of regulatory links and genes, the number of inward links and the number of 
outward links for each gene, and the activations from Oct4, Sox2 to OCT4-SOX2.  For 
the Type I random circuit (Figure S3.10a), in addition, we kept the same number of 
excitatory inward links and inhibitory inward links. Compared to the stem cell circuit, the 
random circuits are much more likely to generate oscillatory or chaotic dynamics, and are 
more likely to have only one stable state for each RACIPE model (Figure 4.2a).  When 
the gene states from all the RACIPE models are combined, the expression histogram for 
each gene typically has multiple peaks for the native stem cell circuit (blue in Figure 
4.2c), but has only a single peak for many genes for the random circuits (red in Figure 
4.2c).  We also found that it is difficult to cluster the gene expression data in the case of 
the random circuits (Figure S3.11), partly because the stem cell circuit has much higher 
local density of the RACIPE gene expression data than a random circuit (Figure 4.2d and 
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Figure S3.12).  Furthermore, the RACIPE models of the stem cell circuit match the 
mouse embryo single-cell data significantly better than those of a random circuit (Figure 
4.2b and Figure S3.13).  These findings suggest that the stem cell circuit has evolved to 
be robust to perform its biological function and that RACIPE can reveal that function. 
 
Figure 4.2 Comparison between the stem cell circuit and a random circuit.  
(a) Probability distribution of the number of stable steady states of each RACIPE model 
for the stem cell circuit and random circuits (type I: Figure S3.10a, type II: Figure 
S3.10b, and see Methods).  The error bar for the stem cell circuit shows the standard 
deviation for 10 simulation repeats, while the ones for the random circuits represent the 
standard deviations for the 10 random circuits of each type. (b) Percentage of the 
RACIPE predicted gene expression data in consistent with the experimental single cell 
gene expression data in Figure 4.1b. (c) Histogram of the expression for each gene for the 
stem cell circuit and the random circuits. The multi-peak distributions are in blue and the 
single peak distributions are in red.  The columns represent genes and rows correspond to 
different circuits.  Two representative random circuits for each type are presented, and 
the rest results are shown in Figure S3.12. (d) Histogram of the local density distributions 
of the RACIPE predicted gene expression data (blue, mean value is highlighted by blue 
downward arrows), the random gene expression data resampled from the RACIPE 
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expression distribution of each gene (orange), the random gene expression data 
resampled from standard normal distributions (grey). 
 
Hierarchical structure in stem cell circuit 
In addition to identifying the gene states, RACIPE can also be applied to decode 
the design principles of a gene circuit, as shown in the following example.  We can use 
perturbation analysis (gene knockout (KO) and link removal from the RACIPE analysis) 
to identify the most important genes and regulatory links to the circuit dynamics.  In the 
case of the stem cell system, we found Oct4, Sox2, OCT4-SOX2 and Cdx2 to be most 
sensitive to the knockout treatments (Figure 4.3a-c), as measured by the changes of the 
probability distribution of the number of stable states for each RACIPE model (defined 
by the KL divergence, see Methods).  These gene components form the first decision-
making sub-circuit (Figure 4.3d, top layer, Oct4/Cdx2), and the rest of the components 
form the second one (bottom layer, Gata6/Nanog).  Interestingly, the dynamic behavior 
of the upper sub-circuit is much less disrupted than that of the lower sub-circuit when the 
regulatory links connecting the two sub-circuits are removed (Figure S3.14).  Our 
findings are consistent with our current knowledge of mouse embryo development[201], 
where Oct4/Cdx2 work as the first decision gate for inner cell mass and trophectoderm 
differentiation while Gata6/Nanog specify the lineage between epiblast and primitive 
endoderm. 
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Figure 4.3 Hierarchical structure of the stem cell circuit inferred from the 
perturbation analysis.  
(a) The Kullback-Leibler (KL) divergence between the probability distributions of the 
number of stable states for each RACIPE model computed before and after the knockout 
(superscript KO) of each gene. (b) Similar to (a), but the KL divergences are between the 
distributions before and after removal of each regulatory link. (c) Schematic diagram of 
the stem cell circuit highlighting the important genes and regulatory links.  The larger the 
gene element and the ticker the regulatory link, the more importance the component to 
the circuit behavior, as inferred from the analyses in (a) and (b). (d) The hierarchical 
structure of the stem cell circuit (left) is consistent with the two-step decision-making of 
mouse embryonic development (right).  (e) The roadmap of stem cell differentiation 
inferred from the RACIPE simulations.  All the original RACIPE models (WT) were 
treated by activating (­) or inhibiting (¯) the production of the corresponding genes.  The 
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probability distribution of the gene states for each condition was plotted in the 
corresponding pie chart. 
Understand the population behavior of stem cells 
We further explored the possibility of using the ensemble of the RACIPE models 
to simulate the behavior of a cell population.  Indeed, the idea of kinetic parameter 
variation has been used to model the expression of an inducible gene in an yeast 
population[143].  RACIPE allows us to extend this idea to the stem cell population. Thus, 
the roadmap for the stem cell development can be explained by starting from a population 
of precursor cells modeled by the original RACIPE models and stimulating the 
corresponding gene expressions in each RACIPE model by a relevant external signal 
(Figure 4.3e and Methods).  We found that strong activation of Cdx2 converts most 
RACIPE models to the Cdx2Hi states (trophectoderm)[202], while strong activation of 
Oct4 converts most models to either the NanogHi or the Gata6Hi states (inner cell 
mass)[201,203]. After strong activation of Oct4, additional signaling effects on Nanog 
and Gata6 converts cells to either the NanogHi state (epiblast) or the Gata6Hi gene state 
(primitive endoderm)[201] (Figure 4.3e).  
Within this scenario, we propose to quantify the population heterogeneity in the 
cell culture of stem cells[172,204] by the information entropy of the RACIPE 
models[189].  In the simulation, we then added an activating or inhibiting signal on each 
gene, and evaluated the changes in the entropy (Figure S3.15).  Either activation or 
inhibition of a gene usually decreases the entropy, resulting in a more homogeneous 
population, typically observed during cell differentiation.  This may explain why some 
pluripotent genes, such as Oct4, can commit differentiation with either high- or low-
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expression[205].  Also, we found that the decrease in the entropy is most pronounced 
with the inhibition of Oct4/Sox2 and the activation of Cdx2, consistent with view of these 
genes as determining stem cell differentiation.  All of these findings suggest the 
possibility of using the ensemble of the RACIPE models to quantify and understand 
population behaviors. 
4.4. Discussion 
From RACIPE analysis, we demonstrated that the core regulatory circuit of stem 
cell differentiation, as a well evolved circuit in topology, encodes the robust functions 
against the cell-cell variability caused by internal (gene mutations, low copy number of 
transcripts and transcriptional bursting etc.) and external (epigenetic states and signaling 
states etc.) noises. Moreover, we revealed that stem cell circuit has a hierarchical 
structure, in consistent with the two-step differentiation process for mouse embryo 
development.  We expect RACIPE to be an unbiased computational approach to predict 
and decipher the functions of many other gene circuits or even large gene networks. 
The integration of all the findings from the above analyses seem to provide a new 
picture of stem cell differentiation beyond the traditional Waddington’s epigenetic 
landscape to explain how genes regulate development[206].   Waddington’s epigenetic 
landscape is a popular metaphor, which considers the differentiation of progenitor cells is 
analog to the process of marbles rolling along a landscape, in which cell potency 
decreases from hill to valleys during stem cell differentiation.  However, the exact 
meaning of this epigenetic landscape remains elusive.  Until now, the most common 
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views[184,186] map each of the differentiated phenotypes or each of the progenitor cells 
of different cell potency to a certain cell state with unique stable gene expression profiles, 
and the epigenetic landscape can be quantified by an effective potential[184,186].  Thus, 
cell differentiation was regarded as the transition from the progenitor cell state to the 
differentiated cell states. 
Here we propose a possible different interpretation of Waddington’s epigenetic 
landscape.  A stem cell phenotype, instead of being a specific cell state, is regarded as a 
heterogeneous population of cells in various states, each of which corresponds to a 
differentiated lineage with a distinct gene expression pattern[207].  Cells with high cell 
potency (i.e. the capability of stem cells to differentiate into other cell types) are plastic to 
convert into the various cell states stochastically by both the intrinsic factors (gene 
expression noises, fast process) and the extrinsic factors (transient epigenetic regulation 
and cell signaling, slow process).  However, when cells are subject to stable 
perturbations, they lose the capacity to access certain cell states, therefore being less 
heterogeneous, i.e. smaller informational entropy, and differentiated.  Our view is 
consistent with the following evidences from both experiments and our RACIPE analysis 
on the stem cell circuit.  First, the stem cell progenitors of either totipotency or 
pluripotency have highly heterogeneous gene expression, and several cell sub-
populations of differentiated types, called lineage priming, have been identified in cell 
culture[208–210].  In our model, we also identified fifteen distinct cell phenotypes by the 
RACIPE analysis on the core stem cell circuit (Figure 4.1b, left), some of which became 
inaccessible during the in silico differentiation.  Second, some pluripotency factors[207], 
including Oct4, commit differentiation when they are either down- or over-
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expressed[205].  With RACIPE, we showed that the heterogeneity of cell population 
drops dramatically when down-regulating Oct4, while it is at the maximum when Oct4 is 
expressed at intermediate level (Figure S3.15).  Therefore, we might associate the 
population heterogeneity with stem cell potency. 
One limitation to the current RACIPE method is how to accurately construct the 
core biological circuit for the certain function, although the master regulators in the core 
circuit often have been widely studied in experiments. The core circuit for stem cell 
differentiation here is constructed based on extensive literature search, which might miss 
out some important regulatory links or genes. One practical way to verify the reliability 
of the core circuit is to compare the predicted gene expression data with the experimental 
ones, which may also in turn suggest the missing of the links or genes.  Also, the 
comprehensive combination of genomics data such as ChIP-Seq maps and biochemistry 
experiments[211] may be able to generate an experimentally validated gene circuit 
subject to RACIPE analysis.  However, it still remains a big challenge to build a large 
gene regulatory network in accurate. 
To conclude, we showed from the results of parametric randomization on a 
proposed stem cell circuit, that the circuit topology plays the essential role in determining 
the gene expression patterns of cells.  This result is analogous to findings from protein 
structure modeling, where conformational motions have been found to be determined by 
the overall molecular shape[212] and protein folding process by native residue 
contacts[213].  RACIPE allows the interrogation of the circuit behavior by parametric 
randomization, from which we can learn about its robustness, heterogeneity and function.  
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RACPE is expected to facilitate the discovery of the causal relationship between the gene 
regulatory networks and experimental gene expression data.  
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Chapter 5 
Modeling putative therapeutic implications of 
exosome exchange between tumor and 
immune cells 
Development of effective strategies to mobilize the immune system as a 
therapeutic modality in cancer necessitates a better understanding of the contribution of 
the tumor microenvironment to the complex interplay between cancer cells and the 
immune response. Recently, effort has been directed at unraveling the functional role of 
exosomes and their cargo of messengers in this interplay. Exosomes are small vesicles 
(30–200 nm) that mediate local and long-range communication through the horizontal 
transfer of information, such as combinations of proteins, mRNA and microRNAs. Here, 
we develop a tractable theoretical framework to study the putative role of cell to cell 
signaling through exosome exchange on the cancer-immunity interplay. We reduce the 
complex interplay into a generic model whose three components are cancer cells, 
dendritic cells (consisting of precursor, immature and mature types) and killer cells 
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(consisting of cytotoxic T cells, helper T cells, effector B cells and natural killer cells).  
The framework also incorporates the effects of exosome exchange on 
enhancement/reduction of cell maturation, proliferation, apoptosis, immune recognition 
and activation/inhibition.  We reveal co-occurrence of three cancer states: low risk cancer 
with intermediate immunity (L), intermediate risk cancer with high immunity (I) and high 
risk cancer with low immunity state (H), and establish the corresponding effective 
landscape for the cancer-immunity network.  We illustrate how the framework can 
contribute to the design and assessment of combination therapies. 
5.1. Introduction 
Immunotherapeutic approaches have recently emerged as effective therapeutic 
modalities[214]  exemplified by immune checkpoint blockade with anti-CTLA-4 to 
activate T-cells and induce tumor cell killing which has been shown to be effective for 
some cancers but not others[215].  A better understanding of the intricate interplay 
between cancer and the immune system, and of mechanisms of immune evasion and of 
hijacking of the host response by cancer cells is relevant to the development of effective 
immunotherapeutic approaches [216–219]. 
The immune based suppression of tumor development and progression is 
mediated through non-specific innate immunity and antigen-specific adaptive immunity 
[220].  On the other hand, cancer cells can inhibit the immune response, thus evading 
suppression in multiple ways [221] (see below for details), and additionally hijack the 
immune system to their advantage [216,217].  The challenge to understand the tumor-
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immune interplay stems from the dynamic nature, and complexity and heterogeneity of 
both the cancer cells and the immune system and their interactions through the tumor 
microenvironment [222]. 
Here we consider immune cells as consisting of macrophages [223], natural killer 
cells [224], cytotoxic T cells [225], helper T cells [226],  and regulatory T cells [216].  
These various immune cells are produced, activated and perform their functions separated 
by space and time, which contributes additional complexity [227].  Among the immune 
cells, dendritic cells (DCs) are the most efficient antigen presenting cells (APCs) to 
bridge innate immunity with adaptive immunity [228].  DCs also secrete cytokines that 
promote the antitumor functions of both nature killer cells and macrophages [229,230].  
We consider the tumor microenvironment (TME) as comprised of a heterogeneous 
population of cancer cells [231], stromal cells [232] and tumor infiltrating immune cells
[233].  The interactions among these cell types contribute to tumor development and 
progression.  Tumor-associated macrophages (TAM) and cancer-associated fibroblasts 
(CAF) regulate tumor metabolism and engender an immune-suppressive environment by 
secreting TGF-β and other cytokines [234].  Fluctuations in energy sources and oxygen 
within a tumor contribute to malignant progression and cell phenotypic diversity 
[235,236]. 
While secreted factors play critical roles in cell-cell communications, here we 
focus on the additional role of cell-cell communication mediated by the exchange of 
special extracellular lipid vesicles called exosomes [237]. These nanovesicles of about 
30-200 nm are formed in the multivesicular bodies (MVBs) and then released from the 
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cell into the extracellular space [238]. The exosomes carry a broad range of cargo, 
including proteins, microRNAs, and mRNAs and DNA fragments, to specific target cells 
at a remote location [239]. Membrane markers assign the exosomes to specific targeted 
cells. Notably, upon entering the target cell, the exosomes induce modulation of cell 
function and even identity switch (phenotypic, epigenetic and even genetic) [240]. 
Exosomes have recently emerged as playing an important role in the immune system 
interaction with tumors [241,242]. Tumor-derived exosomes can promote metastatic 
niche formation by influencing bone marrow-derived cells (BMDCs) toward a pro-
metastatic phenotype through upregulation of c-Met [242]. DCs have been shown to 
induce tumor cell killing through release of exosomes which contain potent tumor-
suppressive factors such as TNF and through activation of natural killer cells, cytotoxic T 
cells and helper T cells [237,243–245]. On the other hand, tumor-derived exosomes (Tex) 
can directly inhibits the differentiation of DCs in bone marrow [246], which strongly 
inhibit the dendritic-cell-mediated immune response to the tumor. In addition, Tex can 
also directly inhibit natural killer cells [247]. 
Mathematical models have been devised to study the complex interactions of 
cancer and immune system, including those that consider spatial heterogeneity (as 
reviewed in ref. [248]) and those that consider only spatially homogeneous populations 
(as reviewed in ref. [249]).  Cancer-immunity models have been constructed to 
investigate the effects of therapy [250–252], cancer dormancy [253] and interactions with 
time delay [254]. Other types of modeling methods have also been applied.  For example, 
tumor growth has also been fitted to experimental data by artificial neural networks 
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[255]; a detailed network of cancer immune system has been modeled by multiple subset 
models [256].  
In this study, we have developed an exosome-mediated (EM) model, to 
incorporate the special role of DCs and exosome-mediated communications.  Distinct 
from the previous approaches, our modeling strategy is adapted from methodology used 
in studies of gene regulatory circuits, allowing us to check the multistability features of 
the system [257].  We find that, by including exosome exchange, the cancer-immunity 
interplay can give rise to three quasi-stable cancer states, that may be associated with the 
“elimination/equilibrium/escape phases” proposed in the immunoediting theory [258].  
The EM model is also capable of explaining tumorigenesis by considering the time 
evolution of immune responses.  Guided by the treatment simulations, we assess the 
effectiveness of various therapeutic protocols with and without time delay and noise. 
5.2. Methods 
Exosome-mediated (EM) modeling approach 
Here, we develop a minimal yet workable theoretical framework for modeling the 
cancer-immunity interplay. The concept is to devise EM models that incorporate three 
generic (coarse-grained) components, i.e. the effective cancer cells (C), the dendritic cells 
(D) and the killer cells (K).  C represents the cancer cells that actively interact with the 
immune system, e.g. those at the surface of a solid tumor.  D represents precursor, 
immature and mature DCs that present tumor-associated antigens.  The cytotoxic T cells, 
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effector B cells, helper T cells and natural killer cells are lumped together and referred to 
as killer cells (K), since as a group, they inhibit cancer cells after being activated by DCs.   
To elucidate the effects of cell communications among these representative cell 
types, the dynamics of C, D and K cells are modeled by nonlinear ordinary differential 
equations.  We consider two communication networks as illustrated in Figure 5.1.  For 
both cases, the C population self-activates by means of exosome-mediated cell 
proliferation [259].  The D population self-activates by means of the cell proliferation of 
dendritic cells.  D activates proliferation of K [243–245], while K induces maturation of 
D [260].  Also, K targets C and induces C’s apoptosis [224–226,261,262] while C 
inhibits K by slowing down its proliferation and increasing its apoptosis [263,264].  The 
two networks, however, differ from each other in the interactions between C and D.  In 
case I (Figure 5.1a), D directly kills C by exosomes [237] and/or some cytokines [265]; C 
induces the D maturation by presenting tumor-associated antigens on the surface when 
the concentration of C is low [228,266], but inhibits D differentiation by exosomes and/or 
cytokines when the concentration of C is above a threshold level [246,267].  The 
deterministic rate equations for the dynamics of C, D and K densities are given by 
d
dt C = gC0HCC
S (C,λCC+ )− kCCHDCS (D,λDC+ )HKCS (K ,λKC+ )
d
dt D = gD0HDD
S (D,λDD+ )HKDS (K ,λKD+ )HCD1S (C,λCD1− )HCD2S (C,λCD2+ )− kDD
d
dt K = gK 0DHCK1
S (C,λCK1+ )HCK 2S (C,λCK 2− )− kKKHCK 3S (C,λCK 3+ )
,   (36) 
where 
 138 
 

where gC0 , gD0  and gK 0  are the basal proliferation rates, kC , kD  and kK  are the basal 
apoptosis rates.  We quantify the effect of cell communication by HIS (x,λI )  for 
x ∈C,D,K , the shifted Hill function (for the interaction labeled as I ), defined as 
HI− (x)+ λIH I+ (x) , where HI− (x) =1/[1+ (x / xI )nI ] , HI+ (x) = 1− HI− (x) , and λI  is the fold 
change of the interaction.  λI+  represents activation ( λI >1 ), and  λI−  represents 
inhibition (λI <1 ).  The model parameters are listed in the Table S4.1.  In case II (Figure 
5.1b), we exclude exosome-mediated interactions, so the most prominent interaction 
between C and D is the activation of D by recognizing antigens that are associated with 
C.  We remain using Equation (36) to model the dynamics of the network, but change the 
parameters for the modified interactions, i.e. the fold changes λDC+ = 1  and λCD1
− = 1 .   
HCCS (C,λ +CC ) = (1 [1+ (C CC0 )nCC ])+ λ +CC ((C CC0 )nCC [1+ (C CC0 )nCC ])
HDCS (D,λ +DC ) = (1 [1+ (D DC0 )nDC ])+ λ +DC ((D DC0 )nDC [1+ (D DC0 )nDC ])
HKCS (K ,λ +KC ) = (1 [1+ (K KC0 )nKC ])+ λ +KC ((K KC0 )nKC [1+ (K KC0 )nKC ])
HDDS (D,λ +DD ) = (1 [1+ (D DD0 )nDD ])+ λ +DD ((D DD0 )nDD [1+ (D DD0 )nDD ])
HKDS (K ,λ +KD ) = (1 [1+ (K KD0 )nKD ])+ λ +KD ((K KD0 )nKD [1+ (K KD0 )nKD ])
HCD1S (C,λ−CD1) = (1 [1+ (C CD10 )nCD1 ])+ λ−CD1((C CD10 )nCD1 [1+ (C CD10 )nCD1 ])
HCD2S (C,λ +CD2 ) = (1 [1+ (C CD20 )nCD 2 ])+ λ +CD2 ((C CD20 )nCD 2 [1+ (C CD20 )nCD 2 ])
HCK1S (C,λ +CK1) = (1 [1+ (C CK10 )nCK1 ])+ λ +CK1((C CK10 )nCK1 [1+ (C CK10 )nCK1 ])
HCK 2S (C,λ−CK 2 ) = (1 [1+ (C CK20 )nCK 2 ])+ λ−CK 2 ((C CK20 )nCK 2 [1+ (C CK20 )nCK 2 ])
HCK 3S (C,λ +CK 3) = (1 [1+ (C CK30 )nCK 3 ])+ λ +CK 3((C CK30 )nCK 3 [1+ (C CK30 )nCK 3 ])
λ +DC = 1+ ρ(λ 0DC −1)
λ +KC = 1+ ρ(λ 0KC −1)
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Figure 5.1 Illustration of the EM model for cancer-immune interplays.   
The coarse-grained network model contains three major components: the effective cancer 
cells (C), the dendritic cells (D) and the killer cells (K).  The links among different cell 
types represent the effects of cell-cell communication.  An arrow denotes activation; a bar 
denotes inhibition; an arrow plus a bar from C to D represents activation when the C 
population is small, and inhibition when the C population is large.  The green spheres 
represent cell communications that are partially mediated by exosomes.  Panel a shows 
the full model (case I); panel b shows the model without exosome-mediated interactions 
between C and D (case II). 
 
The effects of immune recognition are incorporated by varying the interactions 
from D to C and K to C using a recognition parameter (ρ) as follows:  
λDC
+ = 1+ ρ(λDC0 −1)
λKC
+ = 1+ ρ(λKC0 −1)
,  (37) 
where ρ represents the effective immune recognition: ρ = 0 corresponds to no recognition 
so that there is no effect from D or K to C, i.e. λDC
+  and λKC
+  equal to one.  ρ = 1.0 
corresponds to full recognition so that λDC
+  and λKC
+  are equal to a basal strength λDC
0  
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and λKC
0  respectively.  Note that in principle ρ can also be larger than one, which 
represents the case of enhanced immune response above the basal level that can be 
induced for example by immunotherapy.    
Stability analysis 
The dynamics of the EM model is described by a set of three-dimensional 
nonlinear rate equations Equation (36).  To compute the steady state solutions, we 
calculate two nullclines – the first one satisfies dD/dt = 0 & dK/dt = 0 (solid navy line, 
Figure 5.2), and the second one satisfies dC/dt = 0 & dK/dt = 0 (solid brown line, Figure 
5.2).  The nullclines are projected onto the phase plane, constructed by the concentrations 
of the D (x-axis) and C (y-axis).  The intersections of these two projected lines are the 
steady states for the whole system.  The stability of the steady states can be further 
determined by the linear approximation method.  The nullclines are computed by 
contour-based method, and the bifurcation diagrams are calculated by PITCON7 package 
[22]. 
Simulation with time delay 
We consider the time delays caused by the exosome-mediated communications 
between the C and D cell populations.  Instead of directly using Equation (36), we 
replace the terms HDCS (D,λDC+ ) , HCD1S (C,λCD1− )  and HCD2S (C,λCD2+ )  by HDCS (D*,λDC+ ) , 
HCD1S (C*,λCD1− ) , and HCD2S (C*,λCD2+ )  respectively, where for X ∈C,D  and time delay τ , 
X*  at time t  is 
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X*(t) = X(0) t ≤ τX(t −τ ) t > τ
⎧
⎨
⎪
⎩⎪
.    [38] 
The delay differential equations are integrated by dde23 from MATLAB [268]. 
Stochastic simulation 
 Equation (36) can be rewritten in a vector form as  !x = f (x) , where 
x = (C,D,K )T .  In this study, we consider Gaussian white nosie.  So the dynamics can be 
described by a Langenvin equation  !x = f (x)+L(x,t) , where 
Li (x,t)Lj (x, ′t ) = 2ϒδ (t − ′t )  for i, j ∈C,D,K , ϒ  is a constant representing the noise 
level.  The stochastic differential equation is integrated by Euler-Maruyama method 
[269].  The effective landscape for the state x  is defined as E = − ln(P(x))  [96,97], 
whereP(x)  is the probability for the system in state x. 
Tumorigenesis and Treatment Modeling 
We specifically model the time evolution of the level of immune recognition ρ for 
the tumor onset process.  ρ follows 
ρ = 1− e− t /τ  , [39] 
where τ  is the half time for developing the full immune recognition.  ρ initially starts at 
zero, and increases until it saturated at one.  The tumor onset is simulated by both 
Equation (36) and Equation (39), and the initial condition for (C, D, K) is (0, 100, 0) 
(cells/µL). 
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In the simulation of the radiation therapy, additional terms −kRC , −kRD  and 
−kRK  are included to the three equations in Equation (36) respectively, where kR  is the 
cell death rate of all these cell types by the radiation therapy.  In the EM model, kR  is 
treated to be proportional to the dose strength.  In the simulation of DC immunotherapy, 
an additional constant term gI  is included to the D equation in Equation (36). 
5.3. Results 
Co-occurrence of multiple cancer states during tumorigenesis 
We first consider two cases whereby case I includes exosome exchange and case 
II excludes exosome exchange. The quasi-steady state solutions of Equation (36) are 
obtained by the phase plane analysis (see Method section) for these two cases.  In case I, 
when ρ equals 0.2, the interplay yields only one stable steady state, corresponding to high 
cancer/low immune (denoted as the H state, Figure 5.2a). That is because the effect of the 
immune system is not strong enough to limit cancer progression.  When ρ equals 1.0, the 
interplay can give rise to three co-occurring quasi-stable steady states Figure 5.2b), 
corresponding to the (H) state, to intermediate cancer/high immune (denoted as the I 
state), and to low cancer/intermediate immune (denoted as the L state).  At this stage, the 
strength of the effect of the cancer on the immune system and of the immune system on 
cancer are comparable, therefore allowing the co-occurrence of multiple states.  The 
relative stability of each state can be inferred from the stochastic simulations (see Method 
section).  When ρ=2.0, the immune system outweighs cancer, allowing only the low 
cancer/low immune state deterministically.  It could, however, have some rare chances to 
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switch to the high cancer/low immune state stochastically (Figure 5.2).  Notably, the 
predicted co-occurrence of three quasi-stable states in the EM model is likely related to 
the clinical classification of the equilibrium stage during tumor progression as defined in 
the immunoediting theory [258], which considers both the host-protection and tumor-
sculpting action of immune system on tumorigenesis. 
In case II, the interplay does not include negative interactions between C and D. 
These interactions are mainly mediated by the exosome exchange.  As a consequence, 
case II dynamics are significantly different from those of case I.  When ρ equals 0.2, the 
interplay leads to the high cancer/high immune state (Figure 5.2c).  However, when ρ 
equals 1.0, the interplay leads to bistability – co-occurrence of the high cancer/high 
immune state and the low cancer/intermediate immune (L) state, meaning that the (I) 
state does not occur (Figure 5.2d). When ρ equals to 2.0, the interplay gives rise to the 
low cancer/intermediate immune state in both the deterministic and the stochastic 
analyses (Figure S4.1).  
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Figure 5.2 Phase plane analysis for the EM model.  
In each case, a phase plane is constructed by the concentration of the dendritic cells (D, 
x-axis) and the effective cancer cells (C, y-axis).  The nullcline dD/dt = 0 & dK/dt = 0 is 
shown in solid navy line and dC/dt = 0 & dK/dt = 0 is shown in solid brown line.  The 
intersections of these two nullclines are the steady states, represented by solid green 
circles for stable states and by hollow green circles for unstable states.  The grey arrows 
represent the vector field in a stream plot.  The background colors illustrate the values of 
the effective landscape (-log(P)) computed by stochastic simulations of the network with 
white Gaussian noise.  The states are most probable at the blue regions, and are least 
probable at the red/white regions.  Panel a and b are for the case I network, and panel c 
and d are for the case II network.  The immune recognition is at a low level (with value ρ 
= 0.2) for a and c, and is at the basal level (with value ρ = 1.0) for b and d.  For the full 
model and ρ = 1.0 (panel b), the network allow three stable steady states – high 
cancer/low immune (H), intermediate cancer/high immune (I), and low 
cancer/intermediate immune (L). 
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We also show a comparison with the stability analysis for two additional cases in 
which a part of exosome exchange interactions are not included (Figure S4.2).  The 
comparison between these different cases implies that exosome exchange facilitates 
tristability – the co-occurrence of the (H), (I) and (L) states. As we show next, the 
occurrence of the (I) state, which is possible due to the exosome exchange, has very 
important implications regarding the effectiveness of therapeutic strategies.  
Bifurcation diagram for immune recognition  
To further assess the effect of immune recognition in case I, we calculate and 
investigate the bifurcation diagrams of the cancer-immunity interplay with respect to the 
level of ρ as a control parameter (Figure 5.3).  As is depicted in this figure, the 
bifurcation diagram exhibits four different regimes (phases), each corresponding to the 
co-occurrence of different quasi-stable cancer states: 1. a phase in which only the (L) 
state occurs (denoted as {L}, blue); 2. a phase in which the (L) and (H) states co-occur 
(denoted as {L,H}, yellow); 3. a phase in which the (L), (I) and (H) states co-occur 
(denoted as {L,I,H}, green); 4. a phase in which only the (H) state occurs {denoted as 
{H}, red}.  Further inspection reveals that when ρ is above 1.1, the (L) state is the 
dominant one; when ρ is between 0.84 and 1.1, all three states co-occur, making the 
transitions among these states more likely; when ρ is below 0.84, the (H) state is the 
dominant one.  It is worth noting that a bifurcation curve may cross itself, because the y-
axis of the bifurcation diagram is projected from a 3D phase-plane (Figure 5.3c and d).  
Immune recognition and tumorigenesis 
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Before tumor onset, immune recognition has yet been established, i.e. ρ is zero, 
and the C population is close to zero and the D population is low. As the tumor starts to 
develop, it triggers immune recognition.  The fate of tumor development is determined by 
the relative rate of tumor growth versus the rate of increase in immune recognition.  In 
general, for fast growing tumors, the dynamics will lead to the (H) cancer state.  More 
specifically, depending on how fast the immune system responds (the level of immune 
recognition increases), which is characterized by the mean lifetime (τ ) for the 
development of full immune recognition (ρ = 1) (see Method section), the interplay (for 
the model parameters of cancer growth used here) can lead to either the (H) state (when 
τ > 77  days), the I state (when 12 < τ < 77  days) or the (L) state (when τ <12  days) 
states.  Some typical examples are shown in purple lines and circles in Figure 5.3a.  
Further enhancement of immune recognition causes the transition of the tumor from the 
(H) or the (I) states to the (L) state (downward dashed arrows labeled as 1 and 2 in Figure 
5.3a), suggesting possible control of the tumor by the immune system and the putative 
importance of boosting the immune system during early stages of tumorigenesis. 
Effect of tumor evasion on immune recognition 
As is now widely recognized, cancer cells can evade immune suppression during 
tumor development, which causes the immune recognition to gradually decrease.  In 
general, tumor size, as quantified by the size of the C population, increases when ρ 
decreases.  Marked growth of C can be observed in some stages either deterministically 
(upward dashed arrows labeled as 3 and 4 in Figure 5.3a), or stochastically when the 
system overcomes a dynamic barrier of the transition between two co-occurring cancer 
 147 
 
states.  Interestingly, such marked growth of C happens within phase {L, I, H} and the 
leftmost part of phase {L, H}.  At these phases, the levels of both D and K are relatively 
higher than those at the other phases, which is consistent with experimental evidence 
[270]. At the late tumor stage (low ρ again), certain processes including epithelial-
mesenchymal-transition (EMT) may trigger cancer metastasis, in which some small nests 
of cancer cells migrate to a remote location.  From the new site, they initiate the 
development of a new metastasis with tumor cells that may have different identity and 
therefore require renewed immune recognition for tumor control. 
 
Figure 5.3 Bifurcation diagrams for the steady states as a function of the level of 
immune recognition ρ.   
The diagrams show, for each value of immune recognition (ρ, x-axis), the steady state 
concentrations for the effective cancer cells (panel a) and the dendritic cells (panel b).  
Ef
fe
ct
iv
e 
ca
nc
er
 c
el
ls
 (c
el
l/µ
L)
 
H 
I 
L 
1 
2 
3 
4 
De
nd
rit
ic 
ce
lls
 (c
ell
/µ
L)
  
D
en
dr
iti
c 
ce
lls
 (c
el
l/µ
L)
  
1 
2 
3 
4 
Effective cancer cells (cell/µL)  
H 
I 
L 
I 
H 
{H} {L} {H,L} {H,L} {H,I,L} 
1 
2 
3 
4 
0.0 0.5 1.0 1.5 2.5 3.0 
0 
500 
1000 
L 
2.0 
 Immune recognition (ρ) 
Ef
fe
ct
iv
e 
ca
nc
er
  
ce
lls
 (c
el
l/µ
L)
 
{H} {L} {H,L} {H,L} {H,I,L} 
H 
I 
L 
1 
2 
3 
4 
0 
500 
1000 
0.0 0.5 1.0 1.5 2.0 
 
2.5 3.0 
Immune recognition (ρ) 
D
en
dr
iti
c 
ce
lls
 (c
el
l/µ
L)
 a b
c d
 148 
 
The states along the solid blue curves are the stable states, and those along the dashed red 
curves are the unstable states.  The whole bifurcation curve is composed of segments of 
stable/unstable states, from which we define the high cancer state (H), the intermediate 
cancer state (I) and the low cancer state (L). Depending on the level of immune response, 
the system is at one of the four phases as represented by different background colors.  
Red is for the phase {H}, which has only the H state; yellow is for the phase {L,H}, 
which  allows co-occurrence of both the L and H states, green is for the phase {L,I,H}, 
which allows occurrence of all three states; and blue is for the phase {L}, which has only 
the L state.  During tumorigenesis when ρ changes, some transitions among different 
states could take place, as illustrated in dashed black lines and arrows, and are labeled 
with numbers.  Three purple lines show the trajectories of development of tumor (with 
different rates of immune respond to tumor), and solid purple circles show the final states 
when full immune recognition is established.  Panel c and d show the same bifurcation 
diagram in 3-D (with axes C, D and ρ) and in two perspectives. 
 
Sensitivity to model parameters 
We further explore sensitivity of the occurrence of the intermediate state and the 
tristability (Figure S4.3) to model parameters assuming that each tumor is characterized 
by a specific set of parameters. For this aim, we calculated the bifurcation diagram with 
respect to ρ for different sets of parameters.  More specifically, we randomly vary all 36 
model parameters simultaneously away from the original values by a uniform distribution 
with maximum of range of d% (chosen from 10%, 20% … 60%).  We find that the 
intermediate (I) cancer state occurs for a significant range of model parameters (blue 
columns in Figure 5.4).  For example, the (I) state occurs for about 50% of the parameter 
sets (or 50% chance) when the 36 parameters are varied randomly within a range of 40% 
about their original values.  The chance for observing the tristability (red columns in 
Figure 5.4a) is slightly lower than that for the occurrence of the (I) state.  Among those 
parameter sets in which the (I) state occurs (blue columns in Figure 5.4b) both the 
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average length of the (I) state and its standard deviation (Figure S4.4) go up with the 
range of the distribution from which the parameters are taken.  Similar behavior is 
observed for the tristability (red columns in Figure 5.4b).  For a larger perturbation of the 
parameters, the length of the (I) state is much wider than the length of the tristability 
(Figure 5.4b).  The results imply that, when exosome exchange is operative, the 
intermediate cancer state and the tristability are characteristic features of the EM model 
for a wide range of model parameters. 
 
Figure 5.4 Sensitivity of the occurrence of the intermediate state to the model 
parameters.   
In each test, all 36 parameters are randomly perturbed by a maximum of d% (chosen 
from 10%, 20% … 60%).  Similar to Fig. 3, a bifurcation diagram with respect to the 
level of immune recognition ρ is generated to check the occurrence of the intermediate 
state and the co-occurrence of three stable states.  Panel a shows the percentage of the 
occurrence of the intermediate state (blue columns) and the tristability (red columns) 
from a total of 10000 tests.  From those cases in which the intermediate state or the 
tristability occurs, panel b shows the mean and standard deviation of the length of them in 
ρ.  The dotted line shows the baseline, responding to the lengths of the intermediate state 
and the tristability for the case with the original (unperturbed) parameters (They overlap, 
as both lengths have the same values in ρ). 
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We further assess the effect of individual parameters on the occurrence of the (I) 
state and the tristability (Figure S4.5 and S4.6). We find that when any one of the 
parameters is varied by 10%, the length of the (I) state and of the tristability are only 
slightly affected (Figure S4.5a and S4.5b ), but a variation of 30% in a single parameter 
can sometimes lead to significant difference (Figure S4.5d and S4.5d).  The three most 
significant model parameters are associated with tumor growth (the Hill threshold of C 
self-activationCC0 , the fold change of C self-activation λCC+  and the basal proliferation 
rate of C, gC0  (Figure S4.7).  These results imply that the occurrence of tristability and 
the (I) cancer state arises from a balance between cancer and immunity due to exosome 
exchange.   
Building the cancer-immunity landscape 
Motivated by the notion of Waddington landscape for cell differentiation [96], we 
proceed to introduce an effective landscape [97] corresponding to the dynamic states of 
the cancer-immunity interplay. Doing so helps to better understand the nature of the co-
occurring cancer states and to design and assess possible therapeutic protocols by 
visualization of their effect as trajectories connecting different cancer states (or as a 
transition rate problem) in established landscape.  In principle, the dynamics should be 
presented as a 4-dimension landscape whose axes are the densities of C, D, K, and the 
strength of the immune recognition ρ.  Here, by assuming quasi-steady state for ρ, we 
consider 3-dimension landscapes (C, D, K) for different values of ρ. The landscape 
defines an effective potential computed as minus the logarithm of the probability (-
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log(P)) of each dynamic state (C, D, K) in the presence of noise.  The noise could 
originate from multiple sources, including cell-cell communications, birth-death 
processes of individual cells, coarse-graining of different cell types, and the effect of 
some other cancer/immune cell types or factors that are not included in the EM model.   
In practice, it is easier to visualize the landscape in two dimensions. Therefore, we 
rely on projection of the 3-dimensional space onto a corresponding 2-dimensional one.  
For example, in Figure 5.2, the landscape is projected onto a 2-dimensional space whose 
axes are C and D.  As shown in Figure S4.8 and Figure S4.9, we find that the landscape 
could be better presented if we replace D with a combination of D and K as one of the 
axes, since D and K are highly correlated (although in a nonlinear manner). We propose 
that the concept of the cancer-immunity landscape is very valuable for the design and 
assessment of effectiveness of novel therapeutic strategies.  In particular, the landscape 
makes it clear that the desired/optimal treatments are not those that simply reduce the 
tumor size.  As is illustrated further below, treatment effectiveness should be assessed by 
its efficacy to cross the dynamic barrier between high and low cancer states.  It also 
shows that in most cases a direct transition from the H cancer state to the L state (H-to-L) 
is very hard to achieve.  In the majority of cases, two-stage strategies are the desired ones 
– one treatment is used for effective H-to-I transition and a second treatment is used for 
effective I-to-L transition.   
Effects of time delay on the cancer-immunity landscape 
Communication between C, D and K cell types involves time delay.  A longer 
time delay is expected for exosome exchange, because of the need for their production 
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and transport potentially across long distances.  From a dynamic system perspective, time 
delay can have a significant effect on transitions between cancer states and on the effect 
of noise on the cancer-immunity interplay.  We note that steady state solutions are not 
affected when the time delay is considered.  However, the time delay might alter 
dynamics by changing the stability of the steady states (the cancer states) and the shape 
of the landscape. To this end, we evaluate the possible effects of time delays on the 
cancer-immunity interplay by performing simulations of the EM model (case I)  
We examine the basin of attraction for each of the stable states (H, I and L) while 
incorporating the time delay in exosome exchange between C and D.  From a dynamic 
systems perspective, the basin of attraction of each of the states is the domain of initial 
conditions from which the cancer/immunity evolve towards the particular dynamical state 
of the cancer-immune interplay (H, I or L). To construct the basin of attraction, we 
initially set the system at the high cancer (H) steady state.  Assuming a subject is at the 
high cancer state (H), we simulate possible consequence of “hypothetical treatments”. 
This is done by changing the population values of both C and D, while K cells are not 
affected.  Such a treatment changes the system from the (H) state to a new state in the 
phase plane (Figure 5.5a). We then perform simulations with time delay (see Method 
section) for the dynamics starting from the newly induced location (new values of C and 
D). The simulations reveal that the dynamics after the initial induced deviations generate 
a trajectory that ends in one of the quasi-stable states (H, I and L).  When starting from 
the (H) state, we define its corresponding basin of attraction as the region in the 
landscape (the phase plane), from which the dynamic trajectories evolve back towards the 
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(H) state. The basin of attraction for the (I) and (L) states can be constructed in a similar 
manner.   
The upper left of Figure 5.5 shows the basins of attraction for the H (navy), I 
(blue) and L (light blue) states for case I and without time delay.  An effective treatment 
should cause a transition from the (H) state to either the (I) or the (L) state.  Our results 
indicate that, if a treatment aims to only reduce the C population, it requires a reduction 
of more than 90%, otherwise the system is still within the basin of attraction of the (H) 
state (see also left panel of Figure 5.5).  Alternatively, it is more effective if the treatment 
targets the D population or both the C and D populations.  By adding and increasing time 
delay, the basin of attraction for the (H) state increases linearly for small values of time 
delay and is saturated for large values of time delay (Figure 5.5), and that for the (L) state 
is mostly unaffected. 
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Figure 5.5  The effects of time delay in exosome-mediated communication on the 
cancer-immunity landscape.   
The dynamics of the EM model are tested in multiple cases, each of which has different 
time delays for exosome-mediated communication between C and D (see Method 
section).  In the test, the system is suddenly moved from the high cancer state (the initial 
state) to a new state in the phase plane as a consequence of “hypothetical treatment”.  
Once released, the system follows its dynamic trajectory, and eventually reaches to one 
of the quasi-stable steady states.  The basin of attraction for each quasi-stable steady state 
is defined as the region in the landscape (phase plane), from which the dynamic 
trajectories converge back to the target stable state.  The whole phase planes is divided by 
the three basins for the high cancer state (navy), the intermediate state (blue), and the low 
cancer state (light blue).  Panel a shows the phase planes for the cases of no delay (top 
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left), 15-day delay (top right), 50-day delay (bottom left) and 150-day delay (bottom 
right).  The scatter plot in panel b shows the dependency of the fraction of the high-
cancer basin of attraction (in area) on the value of the time delay.  
 
Model-based design and assessment of therapeutic strategies 
We present a design of several hypothetical therapeutic strategies and assessment 
of their effectiveness.  Again, we assume that a subject’s cancer is initially in the (H) 
state.  Since the (H) state is located away from the L state in the phase-space (Figure 
5.2b), it is hard to envision a treatment that can induce direct transitions from the (H) 
state to the (L) state (H2L).  For this reason, in most cases (model parameter or cancer 
type) a more efficient protocol is likely to be based on a two-stage strategy: the first 
involves a treatment to induce the transition from the (H) state to the (I) state (H2I) and 
the second involves a treatment to induce the transition from the (I) state to the (L) state 
(I2L). We note that use of this more efficient two-stage strategy is suggested by the 
occurrence of the (I) state due to the exosome exchange.  
To illustrate the concept in a quantitative manner, we mainly focus here on two 
types of common anti-cancer therapies – radiation therapy and DC based immunotherapy.  
The effect of the radiation therapy is incorporated into the EM model as elevation in 
apoptosis rates of C as well as of D and K during treatment.  Note that apoptosis of D and 
K represents the inhibitory effect of radiation on the immune system [271,272].  DC 
immunotherapy is represented in the EM model as elevation in proliferation rates of D 
cells (see Method section). 
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The effect of hypothetical radiation therapy is shown in Figure 5.6.  This example 
is composed of 30 one-per-day radiation sessions from day 10 (point 0) to day 40 (point 
1) (Figure 5.6b).  The population of D cells decreases during the 30 days (solid red line, 
Figure 5.6c). After the therapy ends, the population of D cells increases and reaches 
maximum at about day 90 (point 2), and then gradually decreases towards its initial level 
before therapy started (point 3, dashed back line).  These results are in excellent 
agreement with clinical data for breast cancer patients after 30-day radiation therapy 
(Figure 5.6d, as adopted from ref. [272]).  We note that the percentage of phagocytic 
activity of monocytes was measured in the clinical tests and not the density of D cells.  
However, the latter is correlated with the percentage of phagocytic activity of monocytes.  
We note that the model simulations are done independently of the clinical data, meaning 
that we do not fit the model parameters for this specific clinical test. For this reason, 
while in the model simulations the time recovery of the immune system to its value prior 
to the hypothetical radiation treatment is seven weeks, in the clinical test it is two weeks.  
For the treatment described in Figure 5.6, not only the immune system, but also the tumor 
load returns to its original high level as illustrated by the treatment trajectory in the 
cancer-immunity phase-space (Figure 5.6a).  The trajectory exemplifies the fact that, 
although the radiation therapy reduces the tumor load (cancer level C) by 40%, after the 
treatment ends, C gradually increases (within a few weeks) back to its original (prior to 
the treatment) high level.  Even if the radiation therapy is applied for 100 days instead of 
30 days, so that C is further reduced by more than 50%, tumor load gradually returns to 
its original level (left panel of Figure 5.6a).  It should be noted that a 100-day treatment is 
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not realistic since it is usually above the maximum permissible dose for the radiation 
therapy.   
 
Figure 5.6 Assessment of hypothetical radiation therapy with the EM model.   
The hypothetical therapy is composed of 30 one-per-day radiation sessions (modeled as 
an increase in the apoptosis rate of all cell types, see Method section) from day 10 (point 
0) to day 40 (point 1, panel b).  Panel a shows the dynamic trajectory in the phase plane, 
and panel c shows the time evolution of the concentrations of the dendritic cells.  Panel d 
shows the experimental data on the phagocytic activity of monocytes for breast cancer 
patients after 30-day radiation therapy (data from [272]).  The solid red lines and areas 
are the trajectory and doses for the radiation therapy, and the dashed black lines are the 
trajectory for the system after the treatment.  Same as those in Figure 5.2, nullclines are 
shown in navy and brown solid lines, and steady states are shown as solid green circles 
(stable) and hollow green circles (unstable). 
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that can induce a transition from the high cancer state H to the intermediate state I (H2I 
stage), followed by an effective alternate therapy that can induce a transition from the 
intermediate cancer state I to the low cancer state L (I2L stage).  Only in rare situations 
direct H2L transitions can be induced. 
Assessment of simulated immunotherapy 
The effect of hypothetical DC immunotherapy is shown in the right panel of 
Figure 5.7a.  In this hypothetical therapy, the C level decreases to only about 85% of its 
original value at the end of therapy.  Yet, since the therapy leads to a significant increase 
in the D level, it induces a transition from the high cancer state to the intermediate cancer 
state (H2I transition, right panel of Figure 5.7a).  The induced transition is very slow 
though.  Inspection of the time dependence of the H2I trajectory in the phase-plane 
reveals that it takes about three months for the system to approximate the unstable steady 
state (or the dynamic barrier) between the (H) and (I) states (hollow green circle in the 
phase-plan).  Upon crossing this dynamic barrier, the system gradually approaches the 
intermediate state and converges to this state after about two years. Although the outcome 
of stand-alone immunotherapy is far better than that of the stand-alone radiation therapy, 
the slow convergence makes the process more sensitive to noise and increases the chance 
that random mutations or other events will cause the trajectory to change its course 
towards the high cancer state. In addition, application of too intense immunotherapy 
and/or application of immune boost for long periods of time increases the risk for side 
effects such as autoimmunity diseases, making stand-alone strong immunotherapy less 
desirable. 
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The Merit of alternating combined treatments 
We proceed to test the efficiency of therapies that are based on alternating 
radiation therapy and immunotherapy. In the hypothetical example shown in the left 
panel of Figure 5.7b, we simulate three consecutive alternating treatments.  Each 
treatment consists of combining a set of eight days of radiation therapy, followed by a set 
of eight days of immunotherapy. As illustrated in the left panel of Figure 5.7b, this 
hypothetical alternating combined therapy successfully induces H2I transition. Moreover, 
the alternating combined therapy uses far lower doses of radiation, and thus has 
significantly reduced side effects in comparison to a single stand-alone radiation therapy 
[273] and induces H2I transitions without the need to over boost of the immune system 
(in comparison to a stand-alone immune therapy) that also can have its own side effects.   
Interestingly, inclusion of additional radiation therapy has an alarming effect – it 
causes a change in the therapy trajectory to converge back to the original high cancer 
state (right panel of Figure 5.7b).  Moreover, even if the total dose of radiation therapy is 
reduced, it still can cause the same negative effect (Figure S4.10c).  We also test 
treatments, in which both radiation therapy and immunotherapy are applied 
simultaneously on the same day, instead of consecutively on different days.  In this case, 
the H2I transitions can be retained by using slightly reduced doses for radiation therapy 
and slightly milder amplification of the immune response (Figure S4.10a and S4.10b). 
However, the potential benefits might not justify the practical difficulties of applying 
both therapies simultaneously. 
Therapeutic protocols for inducing I2L transitions 
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The dynamics of the cancer-immunity interplay in the vicinity of the intermediate 
(I) and low (L) cancer states are very different from those in the vicinity of the high (H) 
cancer state (Figure 5.2).  For this reason, therapeutic protocols for inducing I2L 
transitions are expected to be different from those that are efficient for inducing H2I 
transitions.  To devise an efficient protocol, we follow the same approach as before to 
assess the effectiveness of stand-alone radiation therapy, of stand-alone immunotherapy 
and of alternating combined therapy. As is illustrated in Figure S4.10d, stand-alone 
radiation therapy fails to induce the I2L transition similar to the inefficiency of radiation 
therapy to induce H2I transitions. However, stand-alone immunotherapy (five sets of ten 
days of immunotherapy, with ten-day break between any two consecutive sets) is found 
to be efficient to induce I2L transitions (left panel of Figure 5.7c).  Surprisingly, 
alternating combined therapy turns out to be inefficient to induce the I2L (right panel of 
Figure 5.7c). The reason for the inefficiency is that the trajectory of the alternating 
combination is mostly orthogonal to the shortest path line that connects the (I) state with 
the dynamic barrier between the (I) and the (L) states (the unstable steady state marked 
by hollow green circle).   
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Figure 5.7 Assessment of various therapeutic strategies with the EM model.   
a
b
c
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Similar to Figure 5.6, we show in each case the dose usage (top part) and the dynamic 
trajectory in the phase plane (bottom part).  The session of radiation therapy is shown in 
red and the session of DC immunotherapy (modeled as an increase in the proliferation 
rate of the dendritic cells, see Method section) is shown in green.  Panel a shows the 
hypothetical treatment from the high cancer state (H) to the intermediate cancer state (I) 
in the case of the stand-alone radiation therapy (left), and the stand-alone DC 
immunotherapy (right).  Panel b shows two cases of alternating combined therapy by 
both radiation therapy and immunotherapy.  Panel c shows the hypothetical treatment 
from the intermediate cancer state (I) to the low cancer state (L) by the stand-alone 
immunotherapy (left), and an alternating combined treatment by both the radiation 
therapy and the immunotherapy (right). 
 
Effect of time delay on treatment efficacy 
To assess the effect of time delay on treatment efficacy, we convert the 
deterministic equations to include the time delay (see Method section).  Specifically, we 
assess the case of 15-day delay for exosome exchange between C and D.  Treatment 
simulations (Figure S4.11) show that treatment trajectories are similar to those for the 
cases without considering time delay.  However, most treatments become less effective, 
because time delay makes transitions harder [274] as discussed in the proceeding time 
delay section. 
The effect of noise on treatment efficacy 
We also evaluate the effect of noise by turning the deterministic model into a 
stochastic model whose equations contain noise terms that represent white Gaussian 
noise (see Method section). The presence of large noise can induce spontaneous 
transitions between the different quasi-stable cancer states. To test the noise effect on the 
dynamics itself, we select the noise level to be sufficiently low to avoid noise induced 
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spontaneous transitions during the duration of treatments. Still, noise affects treatment 
effectiveness.  Starting with the example presented previously, in which a 25-day 
immunotherapy in the absence of noise can trigger transition from the (H) to the (I) state 
(solid green line, Figure 5.8a), we find that the success rate for H2I transitions drops to 
60% when the simulations start exactly from the levels of C, D and K of the (H) state.  
The reason is that it is possible for the noise to divert the treatment trajectory away from 
the path to cross the dynamic barrier between the (H) and the (I) states (Figure 5.8b, 
condition 3).  However, in the presence of noise, the values of C, D and K vary in the 
vicinity of the exact steady state values before the treatment.  Therefore the initial point at 
which the therapy starts can be close to but not exactly at the (H) state.  Hence we 
continue to test the effects of the initial state on treatment outcome.  To do so, we choose 
five different initial conditions 1-5 (insets of Figure 5.8a), whereby condition 3 is the 
exact (H) state, condition 1 is farthest from the transition state (the unstable steady state 
shown in hollow green circle) between the (H) and the (I) state, and condition 5 is closest 
to the dynamic barrier between the (H) and (I) states.  As expected, the simulations reveal 
that the closer the initial state (when the therapy starts) to the dynamic barrier, the higher 
the probability to induce H2I transition, with the lowest probability being 20% when the 
therapy starts from condition 1.  Notably, in the absence of noise, the therapy cannot 
induce H2I transition at all starting from this state.  Considered together, the results 
indicate that noise sometimes can facilitate transitions during the treatment.  In addition, 
when noise is included, there is low probability to induce direct H2L transitions that 
would not be possible in the absence of noise.  Moreover, the results also demonstrate 
that it is crucial to start the treatment at the right time when the cancer-immunity 
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interplay is at a state as close as possible to the dynamic barrier for transitions to be 
induced.  It follows that the cancer and immune states should be monitored closely and 
that therapy should be individualized and timed to increase the likelihood of the treatment 
success. 
 
Figure 5.8 The effects of noise on the treatment by hypothetical immunotherapy.   
Panel a shows the landscape for the system with white Gaussian noise.  The noise level is 
not big enough to trigger transitions from high cancer state (H) to the intermediate cancer 
state (I).  Without noise, a treatment of 25-day immunotherapy (solid green line, same as 
the right panel in Figure 5.7) causes the system to transit from H to I.  With noise, the 
same treatment could either succeed (solid yellow line) or fail (solid black line) in 
making such a transition.  We further select five different states (white dots in the inset) 
as the initial states for the treatment, where the state 3 is the original stable steady state.  
Panel B shows the percentage of successful transitions by the same treatment.  In the 
absence of noise, the system always makes H to I transitions for the states 3, 4 and 5 
(blue columns).  In the presence of noise, the system has higher successful transitions 
from H to I when the initial state is closer to the saddle point (e.g. the state 5, orange 
columns).  In some rare occasions (<5%), the system can also directly transit to the L 
state from the H state (red columns). 
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5.4. Discussion 
In this study, we devised a theoretical framework (the EM model), to examine the 
contribution of exosome exchange to the intricate cancer-immunity interplay.  We 
combined the complex interplay into a simplified generic model whose three components 
are cancer cells C, dendritic cells D (representing precursor, immature and mature types) 
and killer cells K (representing cytotoxic T cells, helper T cells, effector B cells and 
natural killer cells).  Distinct from other models [249,251], the time evolution dynamics 
for each cell population was modeled with a set of nonlinear rate equations in a way 
similar to the analysis for gene regulatory circuits.  Due to the specific cell-cell 
interactions among C, D and K cells, the EM model resembles the self-activating toggle 
switch, a gene circuit module that plays an important role in decision-making for many 
biological processes, e.g. epithelial-mesenchymal transitions [24,257], and cell 
differentiation [275–277].  It has been shown that such a circuit topology allows for three 
stable steady states [257].  For the current EM model, we also found that the cancer-
immune system, at a certain level of immune recognition ρ and when exosome exchange 
is included, can allow three cancer states: high (H), intermediate (I) and low (L).  The 
model prediction regarding the (I) state is consistent with the immunoediting theory 
[258].  Interestingly, owing to the special interactions among different cancer and 
immune cells, the immune system is most active in the intermediate state.  
To study tumorigenesis, we incorporated the immune recognition represented by a 
variable ρ. During tumorigenesis, ρ gradually changes depending on the cancer stages.  
We proposed that, at the onset of a solid tumor, ρ starts from zero and increases to full 
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recognition (ρ = 1) at a certain response rate.  We found that, depending on how fast the 
DCs recognize the new tumor, cancer development ends up at high, intermediate or low 
cancer states.  Once the cancer population reaches a quasi-steady state, ρ gradually 
decreases due to immune escape.  This dynamics of immune recognition are consistent 
with change in tumor immunogenicity in the immunoediting theory [258], However, it is 
still unclear if the equilibrium state exists, what derives and maintains the equilibrium 
and how to detect the equilibrium state [218].   
We further analyzed the multi-stability of the model with respect to ρ within 2D 
and 3D bifurcation diagrams, from which we identified four different phases.  In each of 
the phases, the model can be at one state, or stay in one of the multiple states.  It is worth 
noting that the current EM model does not consider the situation in which the tumor 
actively escapes the immune suppression, which also contributes to reduced immune 
recognition.  For example, the tumor can limit antigen presentation [278] during cancer 
treatment.  We will take into account these effects by modeling the time evolution of ρ in 
a future study. 
We also performed stochastic analysis on the EM model, from which we 
constructed a corresponding effective landscape.  The effective landscape not only shows 
the relative stability of each steady state, but also provides an insight into cancer 
prognosis.  Our findings imply that an effective treatment should not aim to simply 
reduce the size of the tumor, but to lead the dynamics of the cancer-immunity interplay to 
cross the dynamic barrier (effective potential barrier) during treatment from the (H) state 
to the (I) and from the (I) state to the (L) states.  In many cases, effective therapeutic 
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protocols would be different for the H-to-I and the I-to-L transitions. Finally, we assessed 
the effects of time delays and biological noise on the design and effectiveness of 
therapeutic strategies. We note that noise effects of the cancer-immunity are still poorly 
understood [249]. 
The EM model enables us to evaluate the effectiveness of various treatment 
strategies.  Our current model suggests that stand-alone radiation therapy is mostly 
ineffective, as the system usually goes back to the original quasi-stable state after the 
treatment.  Radiation therapy may reduce not only the tumor load but also the immune 
response [271,272,279], making the system leans more towards the basin of the high 
cancer state.  We also found that the immunotherapy is more effective.  However, we 
may overestimate the effectiveness of the immunotherapy due to the following two 
factors.  First, the slow convergence of cancer-immunity interplay to the L state during a 
stand-alone immunotherapy may increase the risk of failure due to some unpredicted 
factors de novo mutations in the tumor.  Second, we do not know the maximum tolerated 
dosage for the immunotherapy, so it is possible that too much drug was applied causing 
intolerable side effects.  For example, excessive use of immunotherapy may result in 
strong immune tolerance, and it can in turn reduce the immune recognition ρ or induce 
autoimmune diseases.  Such potential effects will be taken into account in future studies. 
While the EM model presented here turned out to be a valuable starting point, it 
calls for future studies in which the cell subpopulations in C, D and K are individually 
included in the EM model. For example, macrophages usually play a role in eliminating 
tumor cells and in priming Naïve T and B cells by antigen presentation, while tumor-
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associated macrophages may stimulate tumor growth [223,280].  Moreover, regulatory T 
cells can induce immune tolerance, and may cause oscillatory cycles of the immune 
system [281].  Presumably, the effectiveness of cancer treatment could be affected by the 
dynamics of the regulatory T cells.  It is crucial to investigate their roles in the population 
dynamics of the cancer-immune system. 
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Supplementary Information 
Appendix 1: Towards elucidating the plasticity of cell migration phenotypes during 
cancer metastasis 
Table S1.1 - Experimental evidences for Rac1/RhoA regulatory circuits. 
Regulations Involved Molecules* References Cell lines 
Rac1-GTP inhibits 
RhoA-GTP p190RhoGAP 
Anjaruwee et al., 
2003[1] 
William et al., 
2001[2] 
Che-Hung et al., 
2008[3] 
Breast cancer cells, 
Hela cells, 
Rat1 fibroblasts 
RhoA-GTP inhibits 
Rac1-GTP 
FilGAP Koji et al., 2012[4] 
Breast, lung, prostate 
and colorectal 
adenocarcinoma cells 
ARHGAP22 Victoria et al., 2008[5] Melanoma cells 
Rac1-GTP self-
activation 
IRSp53/EP58 Yosuke et al., 2004[6] 
Breast cancer cells, 
Melanoma cells, 
Fibrosarcoma cells et 
al. 
Hem-1 Orion et al., 2006[7] Human neutrophil-like cells 
RhoA-GTP self-
activation Dia1 
Thomas et al., 
2007[8] 
Breast cancer cells, 
Human embryonic 
kidney cancer cell 
RhoA 
transcriptional self-
activation 
c-Myc 
Chia-Hsin et al., 
2010[9] 
Xose, 2010[10] 
Breast cancer cells, 
Fibroblasts 
Grb2 activates 
Rac1-GTP Ras 
Esther et al., 
2011[11] 
John et al., 2002[12] 
Breast cancer cells, 
Human embryonic 
kidney 293 cells et al. 
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Peter et al., 1994[13] 
Gab1 activates 
Rac1-GTP Crk 
Takuya et al., 
2006[14] 
Breast cancer cells, 
Human synovial 
sarcoma cells 
Gab1 activates 
RhoA-GTP LARG 
Dong et al., 
2009[15] 
Rat vascular smooth 
muscle cells 
* Most regulations are mediated indirectly through GEFs or GAPs, such as 
p190RhoGAP.  
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Table S1.2 - Parameters for Rac1/RhoA regulatory Circuit 
Parameters Value Unit Description 
Rac1    
gRc  3.4×105 molecules/h Production rate 
KRc  0.1 h
-1 Degradation rate for Rac1-GDP 
KRc*  0.1 h
-1 Degradation rate for Rac1-GTP 
gdi_Rc  2.0×103 h-1 Binding rate for GDI to Rac1-GDP 
dgdi_Rc  2.0×103 h-1 Dissociation rate for Rac1-GDI  
gtp_Rci  0.54 h-1 Intrinsic GTP loading rate 
gtp_RcB  19.46 h-1 Activated GTP loading rate 
gtp_RcA  530 h-1 Activated GTP loading rate by self-activation 
gtp_RcA0  1.9×106 molecules Threshold for self-activation 
ngtp_RcA  4 - Hill coefficient for self-activation 
dgtp_Rci  6.6 h-1 Intrinsic GTP hydrolysis rate 
dgtp_RcB  105.4 h-1 Activated GTP hydrolysis rate 
dgtp_RcA  198 h-1 Activated GTP hydrolysis rate by RhoA 
dgtp_RcA0  1.2×106 molecules Threshold for RhoA inactivation 
ndgtp_RcA  4 - Hill coefficient for RhoA inactivation 
RhoA    
gRh  1.6×105 molecules/h Basal production rate 
gRhA  3.4×105 molecules/h Excitatory production rate 
gRhA0  8.0×105 molecules Threshold for transcriptionally self-activation  
ngRhA  4 - Hill coefficient for self-activation 
KRh  0.1 h
-1 Degradation rate for RhoA-GDP 
KRh*  0.1 h
-1 Degradation rate for RhoA-GTP 
gdi_Rh  2.0×103 h-1 Binding rate for GDI to RhoA-GDP 
dgdi_Rh  2.0×103 h-1 Dissociation rate for RhoA-GDI  
gtp_Rhi  0.54 h-1 Intrinsic GTP loading rate 
gtp_RhB  109.46 h-1 Activated GTP loading rate 
gtp_RhA  196 h-1 Activated GTP loading rate by self-activation 
gtp_RhA0  1.0×106 molecules Threshold for self-activation 
ngtp_RhA  4 - Hill coefficient for self-activation 
dgtp_Rhi  1.32 h-1 Intrinsic GTP hydrolysis rate 
dgtp_RhB  308.68 h-1 Activated GTP hydrolysis rate 
dgtp_RhA  89 h-1 Activated GTP hydrolysis rate by Rac1 
dgtp_RhA0  1.3×106 molecules Threshold for Rac1 inactivation 
 196 
 
ndgtp_RhA  4 - Hill coefficient for Rac1 inactivation 
Signals    
gtp_RcI1  240 h-1 Activated GTP loading rate for Rac1 by Grb2 
gtp_RcI10  5.0×105 molecules Threshold for Grb2 activation on Rac1 
ngtp_RcI1  2 - Hill coefficient for Grb2 activation on Rac1 
gtp_RhI2  240 h-1 Activated GTP loading rate for RhoA by Gab1 
gtp_RhI20  5.0×105 molecules Threshold for Gab1 activation on RhoA 
ngtp_RhI2  2 - Hill coefficient for Gab1 activation on RhoA 
gtp_RcI2  90 h-1 Activated GTP loading rate for Rac1 by Gab1 
gtp_RcI20  5.0×105 molecules Threshold for Gab1 activation on Rac1 
ngtp_RcI2  2 - Hill coefficient for Gab1 activation on Rac1 
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Table S1.3 - Parameters Table for the coupled gene regulatory circuit 
Parameters Value Unit Description 
Rac1    
gRc  3.4×105 molecules/h Production rate 
KRc  0.1 h-1 Degradation rate for Rac1-GDP 
KRc*  0.1 h-1 Degradation rate for Rac1-GTP 
gdi_Rc  2.0×103 h-1 Binding rate for GDI to Rac1-GDP 
dgdi_Rc  2.0×103 h-1 Dissociation rate for Rac1-GDI  
gtp_Rci  0.54 h
-1 Intrinsic GTP loading rate 
gtp_RcB  19.46 h
-1 Activated GTP loading rate 
gtp_RcA  530 h
-1 Activated GTP loading rate by self-activation 
gtp_RcA0  1.9×10
6 molecules Threshold for self-activation 
ngtp_RcA  4 - Hill coefficient for self-activation 
dgtp_Rci  6.6 h
-1 Intrinsic GTP hydrolysis rate 
dgtp_RcB  105.4 h
-1 Activated GTP hydrolysis rate 
dgtp_RcA  198 h
-1 Activated GTP hydrolysis rate by RhoA 
dgtp_RcA0
 
1.2×106 molecules Threshold for RhoA inactivation 
ndgtp_RcA  4 - Hill coefficient for RhoA inactivation 
RhoA    
gRh  1.6×105 molecules/h Basal production rate 
gRhA  3.4×105 molecules/h Excitatory production rate 
gRhA0  8.0×105 molecules Threshold for transcriptionally self-activation  
ngRhA  4 - Hill coefficient for self-activation 
KRh  0.1 h-1 Degradation rate for RhoA-GDP 
KRh*  0.1 h-1 Degradation rate for RhoA-GTP 
gdi_Rh  2.0×103 h-1 Binding rate for GDI to RhoA-GDP 
dgdi_Rh  2.0×103 h-1 Dissociation rate for RhoA-GDI  
gtp_Rhi  0.54 h
-1 Intrinsic GTP loading rate 
gtp_RhB  109.46 h
-1 Activated GTP loading rate 
gtp_RhA  196 h
-1 Activated GTP loading rate by self-activation 
gtp_RhA0  1.0×10
6 molecules Threshold for self-activation 
ngtp_RhA  4 - Hill coefficient for self-activation 
dgtp_Rhi  1.32 h
-1 Intrinsic GTP hydrolysis rate 
dgtp_RhB  308.68 h
-1 Activated GTP hydrolysis rate 
dgtp_RhA  89 h-1 Activated GTP hydrolysis rate by Rac1 
dgtp_RhA0 1.3×106 molecules Threshold for Rac1 inactivation 
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ndgtp_RhA  4 - Hill coefficient for Rac1 inactivation 
c-Met Signals   
gtp_RcI1  240 h-1 Activated GTP loading rate for Rac1 by Grb2 
gtp_RcI10 * 5.0×10
5 molecules Threshold for Grb2 activation on Rac1 
ngtp_RcI1  2 - Hill coefficient for Grb2 activation on Rac1 
gtp_RhI2  240 h-1 Activated GTP loading rate for RhoA by Gab1 
gtp_RhI20 * 5.0×10
5 molecules Threshold for Gab1 activation on RhoA 
ngtp_RhI2  2 - Hill coefficient for Gab1 activation on RhoA 
gtp_RcI2  90 h-1 Activated GTP loading rate for Rac1 by Gab1 
gtp_RcI20  5.0×10
5 molecules Threshold for Gab1 activation on Rac1 
ngtp_RcI2  2 - Hill coefficient for Gab1 activation on Rac1 
microRNAs   
nµ  2 - Hill coefficient for microRNAs  
l0  1 - Coefficient for L(µ)  l1  0.6 - Coefficient for L(µ)  l2  0.3 - Coefficient for L(µ)  
γ m1  0.04 h
-1 Coefficient for Ym (µ)  
γ m2  0.2 h
-1 Coefficient for Ym (µ)  
KmRc  0.5 h
-1 Degradation rate for mRNA of Rac1 
KmRc  0.5 h
-1 Degradation rate for mRNA of RhoA 
µ0  1.0×10
4 molecules Threshold for microRNA regulation 
* There are two thresholds for Grb2 and Gab1 regulations are changed to 2.5×105 
molecules for Figure. 2.13.  
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Figure S1.1 - The circuit connecting RhoA and Rac1 to Gab1 and Grb2 signals.  
Grb2 can accelerate the GTP loading rate of Rac1 through Ras with the help of Sos, 
PI3K. When Grb2 binds and activate SOS, Ras is then activated[11,13]. The activated 
Ras can activate Rac1 either in PI3K dependent pathway[11] or by Tiam1 in PI3K 
independent way[12]. Gab1 can accelerate the GTP loading rate of either Rac1 or RhoA 
through Crk/DOCK180[14] and LARG[15] respectively.  
 
RhoA Rac1 
Gab1 Grb2 
LARG Crk Ras 
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Figure S1.2 - Bifurcations and phase diagram of the circuit when driven by external 
signals. 
(a) The complementary bifurcation for Figure 2.4b. Here it is showed in the term of 
Rac1-GTP protein level.  (b) Bifurcation of Rac1-GTP protein levels when driven by 
external signal on Rac1.  (c) Bifurcation of RhoA-GTP protein levels when driven by 
external signal on Rac1.  The red solid line stands for stable states and the blue dash line 
stands for unstable states. (d) Phase diagram of external signals both on RhoA (I1) and 
Rac1 (I2).  The positive values stand for activation signals, while the negative values 
represent the inhibition signals. The circuit for each quadrant is showed beside it. 
Different coexistences (Phases) are highlighted by different background colors, as 
illustrated at bottom.  
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Figure S1.3 - One-parameter bifurcation diagrams for Grb2 and Gab1 regulation.  
(a) Bifurcation diagrams as the function of Grb2 and Rac1-GTP.  (b) Bifurcation 
diagrams as the function of Grb2 and RhoA-GTP.  (c) Bifurcation diagrams as the 
function of Gab1 and Rac1-GTP.  (d) Bifurcation diagrams as the function of Gab1 and 
RhoA-GTP.  When Gab1 signal increase further, the cells finally are induced to A/M 
phenotype (e, f). Blue dashed lines stand for the unstable states, while red solid lines 
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stand for the stable states.  The phenotypes corresponding to each stable line are labeled 
in the figures.  
 
 
Figure S1.4 - Details about the different phases in Grb2/Gab1 phase diagram for 
Rac1/RhoA regulatory circuit.   
(a) Phase diagram using Grb2 and Gab1 signals as two parameters (also in Figure 2.5).  
(b) to (h) show the nullclines for the circuit at different phases - one phase for tri-stability 
(b), three phases for bi-stability (c, d, e) and three phases for mono-stability (f, g, h). 
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Figure S1.5 - Bifurcation of RhoA-GTP protein levels in response to signal µ.  
This diagram is complementary to Figure 2.9, but it is in the term of RhoA-GTP protein 
level. The red solid lines indicate stable states and the blue dashed lines indicate unstable 
states. 
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Figure S1.6 - Different phases in µ1 /µ2  phase diagram for Rac1/RhoA regulatory 
circuit.   
(a) Phase diagram using µ1  (y-axis) and µ2  (x-axis) signals as two parameters (also in 
Figure 2.10).  (b) to (h) show the nullclines for the circuit at different phases - two phase 
for tri-stability (b, c), three phases for bi-stability (d, e, f) and three phases for mono-
stability (g, h, i). 
 
0 2000 40000
1000
2000
3000
4000
5000  
miR on Rac1 (x103 molecules)
 m
iR
 o
n 
Rh
oA
 (x
10
3 m
o
le
cu
le
s)
RhoA-GTP (×106 molecules) 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ul
es
) 
RhoA-GTP (×106 molecules) 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ul
es
) 
RhoA-GTP (×106 molecules) 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ul
es
) 
RhoA-GTP (×106 molecules) 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ul
es
) 
RhoA-GTP (×106 molecules) 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ul
es
) 
RhoA-GTP (×106 molecules) 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ul
es
) 
RhoA-GTP (×106 molecules) 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ul
es
) 
RhoA-GTP (×106 molecules) 
R
ac
1-
G
TP
 (×
10
6  m
ol
ec
ul
es
) 
  µ2 on Rac1 (molecules) 
µ 1
 o
n 
R
ho
A
 (m
ol
ec
ul
es
) 
a b c 
d e f 
g h i 
{A, A/M, M} {A, E/M, M} 
{A, E/M} {A, M} {M, E/M} 
{M} {A} {E/M} 
 206 
 
 
Figure S1.7 - Boundaries for each state. Four different color areas are defined to 
distinguish the four possible states (E/M, M, A, A/M).  
The numbers by the arrow indicate the position of the boundaries.  The numbers by the 
arrow indicate the position of the boundaries. Trajectory 1 and 2 both started from same 
initial state, but trajectory 1 finally make successful transition from M to A/M while 
trajectory 2 failed and returned to M state. Based on these boundaries, we could calculate 
the number of transition per hour for specific transition (Figure. S1.8a) and the 
probability of specific state (Figure. S1.8b).  The probability of specific state is defined as 
the ratio of accumulating time staying in the state over the total time of the simulation 
(106 hours). 
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Figure S1.8 - Number of transition per hour between different states and the 
probability of each state.  
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(a) At different level of signal µ  (0, 1000, 3000, and 5000 molecules), the number of 
transition per hour for 12 possible transitions are shown by different lines. (b) At 
different level of signal µ , the probability of each state (E/M, M, A/M, A) is shown by 
different lines.  
 
Figure S1.9 - Two-parameter bifurcation diagram for signal µ and signals from c-
Met pathway.  
(a) Diagram for µ and Grb2, which could activate Rac1 protein. (b) Diagram for µ  and 
Gab1, which could activate both Rac1 and RhoA. The colors for different phases are 
shown at the bottom. 
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Appendix 2: Development of Random Circuit Perturbation (RACIPE) method to 
interrogate the topological robustness of gene regulatory circuits 
 
Table S2.1 - Ranges of the parameters for randomization 
Parameter Range# 
Maximum production rate ( ) 1-100 
Degradation rate ( ) 0.1-1 
Fold change ( )* 1-100 
Threshold ( X0 ) Depend on inward regulations 
Cooperativity of the regulation ( ) 1, 2, 3, 4, 5, 6 
 
#Units: the range of values for each parameter may have different meanings/units for 
different organisms.  For example, the maximum production rate (G) can be 102 – 104 
copies per hour per cell for E. Coli, and it can be 103 - 105 copies per hour per cell for H. 
sapiens.  The degradation rate (k) can be 0.1 – 1 hour-1 for E. Coli, and it can be 0.01 – 
0.1 hour-1 for H. sapiens (data inferred from bionumbers.org[16]).  In the current 
RACIPE method, the exact unit is not crucial to the results, because the gene expression 
data for all the RACIPE models were normalized before further analysis. 
*For inhibition, fold change ranges from 0.01 to 1, but a uniform distribution is sampled 
for the inverse of . 
 
G
k
λ
n
λ
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Figure S2.1 -Application of RACIPE to study oscillatory dynamics of a repressilator 
gene circuit.  
(a) Illustration of a repressilator circuit with three genes, where each gene represses the 
next gene in the circuit. (b) Tests of the half-functional rule for all RACIPE models 
(leftmost panel), the models with stable steady states (middle panel), and the models with 
stable oscillation (right panel). For the models with stable oscillation, we computed the 
ratio (x/x0) of the mean level of each gene X during oscillation and the threshold (x0) for 
the outward regulations from gene X.  The yellow region shows the probability of x/x0 > 
1 for the models, and the green region shows the probability of x/x0 < 1. (c) 2D 
probability density map of the RACIPE-predicted gene expression data of the models 
with stable steady states projected to the 1st and 2nd principal component axes. (d) 
Projection of the oscillatory trajectories of the models with stable oscillations to the same 
1st and 2nd principal component axes in (c).  (e) The overlapping of the PCA results 
between (c) and (d). 
 
a b 
c d e 
 211 
 
 
Figure S2.2 - Tests of several random sampling schemes with and without the half-
functional rule.  
(a) Test of the half-functional rule of a toggle-switch with one-sided self-activation where 
different ranges were used to randomize the threshold parameters. The leftmost panel 
shows the circuit and the sampling ranges of the threshold parameters by RACIPE 
according to the half-functional rule.  The middle and the rightmost panels show two 
examples where same ranges of threshold parameters are used for all regulations.  (b) 
a 
b 
c 
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Probability distributions of the number of stable steady states for each circuit. (c) 
Probability density maps of the gene expression data from all the RACIPE models, where 
the fraction of RACIPE models in each quadrant is shown. 
 
 
Figure S2.3 - Probability density maps of the gene expression data from all the 
RACIPE models with a fixed number of stable states for TS (a, b), TS1SA (c, d) and 
TS2SA (e, f and g) motifs.  
a, c and e are the maps for mono-stable models, b, d, and f are the maps for bi-stable 
models while g is for the tri-stable models.  For models with different number of gene 
states, the gene state clusters remain the same, but the percentage of models in each gene 
state varies.   
 
a b 
c d 
e f g 
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Figure S2.4 - The effects of the range of parametric perturbations on the robust 
gene states of a toggle-switch circuit motif.   
Each panel shows the probability density map of the gene expression data from all the 
RACIPE models for a version of RACIPE with different range of parametric 
perturbations. (a) The range of the production rates was randomized from 1-1000. (b) 
The range of the degradation rates was randomized from 0.1-10. (c) The range of the fold 
changes was randomized from 1-1000.  In each case, the range of variations is 10 times 
as large as the original method. The sampling distribution for parameter randomization 
for these cases is still a uniform distribution. 
 
a b c 
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Figure S2.5 - The effects of Hill coefficients on the robustness of the sampling 
scheme and gene states of a toggle-switch circuit motif.  
Test of the half-functional rule (top-panels) and 2D probability density map (bottom-
panels) of RACIPE-generated gene expression data are shown for cases where Hill 
coefficients are randomized with different ranges -- a: 1-3; b: 4-6; c: 7-9. 
  
a b c 
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Figure S2.6 - Gene expression distributions of each gene state for the CTS motif 
with three coupled toggle switches.  
The gene expression distribution of each gene for all of the RACIPE models is shown in 
blue, while that for each gene state is shown in red (50 bins for the histogram of each 
distribution).  Below, each row shows the distribution of each gene for every gene state, 
listed in the same order as Figure. 3.5b. For clarity, each distribution is normalized by its 
maximum probability. Each column represents a gene and each row represents a gene 
state. For each state, the expression of a gene could be assigned as a high, intermediate or 
low level according to the relative location of its distribution (red) with respect to the 
distribution (blue) for all the RACIPE models. 
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Figure S2.7 - Gene expression distributions of each gene state for the CTS motif 
with five coupled toggle switches.  
The gene expression distribution of each gene for all of the RACIPE models is shown in 
blue, while that for each gene state is shown in red (50 bins for the histogram of each 
distribution).  Below, each row shows the distribution of each gene for every gene state, 
listed in the same order as Figure 3.5b. For clarity, each distribution is normalized by its 
maximum probability. Each column represents a gene and each row represents a gene 
state. For each state, the expression of a gene could be assigned as a high, intermediate or 
low level according to the relative location of its distribution (red) with respect to the 
distribution (blue) for all the RACIPE models. 
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Appendix 3: Decoding Stem Cell Regulatory Circuit by Random Circuit Perturbation 
Method 
 
 
Figure S3.1 - Identification of major gene states for the stem cell gene regulatory 
circuit.  
(a) A total of 54 gene clusters were identified by the hierarchical average linkage 
clustering analysis on the RACIPE gene expression data for the stem cell circuit in Figure 
4.1b.  With a minimum probability cutoff of 0.005, we identified 15 clusters, referred to 
as major gene states.  The coloring scheme for these 15 clusters is consistent with that 
used in Figure 4.1b, and the other clusters are shown in grey. (b) Characteristic gene 
expressions and experimental evidences for each of these gene states, ranked by the 
likelihood in the RACIPE models as in (a).  The four gene states that match the single 
cell experimental data (Figure 4.1b, right) are highlighted by blue asterisks and their 
likelihoods.  
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Figure S3.2 - Contribution of each gene to the 1st and 2nd principal component axes. 
The principle component axes were obtained by the PCA of the gene expression data 
from all of the RACIPE models. The position of each gene in the diagram illustrates its 
contribution to the two axes.  Oct4/Sox2/Nanog have position contributions to the first 
axis, while Cdx2 and Gata6 have negative contributions to the first axis. 
 
 
 
Figure S3.3 - The effects of the number of random initial conditions to the 
convergence of the RACIPE results.   
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For each RACIPE model, all the possible stable steady states are obtained by running 
ODE simulations starting from different random initial conditions.  Here, we checked 
whether the statistical results converged by varying different numbers of initial 
conditions (blue: 1000 times, red: 1500 times, and green: 2000 times).  Each case was 
repeated 10 times to estimate the mean and the standard deviation of the histogram.  (a) 
Probability distribution of the number of stable steady states for each RACIPE model.  
(b) Probability distribution of the gene states. 
 
 
Figure S3.4 - Gene expression distributions of each gene state.  
The gene expression distribution of each gene for all of the RACIPE models is shown in 
blue, while that for each gene state is shown in red (50 bins for the histogram of each 
distribution).  For clarity, each distribution is normalized by its maximum probability. 
Each column represents a gene and each row represents a gene state.  The results 
illustrate that RACIPE, unlike the traditional Boolean network model[17], allows the 
identification of the intermediate expression for some gene states.  
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Figure S3.5 - Hierarchical clustering of mouse embryo single cell gene expression 
data.  
(a) Clustering result of a total of 48 genes[18]. (b) The extracted gene expression data for 
6 genes (Cdx2, Gata6, Klf4, Nanog, Oct4 and Sox2). Each column represents a gene 
while each row represents a cell.   
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Figure S3.6 - Comparison between the experimental gene states and the RACIPE 
gene states. 
The comparison analysis was done by the cluster-based analysis (See Methods).  First, 
we calculated the average gene expression vector of each experimental cluster 
(experimental gene state) and each RACIPE cluster (RACIPE gene state).  Then, for each 
experimental gene state, we calculated the mean square errors (MSEs, see Methods) 
between the average gene expression vector of the experimental gene state and that of 
every RACIPE gene state (shown as solid lines, labeled on the top).  The blue histogram 
is the cumulative probability distribution of the MSEs between the average gene 
expression vector of the experimental gene state and 10,000 random gene expression 
vectors.  We considered that an RACIPE gene state matches the experimental gene state 
if the corresponding MSE between them is below 1% of the cumulative probability (the 
cutoff, shown as red dashed lines).  According to the plots, no match was found for the 
1st, 2nd, 3rd and 4th experimental gene states.  The 5th experimental gene state matches the 
6th RACIPE gene state; the 6th experimental gene state matches the 1st RACIPE gene 
state; both the 7th and the 8th experimental gene states match the same 4th RACIPE gene 
state; the 9th experimental gene state matches the 3st RACIPE gene state. 
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Figure S3.7 - Comparison between experimental gene expression data and random 
gene expression data.   
Random resampling was performed to generate random datasets to calculate the 
statistical significance (i.e. p-value) of the comparison between experimental data and the 
RACIPE generated data.  Here three different tests were performed.  (a) Histogram of the 
fraction of a random dataset that matches the experimental gene states by the cluster-
based analysis (see Methods).  In this test, we generated 10,000 random datasets, each of 
which has 15 resampled gene expression vectors representing the average gene 
expression vectors of a null model (see Methods for the procedure of the resampling).  
For each random vector, we also randomly assigned the probability of a different 
RACIPE cluster to the vector.  (b) Histogram of the fraction of a random dataset that 
matches the experimental gene states by the individual-based analysis. Here we generated 
10,000 random gene expression vectors (same size as the RACIPE dataset) resampled 
from the distributions of gene expression of each gene in the RACIPE dataset.  (c) 
Similar to the individual-based analysis used in (b), but the random datasets were 
generated in a different way.  Here, a random dataset was generated by shuffling the gene 
identities for each gene state cluster in the RACIPE dataset.  For all the tests, we found 
the RACIPE dataset (red dotted line) outperforms almost all the random datasets (>99%, 
grey histogram) in matching the experimental dataset. 
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Figure S3.8 - Key parameters that are involved in the transitions among certain 
gene states.  
(a) A summary of the results on top of the probability density map of the RACIPE 
predicted gene expression data.  For each transition shown in panel (a), panels (b) to (g) 
show the mean of the normalized values for each parameter for the two corresponding 
gene states (x-axis for the first gene state, and y-axis for the second gene state).  (b): 
states 1 and 2; (c): states 1 and 6; (d): states 6 and 4; (e): states 4 and 5; (f): states 5 and 
2; (g): states 2 and 3. 
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Figure S3.9 - Comparison between the identified gene states from the original 
RACIPE gene expression data and those from the hybrid RACIPE gene expression 
data.  
(a) Hierarchical average linkage clustering analysis on the hybrid RACIPE gene 
expression data (Methods).  At a cutoff distance of 0.78, 44 clusters were identified.  
Among them, 18 clusters correspond to 18 major gene states with probability higher than 
0.005. (b) The probability distribution of all of the gene states highlighted by different 
colors. (c) Comparison between the gene states identified from the hybrid datasets and 
those identified from the original RACIPE dataset.  For each diagram, we computed the 
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MSEs between the gene expression vectors of a gene state from the hybrid dataset and 
each of the gene states from the original RACIPE dataset.  A cutoff MSE value was 
selected so that the gene expression vector of the hybrid gene state matches no more than 
1% of 10,000 random gene expression vectors.  The pairs with the smallest MSE distance 
below the cutoff (the red dashed line) are colored in red. (d) Direct comparison between 
the matched gene states from the hybrid and the original RACIPE datasets.  The heat map 
shows the average gene expression levels for the corresponding gene states.  The results 
illustrate that the hybrid dataset has similar gene state clusters as the original RACIPE 
dataset. 
 
Figure S3.10 - Schematics of random circuits.  
(a) Type I random circuits. (b) Type II random circuits. Red arrow lines stand for 
activations and blue bar lines stand for inhibitions. The index for each circuit is shown at 
the top.  
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Figure S3.11 - Hierarchical clustering of the RACIPE gene expression data of 
random circuits.  
Each column represents a gene and each row represents a steady state. The cutoff value 
for the clustering tree is set to be the same 0.8 as that of the stem cell circuit.  The 
identified major gene state clusters are highlighted by colors for Type I random circuits 
and Type II random circuits. 
 
 
Figure S3.12 - Comparison between the stem cell circuit and a random circuit.  
The figure is similar to Figure 4.2, but it includes the results for all of the random circuits. 
The columns present genes and rows correspond to different circuits.  For the results of 
random circuits, the indices are consistent with those for the random circuits (Figure 
S3.10). 
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Figure S3.13 - Comparison between the RACIPE gene expression data of a random 
circuit and experimental gene expression data.  
(a) Comparison by the individual-based analysis: RACIPE was applied to each random 
circuit to generate a collection of gene expression data, which were subject to direct one-
on-one comparison with each of the experimental gene expression data (by MSEs, see 
Methods).  The plot shows the probability of the RACIPE gene expression data that 
matches the experimental data.  Blue circuits denote the type I random circuits, and red 
triangle denote the type II random circuits.  The index in the x-axis is consistent with the 
order in Figure S3.10. (b) Comparison by the cluster-based analysis.  In addition to the 
above mentioned procedure, the average gene expression vectors were computed for each 
gene state cluster from both the RACIPE data and the experimental data.  All the 
RACIPE data from a cluster was regarded to match the experimental data if the average 
gene expression vector match that of any experimental cluster that belongs to the late 
stage (  32 cells) of embryo development. 
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Figure S3.14 - Behaviors of the sub-circuits Oct4/Cdx2 and Nanog/Gata6.   
According to Figure 4.3, there exist two sub-circuits (top layer: Oct4/Cdx2 and bottom 
layer: Nanog/Gata6) to form a hierarchical structure.  (a) and (d): The RACIPE gene 
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expression data of the full circuit are split into two sets, each of which corresponds to the 
genes from either the top sub-circuit (panel a) or the bottom sub-circuit (panel d). The 
hierarchical clustering results of them are shown in (a) and (f). (b), (c), (e) and (f): 
RACIPE was applied to each sub-circuit whose circuit parameters were randomized with 
the same ranges as those for the full circuit.  The panels show the hierarchical clustering 
results for each RACIPE dataset.  Panels b and e: for each gene, data are normalized by 
the mean and standard deviation of the expression levels for each sub-circuit; panels c 
and f: for each gene, data are normalized by the mean and standard deviation of the 
expression levels for the full circuit.   The results show that the RACIPE results remain 
the same for the Oct4/Cdx2 sub-circuit when the regulatory links connecting the two sub-
circuits are removed.  However, the results for the Nanog/Gata6 sub-circuit are 
dramatically different no matter which normalization methods are used.  
 
 
Figure S3.15 - Heterogeneity of the ensemble of the RACIPE models in response to 
low/high-expression treatments.  
(a) Weighted (phylogenetic) information entropy as the function of the level of 
inhibition/activation for each gene.  The directions of inhibition and activation are shown 
by arrows.  (b) The information entropy is strongly correlated with the average number of 
stable states for each RACIPE model. The black dashed vertical lines represent the case 
without treatment. 
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Figure S3.16 - Dependence of the RACIPE gene expression data on the range of the 
parameters for randomization.   
(a) 2D probability density maps of the RACIPE gene expression data projected to the 1st 
and 2nd principal component axes of the original RACIPE models (as shown in Figure 
4.1d). For each small panel, the parameters were randomly selected from different ranges 
– the original RACIPE protocol was labeled as “100%”; for the other cases, the ranges 
are reduced to the corresponding percentages.  The locations of the major clusters in 
these plots are similar till the ranges are reduced to 60%.  (b) The ratio of the maximum 
and minimum value of fold change (λ) parameters as the function of the shrink of the 
original range of the parameters for randomization.  When there is no reduction (1.0 in 
the x-axis), the ratio is 100.  But the ratio dramatically reduces to about only 10 when the 
range is reduced to 80%. 
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Figure S3.17 - Dependence of the RACIPE gene expression data on the type of the 
sampling distribution.   
So far, we only tested the RACIPE protocol in which the parameters are randomly 
sampled from uniform distributions.  Here we tested RACIPE using Gaussian 
distribution. (a) 2D probability density maps of the RACIPE gene expression data 
projected to the 1st and 2nd principal component axes of the native RACIPE models (as 
shown in Figure 4.1d). Top left panel: the standard RACIPE method; the rest panels: the 
RACIPE protocols using different Gaussian distributions (standard deviations of fold 
change parameter for each case are shown on the top).  The locations of the major 
clusters in these plots are similar except for the one at bottom right. (b) The Gaussian 
distribution of the fold change (λ) parameters for each case: the blue curve corresponds to 
the top right panel; the standard deviations of the Gaussian distribution were taken as half 
of the standard deviations of the uniform distribution, as shown in Table S3.1.  The red 
curve corresponds to the bottom left panel, and the orange curve corresponds to the 
bottom right panel.  
 
  
 233 
 
Appendix 4: Modeling putative therapeutic implications of exosome exchange between 
tumor and immune cells 
Table S4.1 - Parameters for the ECI model 
Symbol Value Unit  Symbol Value Unit 
Proliferation rate   Apoptosis rate 
 
 
 
1.35 
3.6 
0.06 
cell/(µL day) 
cell/(µL day) 
cell/(µL day) 
  
 
 
0.03 
0.03 
0.03 
day-1 
day-1 
day-1 
 
Common interactions 
 2 −   450 cell/µL 
 400 cell/µL   3 − 
 2 −   4 − 
 50 cell/µL   150 cell/µL 
 10 −   10 − 
 2 −   2 − 
 150 cell/µL   100 cell/µL 
 1.5 −   3 − 
 1 −   2 − 
 300 cell/µL   400 cell/µL 
 2 −   0.1 − 
 2 −   2 − 
 1000 cell/µL   400 cell/µL 
 2 −   3 − 
Specific interactions  
Case I      
 0.1 −   2 − 
Case II       
 1 −   1 − 
Case III       
 1 −   2 − 
Case IV       
 1 −   1 − 
 0.03 day-1     
gD0
gC0
gK 0
⋅
⋅
⋅
kD
kC
kK
nCD1 KC0
CD10 λ 0KC
nCD2 nCC
CD20 CC0
λ +CD2 λ +CC
nKD nCK1
KD0 CK10
λ +KD λ
+
CK1
nDD nCK 2
DD0 CK20
λ +DD λ
−
CK 2
nDC nCK 3
DC0 CK30
nKC λ +CK 3
λ−CD1 λ 0DC
λ−CD1 λ 0DC
λ−CD1 λ 0DC
λ−CD1 λ 0DC
kKD
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Noise level γx (cells/µL)2/day   
γx = 312.5 Fig. 2, Fig. S1, Fig. S2 
γx = 1250 Fig. S10 
γx = 1.125x  Fig. S11 
γx = 50 Fig. 8 
  
x ∈C,D,K
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Figure S4.1 - Phase plane analysis for the ECI model.   
In each case, a phase plane is constructed by the concentration of the dendritic cells (D, 
x-axis) and the effective cancer cells (C, y-axis).  The nullcline dD/dt = 0 & dK/dt = 0 is 
shown in solid navy line and dC/dt = 0 & dK/dt = 0 is shown in solid brown line.  The 
intersections of these two nullclines are the steady states, represented by solid green 
circles for stable states and by hollow green circles for unstable states.  The grey arrows 
represent the vector field in a stream plot.  The background colors shows the effective 
landscape values (-log(P)) computed by stochastic simulations of the network with white 
Gaussian noise.  The states are most probable at the blue regions, and are least probable 
at the red/white regions.  Panel a and b are for case I, and panel c and d are for case II.  
The immune recognition is high (with value ρ = 2) for a and c, and is higher (with value ρ 
= 4) for b and d.  For both cases, when immune recognition is high enough, the network 
only has a low cancer load with low immunity level state (L, or (0, 0)) (panel b, c, d). For 
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case I, even when the immune effect is sufficiently strong, there is still some rare chance 
to switch to the high cancer (H) state. 
 
 
Figure S4.2 - Phase plane analysis for additional ECI models.  
The reduced network model contains three major components: the effective cancer cells 
(C), the dendritic cells (D) and the killer cells (K).  The links among different cell types 
represents the effects of cell-cell communication.  An arrow denotes activation; a bar 
denotes inhibition; the green spheres represent cell communications that are partially 
mediated by exosomes.  Panel a shows the model without exosome-mediated interactions 
from C to D (only ); panel b shows the model without exosome-mediated 
interactions between C and D (  and ), but meantime with the apoptosis of 
matured dendritic cells after they encounter and activate the Naïve T and B cells (with an 
additional apoptosis term  added to D’s equation ( )).  In all 
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these cases, we consider ρ = 1, and the rest parameters are kept the same.  The 
corresponding phase plane diagram with effective landscape for each model is shown 
below the network diagram. 
 
 
Figure S4.3 - Illustration of the definition of the intermediate state and the 
tristability.  
This illustrative bifurcation diagram is drawn for the steady state concentration of 
effective cancer cells as the function of the immune recognition ρ.  The blue lines 
represent three segments of stable steady states, while the red lines represent two 
segments of unstable steady states. We define the existence of intermediate state when 
there is a total of five such segments.  Among these segments, the third (middle) segment 
(segment labeled as (I)) is defined as the intermediate stable state.  The range of existence 
for the intermediate state in  (range 1), is defined as the range of existence for the 
intermediate state.  We also define the range of existence for the tristability as the range 
in  within which  the three stable steady states co-existence (range 2). 
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Figure S4.4 - Distribution of the range of existence for the intermediate state and the 
tristability under different levels of parameter perturbations.  
In each test, all 36 parameters were randomly perturbed by a maximum of d% (chosen 
from 10%, 20% … 60%).  Panel a and panel b show the distribution of the range of 
existence for the intermediate state and the tristability with respect to the immune 
recognition ρ from a total of 10000 tests, respectively. With the increase of perturbation 
level, the standard deviations of the average range of existence for the intermediate state 
and the tristability go up. Panel c and d show the distribution of them when the sensitive 
parameters ( ,  and ) are excluded from the perturbations in the test. Without 
these parameters, the standard deviations at same level of perturbation are reduced. The 
black dashed line shows the baseline, responding to the range of existence for them with 
the original (unperturbed) parameters. 
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0.40 0.30 0.20 0.10 0.0 0.10 0.20 0.30 0.40 
Parameters +10% 
Parameters -10% 
Length of intermediate state 
A origin kK 
kC 
kD 
λCK3 
CK30 nCK3 
λCK2 
CK20 nCK2 
λCK1 
CK10 nCK1 
λCC 
CC0 nCC 
λKC 
KC0 
nKC 
λDC 
DC0 
nDC 
λDD 
DD0 
nDD 
λKD 
KD0 
nKD 
λCD2 
CD20 nCD2 
λCD 
CD0 
nCD 
gK0 
gC0 
gD0 
a 
0.40$ 0.30$ 0.20$ 0.10$ 0.0$ 0.10$ 0.20$ 0.30$ 0.40$
Parameters +10% 
Parameters -10% 
Length of tristability 
B origin 
kK 
kC 
kD 
λCK3 
CK30 nCK3 
λCK2 
CK20 nCK2 
λCK1 
CK10 nCK1 
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CC0 nCC 
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λDC 
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nDC 
λDD 
DD0 
nDD 
λKD 
KD0 
nKD 
λCD2 
CD20 nCD2 
λCD 
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nCD 
gK0 
gC0 
gD0 
b 
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0.80 0.60 0.40 0.20 0.0 0.20 0.40 0.60 0.80 
Parameters +30% 
Parameters -30% 
Length of intermediate state 
C origin kK 
kC 
kD 
λCK3 
CK30 nCK3 
λCK2 
CK20 nCK2 
λCK1 
CK10 nCK1 
λCC 
CC0 nCC 
λKC 
KC0 
nKC 
λDC 
DC0 
nDC 
λDD 
DD0 
nDD 
λKD 
KD0 
nKD 
λCD2 
CD20 nCD2 
λCD 
CD0 
nCD 
gK0 
gC0 
gD0 
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Parameters +30% 
Parameters -30% 
Length of tristability 
D origin kK 
kC 
kD 
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CK30 nCK3 
λCK2 
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Parameters +50% 
Parameters -50% 
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Figure S4.5 - Sensitivity of each model parameter to the range of existence for the 
intermediate state and the tristability.  
In each test, one of 36 parameters is changed by ±10% (panel a and b), ±30% (panel c 
and d) or ±50% (panel e and f). Then we check the range of existence for the intermediate 
state and the tristability with respect to the immune recognition ρ. For example, panel a 
shows the range of existence for the intermediate state for each parameter with -10% 
(show in orange bars) and +10% (show in blue bars) deviation. The range of existence for 
the intermediate state for the original parameters is shown at the top and highlighted by 
vertical dashed black lines. From these results, some sensitive parameters are detected, 
such as ,  and . 
  
gC0 CC0 λ +CC
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Figure S4.6 - The range of existence for the intermediate state and the tristability 
upon perturbation of each model parameter.  
Same as Figure S4.5, one of 36 parameters is changed by ±d% (d is chosen from 10, 20 
… 60) each time. The positive deviations of the parameters are shown in panel a and c for 
the intermediate state and the tristability respectively, while the negative deviations are 
shown in panel b and d. All the data are plotted in the same order as the one with 60% 
deviation, which starts from the parameter with the smallest range of existence for the 
intermediate state or the tristability and end with the one with the largest range.  
 
 
Figure S4.7 - The effects of the sensitive parameters on the existence of the 
intermediate state and the tristability.   
Similar as Figure 5.4, in each test, parameters are randomly perturbed by a maximum of 
d% (d is chosen from 10, 20 … 60).  Then, the bifurcation diagram with respect to the 
immune recognition ρ is generated to check the existence of the intermediate state and the 
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tristability.  From Figure S4.5 and S4.6 we detect some parameters to which the existence 
of the intermediate state and the tristability are very sensitive (e.g. gC0, CC0 and ).  
Here, we show the effects of these sensitive parameters on the existence of the 
intermediate state and the tristability by fixing a part of the sensitive parameters ( , 
 and ) in the above test. Panel a and panel b shows the percentage of the 
existence of the intermediate state and the tristability from a total of 10000 tests, 
respectively.  The light blue column is for the all parameters perturbation, the light green 
one is for perturbation with CC0 fixed, and the orange one is for the perturbation with gC0, 
CC0 and  fixed. Panel c and panel d show the mean and standard deviation of the 
range of existence for the intermediate state and the tristability, respectively. The dotted 
line shows the baseline, corresponding to the range of existence for them for the case 
with the unperturbed parameters. 
λ +CC
gC0
CC0 λ +CC
λ +CC
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Figure S4.8 - Choice of the reaction coordinates for constructing effective 
landscapes of the ECI model with white Gaussian noise. 
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The model has three components (C, D, K), but the effective landscapes, as shown in 
panel a, b, and c, are usually presented on 2D by averaging the value of the third axis.  
The effective landscapes computed in this way are very different from each other when 
different coordinates are selected.  Here, for better presentation of the landscape among 
the three components, we define a new reaction coordinate to describe both D and K.  
Since K positively correlates to D in a nonlinear way (panel c), we obtain the new 
reaction coordinate by either fitting the probability distribution to a quadratic function 
(panel c), or fitting that to two line segments (part 1 and part 2 as shown in panel e) 
connected by a quadratic Bezier curve (curve between part 1 and 2).  We name the new 
coordinate as “effective dendritic and killer cells”.  For any state (D, K) in the phase 
plane DK, we first find the closest state (D0, K0) along the new reaction coordinate to the 
state (D, K), and then define the coordinate value as the arc length of the point (D0, K0) 
from a reference point (origin) along the coordinate. The corresponding effective 
landscapes are constructed by choosing C as the first axis and the new reaction coordinate 
as the second axis.  The effective landscapes for the two different (yet similar) choices of 
reaction coordinates, as shown in panel d and f, are similar except that the landscape in 
panel f is a little discontinuous at the connection part of three segments.  In both cases (e 
and f), the new effective landscape for the high cancer state (red box) resembles to that in 
panel a (rescaled and shown in the top insert), while that for the intermediate and low 
cancer state (black box) resembles that in panel b (shown in bottom insert).  The plots 
illustrate the capability of the new reaction coordinate in better describing the effective 
landscape with reduced dimensions. 
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Figure S4.9 - Choice of the reaction coordinates for constructing effective 
landscapes of the ECI model with shot noise.  
Dendritic cells (cells/µL) 
Dendritic cells (cells/µL) 
Dendritic cells (cells/µL) Effective dendritic and killer cells (cells/µL) 
Ef
fe
ct
iv
e 
ca
nc
er
 c
el
ls
 (c
el
ls
/µ
L)
 
Killer cells (cells/µL) 
Ef
fe
ct
iv
e 
ca
nc
er
 c
el
ls
 (c
el
ls
/µ
L)
 
K
ill
er
 c
el
ls
 (c
el
ls
/µ
L)
 
K
ill
er
 c
el
ls
 (c
el
ls
/µ
L)
 
Ef
fe
ct
iv
e 
ca
nc
er
 c
el
ls
 (c
el
ls
/µ
L)
 
Effective dendritic and killer cells (cells/µL) 
Ef
fe
ct
iv
e 
ca
nc
er
 c
el
ls
 (c
el
ls
/µ
L)
 
-lo
g(
P)
 
C 
E 
A B 
D 
F 
3 
2 1 
a b 
c d 
e f
 250 
 
Similar to what is shown in Figure S4.8, we obtain the new reaction coordinate by either 
fitting the probability distribution to a quadratic function (panel c) or to three line 
segments (part 1, part 2 and part 3 as shown in panel e) connected by two quadratic 
Bezier curves (between 1, 2 and 2, 3). The effective landscape for high cancer state (red 
box) resembles that in panel a (rescaled and shown in the top insert), while that for the 
intermediate and low cancer state (black box) resembles that in panel b (shown in bottom 
insert). 
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Figure S4.10 - Assessment of therapeutic strategies with the ECI model.  
In each case, we show the doses usage (top part) and the dynamical trajectory in the 
phase plane (bottom part).  The session of radiation therapy is shown in red and the 
a b 
c d 
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session of DC immunotherapy is shown in green.  Panel a shows the treatment from the 
high cancer state (H) to the intermediate cancer state (I) in case of combined radiation 
therapy and immunotherapy simultaneously. Panel b shows the similar combined 
treatment but with stronger radiation effect. Panel c shows alternating combined therapy 
by both radiation therapy and immunotherapy in same way as right panel of Figure 5.7b, 
but the total dose usages for each therapy are equal to those for the treatment illustrated in 
the left panel of Figure 5.7b. Panel d shows the treatment from the intermediate cancer 
state (I) to the low cancer state (L) by the stand-alone radiation therapy. 
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Figure S4.11 - The effects of time delay on the treatments.  
In each case, we show the dose usage (top part) and the dynamical trajectory without time 
delay (middle part). This is the same as some cases in Figure 5.7b and Figure S4.10. We 
a b
d e
c
f
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also show the dynamical trajectory with 15-day delay for the exosome-mediated 
communications between D and C in the phase plane (bottom part).   
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